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Abstract
Although the relationship between insulin resistance and cardiovascular 
diseases is well established, nature and mechanism of the insulin resistance 
in peripheral tissues is unclear.
In this thesis I have demonstrated that a rodent model of genetic 
hypertension, the stroke-prone spontaneously hypertensive rat (SHRSP), 
displays resistance to the effects of insulin, characterised by defects at the 
level of both carbohydrate and lipid metabolism in primary epididymal 
adipocytes. Insulin-stimulated 2-deoxy-D-glucose uptake is reduced 
SHRSP compared to Wistar-Kyoto (WKY) control, and there is a profound 
reduction in the ability of insulin to inhibit isoprenaline-mediated lipolysis.
The SHRSP is a relative of the SHR, which develops a similar though not 
identical phenotype. The SHR defect has recently been attributed to aberrant 
expression of Cd36, a putative fatty acid transporter in adipocyte 
membranes. Thus, Cd36 has emerged as a potentially important link in 
cardiovascular and insulin resistance syndromes. Interestingly however 
levels of Cd36 mRNA and protein in SHRSP adipocyte membranes are 
comparable to those in WKY normotensive controls. This suggests that 
other molecules may contribute to the development of the SHRSP 
phenotype.
The potential for abenrant insulin signalling to contribute to the 
development of insulin resistance is also apparent in other syndromes such 
as Polycystic Ovarian Syndrome (PCOS). To that end I studied the effects 
of sex hormone treatment in 3T3-L1, as sex hormone levels are elevated in 
PCOS. In sex hormone treated 3T3-L1 adipocytes there is a down- 
regulation of IRS-1, IRS-2 and PI3K. There is also a re-distribution of IRS- 
1 and 1RS-2 from the membrane fraction to the cytosol in sex hormone 
treated cells. This type of movement has previously been implicated in the 
development of cellular insulin resistance, and indeed there is resistance to 
the effects of insulin to stimulate GLUT4 translocation and glucose uptake
11
in these cells. This is independent of any change in expression of GLUT4, 
although insulin-stimulated translocation is dramatically reduced. This data 
suggests a potential mechanism by which insulin resistance could develop 
in syndromes, such as PCOS, where adipocytes are exposed to an abnormal 
balance of sex steroids.
Assessing the contribution of insulin signalling to the development of 
insulin resistance in different disease states will be useful at several levels. 
At the most basic level it will reveal more about the functions of specific 
proteins, and importantly the diseases which result when these proteins are 
abnormally regulated. This will present new avenues for therapeutic 
treatment, aimed at both correcting apparent defects, or by alternative 
mechanisms which could by-pass dysfunctional signalling pathways.
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1 General Introduction
1.1 Glucose as an energy source
To function properly the human body requires consumption of adequate 
amounts of the three main food groups: proteins (composed of a variety of 
essential and non-essential amino acids), fats, and carbohydrates. 
Although all of the food sources are able to provide energy for both 
storage purposes and immediate use, carbohydrates are important as they 
represent the only source of anaerobic non-oxidative energy. The main 
product of carbohydrate breakdown is glucose and in aerobic organisms 
energy is generated from this molecule through glycolysis. Glycolysis 
plays a central role in energy metabolism by providing a substantial 
portion of the energy consumed by most organisms. Due to this ability to 
provide energy, glucose is the preferred source of energy for many tissues 
of the body. This is discussed below (Chapter 27, Zubay, 1998).
1.2 Glucose metabolism in different tissues
1.2.1 Glucose and the brain
The necessity for glucose as an energy source is perhaps best illustrated in 
the brain where there is an absolute requirement for glucose, which varies 
little whether active or at rest. Indeed blood glucose concentrations falling 
to less than half the optimum 5mmoles per litre can result in severe brain 
dysfunction, where subjects will exhibit symptoms such as lack of 
coordination and impairment in concentration. Only in situations of 
extreme starvation will the brain resort to utilising the one other energy 
source available to it, ketone bodies. Ketone bodies, which are essentially 
soluble forms of fatty acids, enter the circulation from the liver where they 
are generated in a process known as ketogenesis. Due to their solubility 
they are able to cross the blood brain barrier, unlike normal fatty acids 
which are unable to do this due to their structure. The brain is therefore
able to metabolise them and generate energy from them. This, however, is 
always a short term energy source and as soon as glucose becomes readily 
available brain metabolism of ketone bodies discontinues (Chapter 27, 
Zubay, 1998.).
1.2.2 Glucose and skeletal muscle
Muscle is not so selective as brain regarding its energy supply, and is able 
to utilise glucose (predominantly in the storage form, glycogen), fatty 
acids and ketone bodies as energy sources. Nevertheless skeletal muscle 
still represents a main glucose sink, and a large percentage of circulating 
glucose is taken up by this tissue. As soon as glucose enters muscle it is 
rapidly converted to the main storage carbohydrate; glycogen, and up to 
2% of a resting well-fed muscle normally constitutes glycogen stores. 
This glycogen is readily utilisable within the muscle as an energy source as 
it can be converted into glucose-6-phosphate, and subsequently glycolysis. 
Muscle is however unable to carryout gluconeogenesis, as it lacks glucose- 
6-phosphatase, the enzyme necessary for hydrolysis of glucose-6- 
phosphate. Nevertheless muscle is able to act as an efficient energy 
reservoir when required in severe starvation, by the mechanism outlined 
over-page in Figure 1.1 (Chapter 27, Zubay, 1998.).
1.2.3 Glucose and adipose tissue
Adipose tissue, like skeletal muscle, is an important energy storage depot, 
and is mostly located just under the skin in the abdominal cavity, around 
skeletal muscle and in the mammary glands. The importance of fat in this 
regard is perhaps best demonstrated by the fact that an average 70 kg man 
will contain around 15kg of his total weight in fat, an amount sufficient to 
maintain life for around 3 months. Nevertheless fat does not function 
simply as a passive storage depot. The main storage components of 
adipose tissue are triacylglcerides (TAG), which are synthesised from fatty
acids obtained either from the liver or the dietary intake (Chapter 27, 
Zubay, 1998.), These TAG’s are rapidly mobilised by hydrolysis into non- 
esterified fatty acids (NEFA’s), and can be secreted into the circulation in 
response to a variety of lipolytic hormones, such as catecholamines. This 
release of fatty acids is nevertheless also closely coordinated with the 
carbohydrate energy available. If glucose is abundant in the blood then a 
percentage of it will enter the adipocyte, and then be converted to glucose- 
6-phosphate as in other tissues. This glucose-6-phosphate in a sense 
serves as meter to indicate whether the mobilisation of fatty acids into the 
circulation is necessary, and should levels of glucose-6-phosphate be low 
then more fatty acids are released (Chapter 27, Zubay, 1998.).
Thus the importance of glucose as an energy source is clearly illustrated in 
these three tissue types which are the main consumers of glucose, and 
indeed these tissues all play an important role in maintaining the energy 
balance of the whole body. However one other tissue plays a crucial role 
in energy, particularly glucose, homeostasis and that is the liver.
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Figure 1.1 Indirect generation of glucose from Muscle Protein 
Stores
adapted from (Chapter 27, Zubay, 1998)
1.2.4 Glucose and the liver
In common with the tissues described above, the liver has the ability also 
to utilise and store glucose. Importantly however, unlike the other tissue 
types, liver can also generate glucose de novo, which can be rapidly 
mobilised into the blood stream when required. The liver is ideally 
situated for this dual function, served by the portal vein which carries all of 
the nutrients (except fatty acids) absorbed from the intestines into the 
blood stream. In the fasted state, where few nutrients reach the liver and 
the blood glucose is hence low, a concerted action involving the liver and 
the pancreas results in secretion of glucose into the blood stream. 
Hypoglycaemia results in the stimulation of pancreatic a  cells to secrete 
the hormone glucagon. This glucagon travels through the blood stream to 
the liver, where it acts on glucagon receptors to stimulate the cAMP- 
mediated breakdown of glycogen. During hepatic glycogenolysis, the 
glycogen is broken down into glucose-1-phosphate and subsequently 
converted to glucose-6-phosphate. In the liver, unlike other tissues, this 
glucose-6-phosphate generated by glycogenolysis can be hydrolysed by a 
specific glucose-6-phosphatase, resulting in the generation of glucose. 
The presence of this hormone is central to the unique function of the liver, 
as it represents the means by which free glucose can be generated and re­
directed back into the circulation. Obviously this then lets available 
glucose be directed to the tissues which require it for their survival 
(Chapter 27, Zubay, 1998.).
As mentioned above the liver can also take glucose up from the blood 
stream when required. However this process is always secondary to the 
consumption of glucose by the main energy consumers, brain, muscle and 
adipose tissue. This is achieved by the unique properties of the variant of 
hexokinase expressed in liver cells- glucokinase. Hexokinase enzymes in 
most cell types have a high affinity for glucose, with a Km of less than 
O.lmM. These enzymes are also inhibited by accumulation of the reaction 
product, glucose-6-phosphate. The liver glucokinase, however, is unique 
in that it has a much lower affinity for glucose, with a Km of 5mM. In
other words the rate of transport of glucose varies proportionally with the 
blood glucose level over the physiological range. In contrast to the other 
main consumers of glucose, liver cells are less sensitive to the actions of 
insulin and freely permeable to glucose. Thus the liver will not consume 
glucose until the requirements of muscle and adipose have been saturated. 
Only then will it serve to ’mop-up’ the excess and convert it to glycogen 
(Chapter 27, Zubay, 1998).
1.3 Hormonal Control of glucose metabolism
Although there is a variety of hormones that will affect how glucose is 
used within the body, the main control comes from the hormones glucagon 
and insulin. As discussed above, glucagon is released from the pancreatic 
a  cells in response to low blood glucose concentrations, and in turn 
stimulates the breakdown of glucose in the liver and subsequent release 
into the blood stream. In the fed state however, when circulating glucose 
levels are high, it is necessary to promote the uptake of glucose into 
tissues. It has already been discussed above how this is mediated in the 
liver but in the other target tissues such as muscle and adipose, this process 
is stimulated by the action of the hormone insulin. High blood glucose 
stimulates the release of insulin from pancreatic p cells, and this promotes 
the uptake of glucose primarily into fat and muscle cells. Although many 
of the actions of glucagon can be partly compensated by other hormones 
such as catecholamines and cortisol, the actions of insulin are unique and 
therefore understanding the action of this hormone at the cellular level are 
very important. This is discussed in more detail below (Chapter 27, 
Zubay, 1998).
1.4 Insulin action at the cellular level
1.4.1 Glucose transporters and facultative transport
As discussed in the beginning of this chapter, a primary biological function 
of insulin is to promote glucose uptake into tissues that are dependent on it 
for survival. Although monosaccharides can enter cells via diffusion or 
active transport, these processes are generally too slow to meet the energy 
requirements of glucose utilising tissues. For this reason glucose uptake 
into tissues is mediated by a family of facilitative glucose transporters 
(Gould, 1997).
Each of these mammalian glucose transporters are similar in basic 
structure, containing twelve alpha-helical trans-membrane spanning 
domains with both the carboxy and amino termini extending into the 
cytoplasm. This folded structure generates 6 exo-facial loops, with the 
first loop being largest and containing an asparagine-linked glycosylation 
site, and five endofacial loops including a large central hydrophillic loop 
(Hunter and Garvey, 1998).
To date ten transporter isoforms have been identified and named GLUT’S 
1-10. However the product of the GLUT6 gene was found to be a pseudo­
gene soon after its discovery. Therefore no functional GLUT6 protein is 
expressed (Gould, 1997). The GLUT5 transporter isoform is unique in 
that, unlike the other transporters, it is a specific fructose transporter. 
g l u t ’s 8, 9 and 10 have only recently been discovered, and thus they are 
still being characterised and assigned to specific cellular functions (Hunter 
et a l ,  1998; Carayannopoulous et al., 2000; Doege et a l ,  2000). 
Therefore, at least five transporter isoforms exist which are able to 
selectively promote glucose uptake into specific cell types in response to 
the appropriate physiological signals. Table 1.1 below illustrates the 
kinetic properties, tissue distribution and important functions of each 
glucose transporter.
Transporter
Isoform
Tissue expression Transports Characteristics Homology 
to GLUTl
GLUTl placenta, brain, blood-tissue barrier, 
adipose, skeletal muscle, cardiac 
muscle, tissue culture cells, 
transformed cells
D-glucose
D-galactose
basal energy requirements 100%
GLUT2 liver, pancreatic beta cell, kidney 
proximal tubule, basolateral 
membranes of small intestine
D-glucose
D-fructose
high Km transporter 56%
GLUTS brain and nerve cells in rodents, 
brain, nerve, placenta humans, liver, 
heart
D-glucose
D-galactose
low Km transporter found 
in tissues metabolically- 
dependent on glucose
64%
GLUT4 adipose, skeletal muscle, cardiac 
muscle
D-glucose insulin-stimulated glucose 
transport in insulin- 
sensitive tissues
65%
GLUTS small intestine, kidney, testis, 
adipose, muscle, brain, small 
intestine, kidney (rat)
D-fructose high affinity for fiuctose 42%
GLUTS pseudogene NA NA
GLUT? Cloning artefact NA NA
GLUTS pre-pubertal testes (absent in 
testicular cancer), low amounts in 
insulin-sensitive tissues
D-glucose probably involved in 
gonadotrophin control, 
possibly involved in 
glucose transport in 
mammalian embryo’s
29%
GLUT9 spleen, leukocytes, brain D-glucose probably involved in 
tissue-specific roles
28.5%
GLUTIO 37.1%
Table 1.1 The mammalian facilitative glucose transporters
adapted from Gould, 1997; Hunter and Garvey, 1998; Carayannopoulous 
et al., 2000; Doege et al., 2000
Within insulin responsive tissues (predominantly adipose and skeletal 
muscle) GLUTl and GLUT4 are the predominantly expressed isoforms, 
each transporter performing a unique role. In the basal state almost 90% 
of GLUTl is located at the plasma membrane, where it is responsible for 
maintaining basal glucose uptake (Gould, 1997; Hunter and Garvey;
1998). Under such conditions glucose transport is the rate-limiting step for 
glucose utilisation.
In contrast, the GLUT4 isoform is located primarily intracellularly in the 
basal state. Upon insulin stimulation however vesicles containing GLUT4 
are re-distributed from this intracellular site and translocate to the plasma 
membrane where they are able to facilitate the entry of large amounts of 
glucose into the cell (Gould, 199; Holman and Kasuga, 1997). The 
precise molecular events and specific regulatory molecules involved in this 
process are still controversial. Some of the current ideas are discussed in 
Section 1.5.
Before insulin-stimulated glucose transport, and indeed any of the other 
biological effects of insulin, can occur it is necessary to activate a cascade 
of signalling proteins. These proteins are responsible for transducing the 
signal of insulin binding to its receptor to the inside of the cell. Although 
insulin is able to promote a variety of different cellular effects, many of the 
initial signalling proteins involved form part of more than one pathway. 
These early signalling steps will be discussed with regard to insulin 
signalling in general. The molecules involved in the specific processes of 
glucose transport, anti-lipolysis and the mitogenic effects of insulin in 
adipocytes will then be discussed with regard to each process.
1.4.2 Insulin Receptor
The insulin receptor is expressed relatively ubiquitously among tissues, 
although the classically insulin responsive-tissues express a much higher 
number of receptors. The receptor itself is synthesised as a single peptide
from a gene located on chromosome 19 (Gould, 1997). The individual 
‘pro-receptor’ subunits generated from this gene are cleaved and 
glycosylated, where-upon they are joined to another identical subunit by 
disulphide bonds. This results in the generation of a hetero-tetrameric 
protein consisting of two alpha and two beta subunits (Gould, 1997). This 
structure is illustrated below in Figure 1.2.
Like other growth factor receptors, the hetero-tetrameric insulin receptor 
possesses ligand-activated intrinsic tyrosine kinase activity. In other 
words, binding of an insulin molecule to the extra-facial alpha subunit 
activates the intrinsic tyrosine kinase activity within the kinase domains of 
the beta subunits (Gould, 1997; Holman and Kasuga, 1997). This kinase 
activity results initially in the rapid tyrosine auto-phosphorylation of the 
beta subunits on specific tyrosine residues located within specific 
recognition motifs (Holman and Kasuga, 1997). The importance of the 
tyrosine kinase activity of the receptor is perhaps best illustrated by studies 
involving kinase inactive (KI) mutants. Using a rat adipocyte transfection 
system, Quon et al illustrated that transfection of wild type insulin 
receptors caused an enhancement in basal GLUT4 translocation and 
glucose transport, a main biological effect of insulin in adipocytes. 
However, when a KI mutant was similarly expressed there was a lack of 
GLUT4 translocation. Therefore, the kinase activity of the receptor is 
clearly intrinsic to its biological action (Quon et a l ,  1994). With regard to 
ligand-induced tyrosine phosphorylation, it is emerging that 
phosphorylation on different tyrosine residues is important in mediating 
the different biological effects of insulin, presumably a reflection of the 
preferred interaction of down-stream effectors with differentially located 
tyrosine residues. Current studies suggest that mutation of the C-terminal 
tyrosine residues 1316 and 1322 has little effect on glucose transport, but 
shifts the dose response to the mitogenic effects (based on insulin- 
stimulated Ras activation) to the right by 5- 10 fold (Holman and Kasuga, 
1997). This is in contrast to previous studies that reported a reduced 
metabolic signalling capacity of C-terminally truncated insulin receptors. 
Indeed C-terminal truncations do show a significantly defective
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phosphorylation, but this appears less to affect the ability of the receptor to 
phosphorylate down-stream proteins, and more a reflection on ability to 
auto-phosphorylate (Holman and Kasuga, 1997). Divergence in signalling 
at the level of the insulin receptor is also evident in studies of mutations in 
the juxta-membrane region, with a tyrosine to alanine mutation at position 
960 showing differential impairment in activation of downstream 
signalling molecules involved in different processes (Chaika et al., 1999).
Alpha NHi NH, Alpha
Beta
COOH COOH
plasma
membrane
Kinase Domain ^  Kinase Domain
COOH COOH
Figure 1.2 The insulin receptor
adapted from Gould, 1997
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Therefore, we can see clearly how the kinase activity of the insulin 
receptor is very important for its function and, importantly, how the 
regulation of this kinase activity allows for selectivity and divergence at 
this level. A similar scenario is seen with other growth factor receptors, 
such as the PDGF receptor where many of the residues by which specific 
enzymes and proteins interact have been effectively mapped through 
mutation studies (Fantl et al., 1992). Nevertheless signalling through the 
insulin receptor does vary from the general model of growth factor effector 
interactions. Although activation of the insulin receptor as described 
above generates potential sites where proteins such as PI3’K or Grb2 could 
interact, these interactions are much weaker than with other growth factor 
receptors (Malarkey et al., 1995; Gould, 1997). Instead, the insulin 
receptor utilises adaptor proteins known as insulin receptor substrate (1RS) 
proteins which, as the name suggests, form a link between the 
phosphorylated insulin receptor and downstream signalling intermediates 
(Malarkey et al., 1995). This is discussed in Section 1.4.3.
Signalling through the insulin receptor is unique from other growth factor 
receptors in one other important respect. Over the last few years, the 
importance of specific cellular location in insulin action has been revealed, 
and the one important protein identified with regard to insulin receptor 
function is caveolin (Yamamoto et al., 1998). Caveolin is a major 
structural protein of caveolae, of which there are 3 sub-types, caveolins-1, 
-2 and -3. Caveolae are cell-surface invaginations, distinct from clathrin- 
coated pits, which have recently been shown to function as sub-cellular 
compartments to which specific signalling processes locate (Yamamoto et 
ah, 1998). This has been illustrated with a variety of signalling molecules 
such as the PDGF receptor and to date, the majority of interactions seem to 
be inhibitory to receptor signalling. The interaction with the insulin 
receptor, however, appears unique. Indeed Yamamoto’s group illustrated 
that through binding to the scaffolding regions of Caveolin-1 or -3 , the 
kinase activity of the insulin receptor towards downstream substrates such 
as IRS-1 is dramatically increased. This occured independently of any 
increase in auto-phosphorylation of the receptor. The precise mechanism
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of this caveolin-induced enhancement in kinase activity is unclear. The 
interaction is thought to be of functional significance and caveolin 
functions somehow to localise and enhance signalling by the insulin 
receptor. Expression of caveolin is enhanced during adipocyte 
differentiation, in common with many of the components of the insulin 
signalling pathway (Kandror, 1995, Baumann et a l,  2000), and this 
therefore supports a positive role for the protein in insulin signalling.
1.4.3 Insulin Receptor Substrates
1.4.3.1 IRS-1
IRS-1 was the first 1RS protein to be discovered. It was identified as a 
185kDa protein in phosphotyrosine immunoprecipitates from insulin- 
stimulated Fao hepatoma cells (Sun et al., 1993). This protein was 
subsequently purified and cloned from rat liver, and was found to be 
expressed in most cell and tissue types (Sun et al., 1993). With regard to 
insulin sensitive tissues, IRS-1 is expressed in a regulated manner like the 
other proteins of the insulin signalling casade. Indeed in the 3T3-L1 
adipocyte, a cell culture model of an insulin-sensitive tissue, expression of 
the insulin receptor, IRS-1 and GLUT4 are all dramatically increased 
throughout the differentiation from the fibroblast to adipocyte phenotype.
IRS-1 interacts with the insulin receptor by utilising structural motifs 
present within the 1RS protein and the insulin receptor. The pleckstrin 
homology domain (PH domain), is responsible for targetting IRS-1 to the 
membrane and the insulin receptor where IRS-1 can then interact with 
specific phosphotyrosine residues located in NPXpY motifs (Sun et al., 
1991; Sun et al., 1993; Virkamaki et al., 1999). Interaction with these 
residues occurs through association of the IRS-1 phosphotyrosine binding 
domain (PTB domain) with the NPXpY sequence in the insulin receptor. 
This then allows phosphorylation of IRS-1 on specific tyrosine residues by 
the insulin receptor. Like the insulin receptor, IRS-1 possesses many of
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these potential regulatory tyrosine phosphorylation sites which exist in 
YXXM/YMXM motifs or in hydrophobic areas. The activated insulin 
receptor phosphorylates at least 8 of these 21 residues, including residues 
608, 628, 939 and 987 (Sun et al., 1991; Sun et al., 1993). Several unique 
signalling proteins are then able to interact with specific phosphotyrosine 
residues via Src homology collagen 2 domains (SH2 domains) located 
within the proteins (Virkamaki et al., 1999). These include proteins such 
as PI3’Kinase, Src homology collagen (She), or Grb2, and these 
interactions are discussed in relation to the biological outcomes in Sections 
1.5, 1.6 and 1.7.
Since the discovery that the insulin receptor activates and utilises IRS-1 to 
activate downstream signalling processes there has been considerable 
interest regarding whether this protein has a unique function within the 
cell. Although many in vitro studies, using over-expression, micro­
injection or similar techniques, have illustrated the ability of IRS-1 to 
activate PI3’K and enhance insulin-stimulated glucose transport, there is 
question over the absolute requirement for this 1RS protein in these 
processes (White and Kahn, 1994; Whitehead et al., 2000). Perhaps the 
most conclusive evidence regarding the role of IRS-1 comes from studies 
using knockout mice. Tamemoto et al illustrated how IRS-l  ^ mice 
surprisingly exhibit only a mild insulin resistance and do not develop overt 
diabetes since the secretion of insulin increases in order to compensate for 
the reduced tissue sensitivity to the hormone. In contrast, there is marked 
growth retardation in these knockout animals (Tamemoto et al., 1994). 
This is therefore suggestive that although IRS-1 can undoubtedly mediate 
the effects of insulin to stimulate glucose transport, it is not absolutely 
necessary. This therefore initiated the search for other proteins which 
could function in a similar manner to IRS-1 and which were potential 
candidates for mediating the 1RS -1 -independent pathway in these animals
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1.4.3.2 IRS-2
IRS-2 was first identified by Tobe et al as a 190kDa tyrosine- 
phosphorylated protein in insulin-stimulated livers from ERS-l'^' mice 
(Tobe et aL, 1995). When compared to wild type mice the tyrosine 
phosphorylation of this protein was greatly enhanced in the knockouts 
compared to wild type, suggesting that activity of this protein was 
somehow up-regulated in the absence of IRS-1 (Tamemoto et aL, 1994). 
Like IRS-1, IRS-2 can also associate with PI3’K and Grb2, suggesting that 
it is also able to mediate the cellular actions of insulin (Gould 1997; 
Holman and Kasuga, 1997). Subsequent work has also revealed that IRS- 
2 is able to promote GLUT4 translocation in a manner analogous to that 
previously demonstrated for IRS-1 (Zhou et aL, 1997).
Analysis of the expression of IRS-2 has revealed that it is also ubiquitously 
expressed, messenger RNA being found in haematopoietic cells, skeletal 
muscle, lung, brain, liver, kidney, heart, spleen, and adipose tissue (Sun et 
aL, 1995). Alignment of murine IRS-2 with mouse, rat or human IRS-1 
has revealed the presence of areas of extensive homology located at the 
amino terminus- termed 1RS homology domains (IH-1 and IH-2) (Sun et 
aL, 1995). Like IRS-1, IRS-2 possesses around 20 potential tyrosine 
phosphorylation motifs which are generally located in similar positions 
(Sun et aL, 1997), This therefore suggests that IRS-1 and IRS-2 are able 
to bind the same downstream SH2 domain containing proteins and that 
there may be some redundancy in function. Interestingly however IRS-2 
does have some unique sites, suggesting also that there are some 
differences in how these proteins interact with the insulin receptor and in 
their ability to activate unique down-stream processes specifically (Sun et 
aL, 1997). 1RS-2" "^ knockout mice have also been generated, and 
chai’acterisation of these animals has revealed a striking phenotype. From 
an early age (around 3 weeks) these animals displayed fasting 
hyperglycaemia which develops into marked glucose intolerance and 
eventually overt diabetes as the animals reach maturity. Male mice 
showed polydypsia, polyuria, ketosis and generally died from dehydration
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and hyperosmolar coma (Withers et al., 1998). Female mice also showed 
a similar disease progression but rarely died. The 1RS-2  ^ knockout mice 
displayed insulin resistance, with higher fasting insulin levels and higher 
insulin concentrations required to stimulate adequate glucose disposal. 
PI3’K stimulation in the 1RS-2" '^ knockout mice was also altered, reflecting 
the importance of IRS-2 in activation of this protein (Withers et al., 1998). 
Although there are similar changes in the IRS-1 knockout mice this is 
largely compensated by the pancreas, where the tissue mass is markedly 
elevated in order to produce more insulin. In the 1RS-2'^’ knockout mice 
however the pancreas is actually reduced in size, and hence there are no 
adequate compensatory mechanisms to overcome the reduced tissue 
sensitivity to insulin (Withers et ah, 1998).
Thus, it appears that both IRS-1 and IRS-2 are involved in mediating the 
biological effects of insulin and undoubtedly there is considerable overlap 
in action. Nevertheless, it is apparent from the knockout studies that there 
are certain functions which one or other protein is able to perform more 
effectively.
1.4.3.3 Additional regulation in IRS-1 and IRS-2 function
It has recently emerged that, although the tyrosine phosphorylation steps 
described above are central to 1RS function, the proteins are also regulated 
in other ways. Indeed, it appears that serine phosphorylation also 
represents an important means of controlling 1RS action in cells. Much of 
this work has focused on IRS-1 and several studies have now illustrated 
mechanisms of serine phosphorylation of this protein. Putative serine 
kinases involved include PKC’s, or MAPK which is able to phosphorylate 
IRS-1 on serine 612. Indeed DeFea et al have demonstrated that 
endothelin-1 is able to phosphorylate IRS-1 in a MAPK-dependent manner 
(DeFea et al., 1997). Interestingly PDGF is also able to stimulate the 
serine phosphorylation of IRS-1. It does this through a rapamycin- 
sensitive pathway, phosphorylating serines 632, 662 and 731. This
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therefore implicates the involvement of proteins such as mTOR. (Li et ah, 
1999). PKB and PKC have also been suggested as potential candidates in 
this role (Li et aL, 1999). In all of these cases, the serine phosphorylation 
inhibited IRS-1 action and therefore functioned in a negative regulatory 
manner. Paz et al also observed lRS-1 phosphorylation and showed this to 
be PKB-dependent (Paz et aL, 1999). In contrast however, they concluded 
that the PKB-mediated phosphorylation was protective to IRS-1 in that it 
prevented the action of protein tyrosine phosphatases on the 
phosphotyrosine residues, thereby maintaining IRS-1 in the active state for 
longer. They conclude that the negative regulation must be mediated by 
some serine kinase other than PKB. This protective role of PKB is unique 
so far. Normally serine phosphorylation is associated with reduced 
signalling through IRS-1 and the development of insulin resistance (Paz et 
aL, 1999). Indeed, tumour necrosis factor alpha (TNFa) is reported to 
cause serine phosphorylation of IRS-1 by unknown mechanisms, resulting 
in the development of cellular insulin resistance (Wang et aL, 1998).
A second mechanism thought to be involved in the development of insulin 
resistance and important for normal 1RS function is the correct 
compartmentalisation of signalling through the IR and 1RS proteins. 
Recent work by Clark et al has illustrated that the 1RS proteins appear to 
associate with a cytoskeletal fraction that is insoluble in non-ionic 
detergents and associates with the particulate fraction of cell membranes 
(Clark et aL, 2000). This complex is believed to perform a unique 
function in that it allows the 1RS proteins to interact with the IR and also 
provides a location for 1RS interaction with downstream target molecules. 
Subsequent release of 1RS proteins from this scaffold occurs after insulin 
stimulation. Interestingly, release from this platform is also associated 
with development of insulin resistance, the 1RS proteins failing to interact 
with or being abnormally released from the scaffold, hence preventing the 
normal interactions (Clark et aL, 2000).
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1.4.3.4 IRS-3
Although IRS-3 is rapidly tyrosine-phosphorylated in response to insulin 
in rat adipocytes, unlike IRS-1 and 1RS-2 it does not bind PI3’K to any 
significant extent (Anai et aL, 1998). Structurally 1RS-3 is much smaller 
than the other 1RS proteins (60kDa versus 165-180kDa), although it does 
also possess a PH and PTB domain that are very highly conserved among 
the proteins (Anai et aL, 1998). Additionally, many phosphotyrosine 
motifs through which the SH2 domains of proteins such as PI3’K bind are 
conserved. Interestingly, however, there are regions present within IRS-3 
which show no sequence homology with any area present in IRS-1 or IRS- 
2 (Anai et aL, 1998). Perhaps the most striking data regarding the role of 
IRS-3 in insulin stimulated glucose transport comes from studies in IRS-3 
knockout mice (Liu et aL, 1999). Data generated from this study 
indicates that these animals have a normal pattern of growth and normal 
insulin sensitivity (normal fasting glucose and insulin levels, and no 
alteration in adipocyte glucose transport in response to insulin). The 
importance of sub-cellular localisation in IRS-1 and IRS-2 action was 
discussed above. Interestingly it seems that IRS-3 is located in a different 
intracellular compartment from IRS-1 and -2  (Anai et aL, 1998). Indeed, 
Anai et al illustrated that most of IRS-3 is located in the plasma membrane 
(PM) fraction, in contrast to the majority of IRS-1 and IRS-2 residing 
within the low density membrane (LDM) fraction. It therefore appears 
that IRS-3 is not one of the major players mediating the metabolic actions 
of insulin and further work to characterise the proteins with which it 
interacts will ultimately reveal the cellular consequences of activation of 
this unique protein.
1.4.3.5 IRS-4
Although IRS-4 is of similar size to IRS-1 and IRS-2 and shares some 
structural similarities, it is unlikely to play a role in the metabolic actions 
of insulin. 1RS-3 was originally identified in haematopoetic cells where it
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was discovered to have a role in insulin-like growth factor 1 (IGF-1), 
interleukin-4 and insulin-induced cell proliferation (Fantin et aL, 1999; Qu 
et aL, 1999). Recent studies have suggested that transfection of this 
protein into rat adipose cells can cause translocation of GLUT4, but a 
physiological role for such a function has not been demonstrated (Zhou et 
aL, 1999). Like 1RS-3, knocking out 1RS-4 leads to mild impairments in 
growth, reproduction and glucose homeostasis (Fantin et aL, 2000), 
suggesting that role for IRS-4 in these processes is likely to be minimal.
1.4.4 Phosphatidy linositide-3 ’ kinase
The first observations of insulin-induced PI3’K activity were in the 1990’s 
when two independent groups observed enhanced PI3’K activity in 
phosphotyrosine immunoprecipitates from insulin treated cells (Endemann 
et aL, 1990). This enhanced activity was originally thought to be through 
an interaction within the IR. However it was subsequently revealed that 
this only accounted for a small proportion of the activity (Endemann et aL, 
1990; Malarkey et aL, 1995). Indeed most of the enhanced activity was 
actually revealed to be a result of interaction with the 1RS proteins 
(Malarkey et aL, 1995; Gould, 1997; Holman and Kasuga, 1997; 
Whitehead et aL, 2000).
The first characterised mammalian PI3’K was found to be a heterodimer, 
which consisted of an 85kDa regulatory subunit and a llOkDa catalytic 
subunit (Shepherd et aL, 1996, 1997a,b, 1998). From this a model of 
PI3’K action was developed, involving PI3’K interaction with 
phosphotyrosine residues on growth factor receptors (or other proteins 
such as the 1RS proteins) through the SH2 domains present on the p85 
regulatory subunit. This in turn activates the catalytic activity of the p i 10 
subunit. As the name suggests this catalytic activity is directed towards 
phosphorylation of the 3 position of the inositol ring of phosphoinositides, 
resulting in the generation of the phosphatidylinositol phosphates PIP, PIP2 
and PIP3 (Shepherd et aL, 1996, 1997a,b, 1998). Because of the emerging
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importance of PI3’Ks in mediating the cellular effects of insulin, work 
focused on characterising these enzymes more fully. Subsequently, it was 
revealed that the original p85-pllO  complex was part of a larger group of 
enzymes, comprising several different regulatory and catalytic subunits. 
The enzyme catalytic subunits can be grouped into 3 classes- class 1 which 
is subdivided into class la  and classlb, class 2 and class 3 (Shepherd et aL, 
1996, 1997a,b, 1998).
Class 3 P B ’K ’s are unique in that that they only possess catalytic activity 
against PI and none of the other phosphoinositides. It is not considered 
that these kinases play a role in mediating the metabolic actions of insulin 
since insulin does not increase the cellular levels of PI3P, the product of 
this enzyme (Shepherd et aL, 1996, 1997a,b,1998).
Similarly, it is not thought that Class 2 P B ’K's are involved in mediating 
the effects of insulin. This is based on the fact that, although insulin- 
mediated responses are sensitive to the effects of inhibitors such as 
wortmannin, this class of enzyme are relatively resistant to these effects 
(Shepherd fl/., 1996, 1997a,b,1998).
The class la  and class lb  P B ’K ’s are differentially activated, the la  
enzymes being activated by binding to the p85 regulatory subunit and lb  
as a result of interactions with G-protein Py sub-units. The class la  and lb  
catalytic subunits share a significant sequence homology. The class Ic 
subunits are activated in a similar manner to the la  enzymes, although by 
different regulatory subunits (Shepherd et aL, 1996, 1997a,b,1998). The 
domain structures of each of the kinase subunits are illustrated below in 
Figure 1.3.
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Figure 1.3 The domain structure of the PI3’K catalytic subunits
adapted from Shepherd et al 1996, 1997a,b ,1998.
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As outlined in Figure 1.3, the class la  P B ’K ’s possess a p85 binding 
domain. As discussed earlier, this allows the interaction of the p i 10 
catalytic subunits with the regulatory isoforms linking them to activated 
receptors or 1RS proteins. Although the p85 regulatory subunit is the most 
well-characterised regulatory subunit, there are actually five such proteins 
p85a, p55a, p50a, p85p and p55y (Shepherd eî aL, 1996, 1997a,b,1998). 
There are at least three splice variants of the p85a subunit and these all 
share considerable structural homology with the p85p subunits. This 
includes the presence of two SH2 domains located at the N- and C-termini, 
an SH3 domain, a Bcr/Rac GTPase-activating protein (GAP) homology 
domain (BH domain) and two proline-rich domains either side of the BH 
domain (PI and P2 domains) (Shepherd et aL, 1996, 1997a,b,1998). 
Although the two SH2 domains both have a high specificity for 
phosphorylated YXXM and YMXM motifs not shared by SH2 domains 
from other proteins, there is a slight variance in exact sequence preference 
of the two different SH2 domains. The relevance of this has not, however, 
been addressed. The in vivo roles of the other domains are also less well 
defined, although it is known that SH3 domains and proline-rich regions 
will interact. This is suggestive of an involvement of these two areas in an 
auto-regulatory mechanism (Shepherd et aL, 1996, 1997a,b,1998). The 
p55 isoforms also possess SH2 domains, but lack the SH3, P I and BH 
domains. p55a, also known as AS53, is expressed in brain and muscle 
and is therefore unlikely to contribute to the actions of insulin in adipose 
tissue. p50a is also unlikely to contribute to insulin action in adipocytes 
as like p55a is not expressed in fat, although it is expressed in brain, liver, 
muscle and kidney. p55y, also known as p55^^^, has a similar domain 
structure to p55a (Shepherd et aL, 1996, 1997a,b,1998). Little is known 
about the expression of this isoform.
The significance of the many different catalytic and regulatory P B ’K 
subunits is unclear and some studies suggest that there may be functional 
redundancy at some levels. Further characterisation of the different 
isoform combinations may reveal specific functions and determine the
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importance of factors such as cell specific expression. Nevertheless the 
importance of class la  PIS’K ’s in insulin action cannot be ignored, and 
this is discussed in more detail in sections 1.5, 1.6 and 1.7.
1.4.5 Other Protein Kinases
1.4.5.1 PKB
PKB (also known as c-akt, RAC-PK) was originally identified due to it's 
homology with the viral oncogene product v-akt. Currently three isoforms 
are known to exist- a , P and y (Walker et aL, 1998). Early work, mainly 
non-isoform specific or concentrating on PKB a, revealed that insulin can 
produce up to 10 fold elevations in PKB activity in both 3T3-L1 and rat 
adipocytes (Cross et aL, 1997; Walker et aL, 1998). Initial characterisation 
studies revealed this protein to be downstream of PI3’K in the signalling 
cascade (Bos, 1995), since its activity was abolished by PI3’K inhibitors 
such as wortmannin or by over-expression of dominant negative forms of 
PI3’K (Bos, 1995). Subsequently a mechanism of PKB activation was 
proposed which was dependent on PI3’K at two levels, and this model is 
now widely accepted. The importance of PI3’K activation is at the level of 
compartmentalisation. In other words, the polyphosphoinostide products are 
responsible for recruiting PKB to a specific cellular location, via an 
interaction with the PH domain of PKB (Bos, 1995; Cross et aL, 1997; 
Wijkander et aL, 1997; Walker et aL, 1998). Once in the correct location 
the enzyme is activated by phosphorylation on specific serine and threonine 
residues. This phosphorylation is carried out by a class of PI3’K -  
dependent enzymes called the phosphoinositide-dependent kinases (PDK’s). 
PK B a is phosphorylated on serine 303 and threonine 473, and PKB(3 is 
phosphorylated on serine 304 and threonine 474 by PDKl (Cross et aL, 
1997; Wijkander et aL, 1997; Walker et aL, 1998). Therefore the PI3’K - 
induced activation of PKB is a two-step process- involving subcellular 
relocalisation and specific phosphorylation events.
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Unlike P D ’K however, a direct role for PKB in insulin-stimulated GLUT4 
translocation has been less easy to demonstrate. Many of the early studies 
produced inconclusive results. Some groups have highlighted the ability of 
over-expressed or constitutively active PKB to promote GLUT4 
translocation (Cong et al., 1997; Tanti et al., 1997; Foran et al., 1999; Hill 
et al., 1999), however other groups have failed to demonstrate such an effect 
(Kitamura et al., 1998). Perhaps one of the most useful studies so far in 
this regard is an extensive study and review of the different PKB isoforms, 
and their potential roles in insulin action (Hill et al., 1999). By using a 
micro-injection based technique they showed that a PKB substrate peptide 
or antibody was able to inhibit insulin-stimulated GLUT4 translocation by 
approximately 60% (Hill et al., 1999). This agrees with some previous 
work to a certain extent, for example Cong et al demonstrated a 20% 
reduction in insulin-stimulated GLUT4 translocation using a kinase inactive 
PKBa, K179A (Cong et al., 1997). In contrast however Hadjuch et al saw 
no such effects similar effects of this peptide in L6 myotubes (Hadjuch et 
al., 1997). Interestingly, Hill et al suggest that much of this controversy 
may lie simply in the way in which these experiments are performed and 
interpreted. Indeed, they suggest that much may be resolved by studying the 
specific PKB isoforms individually, bearing in mind which are 
predominantly expressed in the tissue under question, and how specific the 
reagents in use are. Although much of the preliminary work suggested that 
PK B a is the primary isoform expressed in 3T3-L1 adipocytes, it is 
emerging that in fact PKBP is the most abundant form in these cells. 
Although PK B a was the predominant form expressed in fibroblasts, there 
was a change over to PKBP as adipogenesis proceeded (Hill et al., 1999). 
Indeed the enhanced expression of PKBP occurred in a manner parallel to 
the enhanced expression of GLUT4 (Hill et al., 1999). They therefore 
conclude that PK B a is more likely to involved with the growth capacity of 
fibroblasts, whereas PKBp has a role in mediating the metabolic effects of 
insulin in mature differentiated cells. This is reinforced by the observations 
that there are high levels of PKBP mRNA in brown adipose tissue and that 
expression is increased as two different muscle cell lines (Sol8 and C2C12)
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undergo differentiation (Hill et al., 1999). Further evidence for the apparent 
differing roles of the PKB isoforms comes from studies using PDGF. 
PDGF is unable to activate many of the biological responses activated by 
insulin and, indeed, PDGF is also unable to significantly stimulate PKBp, 
even though it is able to influence the activity of PK B a in non-differentiated 
cells (Hill et al., 1999).
Although the rationale presented above is very convincing regarding the role 
of PKB in adipocytes there are certain caveats. With regard to PKBa, 
credible demonstrations of increased activity in response to insulin have 
been demonstrated in both rat and 3T3-L1 adipocytes (Cross et al., 1997, 
Walker et al., 1998). Clearly this contradicts Hill and colleagues work. 
Nevertheless they raise an interesting point in response. Indeed, they 
suggest that much of the response detected by PK B a antibodies may 
represent other PKB isoforms, since there is demonstrable cross-reactivity 
(Hill et al., 1999). The fact that PKBp appears to play more of a role may 
also explain why some groups such as Kitamura et al have demonstrated 
little effect of PK B a mutants on glucose transport (Kitamura et al., 1998), 
since they are possibly concentrating their studies on the wrong isoform.
Therefore, it seems that although the evidence regarding a role for PKB in 
insulin-stimulated GLUT4 translocation is less than ideal, it is likely that the 
PKBp isoform does play a role in this process. Undoubtedly however other 
proteins are of important in light of the fact that the process is not 
completely inhibited by PKBp inhibition.
Although PKBy can be activated by the PDK enzymes in the same manner 
as the others and has a similar catalytic activity, this protein is not detectable 
in adipocytes or skeletal muscle in vivo. Indeed the main role of this protein 
in insulin-sensitive responses appears to be in the stimulation of glucose 
transport in L6 myotubes (Walker et a l ,  1998; Hill et al., 1999).
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PKB also appears to have a role in mediating some of the other effects of 
insulin. PKB mutated at the specific activating phosphorylation sites (Akt- 
AA), can effectively inhibit insulin-stimulated activation of p70s6kinase by 
around 30% (Kitamura et aL, 1998). Obviously this level of inhibition 
suggests that although PKB is involved in this process, there are probably 
other pathways and intermediates which are involved in this process. The 
role of PKB in mediating the anti-lipolytic actions of insulin is also 
emerging. This is discussed in Section 1.3.
1.4.5.2 PKC
Although a decisive role for Protein Kinase C (PKC) in insulin-stimulated 
glucose transport is still under debate, a wealth of evidence indicates that 
atypical PKC isoforms are able to induce GLUT4 translocation and do so 
in response to insulin (Standaert et aL, 1997; Standaert et al., 1998; 
Standaert et al., 1999). There are many PKC isoforms expressed in 
mammalian tissues and these are broadly grouped into three classes, the 
classical diacylglycerol (DAG)-sensitive isoforms (PKCa and PKCP), the 
novel PKC’s (PKC6 and PKCe), and the DAG-insensitive and 
polyphosphoinositide-sensitive PKC i, Ç and X (Standaert et al., 1997; 
Standaert et al., 1998; Bandyopadhyay et al., 1999; Standaert et al., 
1999).
Both PKC Ç and X are reported to be activated by insulin in several tissues 
including 3T3-L1 adipocytes, rat adipocytes and L6 myotubes. 
Bandyopadhyay and colleagues convincingly illustrated the involvement 
of both of these isoforms in insulin-stimulated GLUT4 translocation, using 
wild type and kinase inactive (KI) mutants and examining the ability of 
these proteins to stimulate translocation of tagged-GLUT4 
(Bandyopadhyay et a l ,  1999). In cells transfected with either KI PKC Ç 
or X, there was a consistent inhibition of insulin-stimulated movement of 
tagged GLUT4. Interestingly both of these peptides were without effect
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on basal or GTPyS-stimulated (insulin-independent) GLUT4 translocation. 
The role of PKCÇ in insulin-stimulated GLUT4 translocation is further 
reinforced by studies demonstrating the ability of wild type PKCÇ to 
enhance insulin-stimulated GLUT4 translocation. Standaert and 
colleagues have taken this a step further and have illustrated how insulin is 
able to influence the phosphorylation state of PKCÇ and the catalytic 
activity of the enzyme (Standaert et al., 1997). Because the enhanced 
phosphorylation could be inhibited by the PKC-pseudosubstrate (PKC-ps), 
it was concluded that this was likely to be an auto-phosphorylation step. 
The effect of insulin was demonstrated also to be PI3’K-dependent, by 
virtue of the fact that the effects of PIP3 and insulin were non-additive 
(Standaert et al., 1997).
In contrast however to the effects of the atypical PKC’s, PKCa, p, Ô, or 8 
appear not to be involved in GLUT4 translocation. Indeed 
Bandyopadhyay demonstrated a lack of effect of KI PKCa, P, 5, or 8 on 
insulin-stimulated glucose translocation. This is reinforced by Standaert 
and colleagues work where they indicate a lack of effect of either PKCa, 
p l , p2 , Ô, or 8 depletion or conventional PKC inhibitors on insulin- 
stimulated GLUT4 translocation (Bandyopadhyay et al., 1999). 
Nevertheless some studies have contradicted this, and there is some 
evidence that DAG-sensitive PKC’s may also be involved in mediating the 
effects of insulin (Bandyopadhyay et al., 1999). Activation is believed to 
be through PI3’K-activated PLD mediated generation of phosphatidic acid 
(PA) and DAG (Bandyopadhyay et al., 1999). There is uncertainty 
regarding the mechanism by which PI3’K can activate PKB, although 
PDKl has been suggested as the link. Certainly PD K l is able to 
phosphorylate threonine 410 on PKCÇ, although it is unclear whether this 
operates as a functional mechanism of activating the DAG-sensitive 
PKC’s (Bandyopadhyay et al., 1999).
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1.4,6 Other putative signalling molecules involved in metabolic 
signalling by insulin
Although the majority of players in the insulin-signalling field have been 
discussed in the previous sections, there are a few other less well 
charactensed molecules that require mentioning.
1.4.6.1 Fyn/Cbl/CAP complex
Fyn is a cytoplasmic tyrosine kinase, which can be activated either by 
association with other phosphotyrosine proteins through its SH2 domain, 
or by dephosphorylation of the carboxy terminal tyrosine (Vikramaki et 
al., 1999). Although the IR does not activate this protein, it can be 
activated by IRS-1 or another tyrosine phosphorylated protein Cbl. Fyn 
activated by binding to Cbl will then translocate to caveolae where it is 
able to cause phosphorylation of caveolin (Baumann et al., 2000). The 
ability of insulin to cause caveolin phosphorylation is unique and 
stimulation of other growth factor receptors does not have a similar effect 
(Vikramaki et al., 1999; Pessin et al., 2000).
Cbl is also able to associate with another caveolin-associated protein CAP, 
a protein which is specifically expressed in insulin-sensitive cells 
(Vikramaki et al., 1999; Pessin et al., 2000, Baumann et a l ,  2000). 
Current lines of evidence suggest that this pathway may represent an 
alternative means of insulin-stimulated GLUT4 translocation, as illustrated 
below in Figure 1.4.
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Figure 1.4 Other signalling molecules potentially involved in the 
steps leading to insulin-stimulated glucose transport
adapted from Vikramaki et al., 1999; Pessin et at., 2000
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1.4.6.2 Csk
Csk is a cytoplasmic tyrosine kinase, responsible for the inactivation of the 
src family of kinases (Vikramaki et a l ,  1999; Pessin et a l ,  2000). This 
protein is also reported to associate with 1RS-1 through its SH2 domain 
(Vikramaki et al., 1999). This interaction promotes dephosphorylation of 
Focal Adhesion Kinase (FAK) in an insulin-dependent manner. This is 
believed to form part of the pathway involved in the insulin-induced 
rearrangement of cytoskeletal elements, now widely accepted to be an 
intrinsic part of insulin-mediated signalling pathways (Vikramaki et al., 
1999).
1.4.6.3 SHIP
This protein is a 145kDa SH2-containing inositol 5-phosphatase, involved 
in the conversion of PIP4 and PIP3 to PIP2 (Vikramaki et al., 1999). 
Although conclusive evidence regarding the role of SHIP remains elusive, 
over-expression studies have illustrated that this protein will inhibit 
insulin-induced glucose transport and DNA-synthesis (Vikramaki et al.,
1999). It is unclear whether SHIP can associate with the IR or 1RS 
proteins but it is known to possess a structure that consists of the following 
structure-
N SH2 phosphatase NPXYNPXY proline rich domain C
Aside from presenting a potential new target in studies of insulin action, 
using SHIP reveals information regarding PI3’K signalling in that it 
appears insulin-sensitive processes prefer PIP3 over PIP2, since SHIP 
reduces efficiency of signalling (Vikramaki et al., 1999).
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1.5 Signalling and trafficking steps leading to insulin-stimulated 
glucose transport
Although there is controversy regarding exactly how PI3’K stimulation 
leads to the movement of GLUT4 from its intracellular store to the plasma 
membrane and whether other signalling factors are involved, there is little 
doubt that PI3’K does play a crucial role (Gould, 1997; Holman and 
Kasuga., 1997). Studies using inhibitors such as wortmannin, or dominant 
negative mutant p85 subunits, clearly inhibit insulin-stimulated GLUT4 
translocation and glucose transport (Gould, 1997; Holman and Kasuga,
1997). There is also considerable documentation regarding the ability of 
P B ’K ’s to influence vesicular transport. In yeast cells, the gene product 
Vps34p is a PI3’K homologue, required for sorting of newly synthesised 
proteins from the Golgi to the yeast vacuole (Corvera and Czech., 1998). 
Since many functions are conserved between yeast and mammalian cells 
this is suggestive of a similar role for PI3K’s in mammalian cells. Another 
line of evidence in support of a role for PI3’K in membrane transport is 
from studies using the PI3'K inhibitor wortmannin. Treatment of 
mammalian cells with wortmannin generates a rapid and striking alteration 
in the morphology of endosomes, with the appearance of tubular structures 
which in some cases form an inter-connected network with enlarged 
perinuclear endosomes (Corvera and Czech., 1998).
Shortly after the discovery of GLUT4, and the realisation that insulin 
administration to adipocytes caused a translocation of this protein from 
intracellular stores to the plasma membrane, the search for molecules 
involved in regulating this process began. It soon emerged that this 
movement of GLUT4-containing vesicles utilised a pathway analogous to 
that of regulated trafficking in neuro-endocrine and yeast cells (Corvera 
and Czech., 1998). Although GLUT4 appears to travel in part through the 
normal endosomal recycling system in order to move from an intracellular 
area to the plasma membrane, the majority is packaged into discrete 
GLUT4 storage vesicles (GSVs) (Corvera and Czech., 1998; Hashimoto 
and James., 1998). Thus in order to understand the molecules and
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processes regulating GLUT4 trafficking to and from the plasma membrane 
in insulin sensitive cells, it is necessary to consider membrane transport at 
the most basic level.
Many in vivo studies have illustrated that multiple fusion events can occur 
between individual components of the endosomal system, and isolated 
endosomes have also been observed to fuse in vitro (Hashimoto and 
James., 1998). To date however, the specific pathways from the early to 
late endosome are poorly understood. Nevertheless work has focused on 
trying to understand these processes and the mechanisms by which they 
are regulated, and consequently two models have been proposed. The first 
model is the ‘Vesicular Transport ModeT which works on the basis that 
the early and late endosomes are pre-formed entities and that proteins 
move between them via vesicular traffic (Hashimoto and James., 1998). 
The second model, the ‘Maturation Model’, is more fluid and transport 
through the endosomal system involves continuous fusion and fission of 
vesicles (Hashimoto and James., 1998). Nevertheless, regardless which of 
these models is closest to the actual situation, they both have one very 
crucial factor in common. In order for correct fusion events to occur at the 
correct time, these fusion events must be very specific. Like all specific 
interactions this relies on the presence of receptor-ligand mediated 
interactions. Within the recycling endosomal system, this interaction 
specificity is brought about by the SNARE proteins (Hashimoto and 
James., 1998).
1.5.1 The ‘SNARE’ hypothesis
The central dogma of the ‘SNARE hypothesis’ is essentially very simple 
and relies on the specific interactions between v-SNARE proteins on the 
vesicle membrane and t-SNARES on target membranes (Hashimoto and 
James., 1998). This specific interaction is believed to then act as a 
platform for the interaction with other proteins necessary for vesicle 
docking and fusion. This mainly involves the interaction with n-
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ethylenemaleimide-sensitive factors (NSF’s) and soluble NSF attachment 
proteins (SNAP’s) (Hashimoto et a l, 1998).
Although the majority of these proteins were not originally identified with 
respect to GLUT4 translocation it is emerging that many of these proteins 
or homologues are actually involved in this process. Some of these are 
discussed below.
1.5.1.1 t-SNARE’s
Two of the most important t-SNARE’s found in neuronal cells are 
Syntaxin la  and SNAP25 (Hashimoto and James., 1998). They are 
expressed on the pre-synaptic plasma membrane and bind to the v-SNARE 
VAMP (vesicle attachment membrane protein) present on vesicle 
membranes (Hashimoto and James., 1998). Although neither of these are 
expressed in insulin-sensitive cells, adipocytes do express two related t- 
SNARE’s- Syntaxin 4 and SNAP23 (Hashimoto and James., 1998). Both 
SNAP23 and Syntaxin 4 are also able to bind VAMP molecules present on 
the vesicle membrane (Hashimoto and James., 1998). Both syntaxin 4 and 
SNAP23 both appear essential for GLUT4 translocation since inhibition of 
their action using either antibodies or recombinant proteins inhibits 
GLUT4 translocation (Hashimoto and James., 1998).
1.5.1.2 v-SNARE’s
Two main v-SNARE’s have been identified in insulin-sensitive cells, 
VAMP2 (synaptobrevin) and cellubrevin (Hashimoto and James., 1998). 
Both of these proteins have been found to co-localise with vesicles found 
to be positive for GLUT4 (Hashimoto and James., 1998), and information 
about their function in this regard had been found with the use of toxins 
which are able to modify these v-SNARE’s. Two clostridial toxins, 
botulinum and tetanus, are able to selectively cleave VAMP2 and
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cellubrevin at specific sites rendering them non-functional. Results from 
these studies indicate that both botulinum and tetanus toxin are able to 
inhibit GLUT4 translocation in permeabilised cells (Hashimoto and 
James., 1998), indicating that both VAMP2 and cellubrevin have a role in 
this process. More specific studies, involving the use of inhibitors which 
affect only one of these v-SNARE’s, have yielded more useful information 
regarding the relative contribution of each protein. Treatment of cells with 
an IgA protease which cleaves VAMP2 but has no effect on cellubrevin 
blocks the majority of insulin-stimulated GLUT4 translocation (Hashimoto 
and James., 1998), indicating that VAMP2 has a major role in this process. 
Further work has confirmed this, with immuno-electron microscopy of rat 
adipocytes indicating that a large fraction of VAMP2 is targetted to the 
GLUT4 storage compartment (Martin et a l, 1996, Hashimoto and James., 
1998). In contrast, the majority of the cellubrevin is observed to localise 
to endosomal structures (Hashimoto and James., 1998). Work using 
synthetic peptides with a unique VAMP2 sequence has also revealed that, 
although expression of this protein blocks GLUT4 exocytosis, it has little 
effect on constitutive GLUTl trafficking in permeabilised adipocytes 
(Martin et a l, 1998). This has led to the conclusion that VAMP2 and 
cellubrevin possess different functions, with VAMP2 involved in the 
docking and fusion steps of GLUT4 regulated exocytosis whereas 
cellubrevin is primarily involved in constitutive endosomal recycling 
(M iW axetal, 1999).
One other v-SNARE, involved in synaptic vesicle exocytosis in neurons, is 
synaptotagmin (Hashimoto and James., 1998). Activation of this protein is 
triggered by a rise in intracellular calcium, and is thought to confer the 
calcium dependency of certain SNARE interactions in neurons (Hashimoto 
and James., 1998). There is controversy over whether calcium is involved 
in GLUT4 translocation, so a role for this protein in GLUT4 exocytosis is 
only speculative. Nevertheless other isoforms exist, and it is feasible that 
they may be regulated in a different way to the calcium-dependent 
isoform(s) (Hashimoto and James., 1998).
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1.5.2 Specific movement of GLUT4 from intracellular stores to the 
plasma membrane
The information presented above clearly illustrates how there are 
multitudes of proteins involved in the recycling of proteins to and from the 
plasma membrane in manamalian cells. Undoubtedly GLUT4 recycles 
through this system like many other cellular proteins. Interestingly, 
however, the exocytic rate of GLUT4 is much less than that of other 
recycling proteins, suggesting that GLUT4 must somehow be sequestered 
away from the normal recycling system (Gould, 1997; Hashimoto and 
James., 1998). Also, in response to insulin, there is a rapid increase in the 
content of GLUT4 and several other specific proteins at the plasma 
membrane (Gould, 1997). This again suggests that these proteins must 
somehow be removed from the normal recycling system to some other 
pool to allow an increased movement to a specific cellular compartment 
when required. There are currently two different models proposed to 
explain how this unique sorting of GLUT4 is achieved (Hashimoto and 
James., 1998). This is illustrated below in Figure 1.5.
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Figure 1.5 Proposed models for GLÜT4 exocytosis
adapted from Hashimoto Hashimoto and James., 1998
see page 37 for explanantory notes
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(I) In both of the models, GLUT4 is sequestered within in the cell 
away from the plasma membrane by an efficient internalisation process.
(II) The rate of GLUT4 recycling is low under these conditions, when 
compared to other recycling proteins.
(Ilia) The vesicle sorting model then works on the assumption that 
GLUT4 is sequestered into a unique population of vesicles away from the 
recycling pathway. These vesicles are then assumed to be highly enriched 
in GLUT4 with a good responsiveness to insulin (Hashimoto and James.,
1998). Insulin stimulation will cause an increased flux through both this 
pathway and the recycling pathway, resulting in a dramatic increase in the 
amount of GLUT4 at the cell surface (Hashimoto and James., 1998).
(Illb) In contrast the protein sorting model is based on differential 
affinity for different sorting proteins being responsible for the movement 
of proteins to specific micro-domains within the tubulo-vesicular network 
(Hashimoto and James., 1998). Insulin may act simply to alter the 
formation of different network connections, resulting in propagation of 
GLUT4 and other molecules to the plasma membrane.
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Current lines of evidence suggest the former model to be more realistic, 
and a wealth of data supports the notion of specific compartments of 
vesicles highly enriched in GLUT4 (the GSVs- discussed in Section 1.5). 
This population of vesicles is highly sensitive to insulin, and will account 
for a large percentage of GLUT4 that translocates to the plasma membrane 
in response acute insulin stimulation.
Nevertheless although insulin-stimulated GLUT4 translocation and 
stimulation of glucose transport are an essential action of insulin, they are 
not the only important biological effect of the hormone.
1.6 Anti-Upolytic effects of insulin
As discussed in Section 1.2.3, a main action of insulin is in the control of 
fat metabolism in adipocytes. Insulin is an anti-lipolytic hormone, and is 
able to reverse the lipid hydrolysing effects of hormones such as 
adrenaline (Chapter 27, Zubay, 1996). Although the steps leading to anti- 
lipolysis are not as well understood as those leading to glucose transport, it 
is generally accepted that the early stages of this pathway also utilise the 
insulin receptor and the 1RS proteins (Botion and Green., 1999 Van 
Harmelen et a l,  1999; Kasuga, 2000). Interestingly it is also emerging 
that the ant-lipolytic actions of insulin are P B ’K-dependent (Botion and 
Green., 1999; Kasuga, 2000).
1.6.1 Activation of lipolysis
In general, it is believed that the lipolytic action of different hormones is 
mediated by the Protein Kinase A (PKA) and cAMP pathway (Botion and 
Green., 1999). Binding of hormone to its G-protein coupled receptor 
results in the activation of the associated G-proteins. G-proteins are
composed of three subunits- alpha, beta and gamma. It is generally
accepted that the activated alpha subunit is responsible for the activation of
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PKA, (although the beta gamma subunits which were originally thought to 
act as structural anchors are now known to also have a signalling ability 
independent of the alpha subunit). Activation of PKA results in the 
generation of cAMP, which in turn activates the hormone sensitive lipase 
(HSL). Although the precise mechanism of HSL activation is not 
completely understood, phosphorylation on specific serine residues has 
been demonstrated to be of importance (Botion and Green., 1999). Indeed 
activation involves multi-site phosphorylation, and serines 659 and 650 
have been established as activity controlling sites with respect to activation 
by PKA (Botion and Green., 1999). Serine 563 is also phosphorylated 
although this protein phosphorylation site plays a minor role. The 
importance of Serine 565 has also been recognised, although 
phosphorylation on this residue is actually thought to be inhibitory to 
subsequent phosphorylation at Serine 563 and activation by PKA (Botion 
and Green., 1999). Studies have illustrated that the phosphorylation state 
of HSL is closely linked to its activity and that the phosphorylation state is 
very important at maximal lipolysis. It is also emerging that HSL will re­
distribute within the cell in response to lipolytic stimuli- moving from the 
cytosol into the lipid droplet (Clifford et a l,  2000). Interestingly, some 
studies have suggested that control exerted by the HSL is not sufficient to 
explain the regulation of lipolysis, and some groups have suggested the 
involvement of additional control mechanisms. One such suggestion is the 
involvement of substrate activation by some interacting factor possibly 
present at the surface of the lipid droplet (Clifford et a l,  2000). 
Nevertheless, to date the HSL is the best characterised factor controlling 
the activation of lipolysis within fat cells. Once activated, HSL will 
catalyse the breakdown of triacylglycerides into the constituent glycerol 
and fatty acids, the fatty acids being exported and utilised as an energy 
source (Chapter 27, Zubay, 1998).
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1.6.2 Activation of anti-lipolysis
It has long been appreciated that insulin is able to influence the activation 
of lipolysis, presumably by an action to inhibit the activity of the HSL. 
Nevertheless only recently have some of the pathways involved began to 
emerge. These are outlined below in Figure 1.6.
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Figure 1.6 Potential mediators of the anti-lipolytic effects of insulin
adapted from Botion and Green., 1999; Van Harmelen et a l,  1999; 
Kasuga, 2000
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Insulin activates the class 3B phosphodiesterase enzyme, although it is 
only recently that the links between PKB and this enzyme have been 
appreciated (Botion and Green., 1999; Van Harmelen et al., 1999; Kasuga,
2000). As discussed in Section 1.4.5.1, PKB is rapidly activated in 
response to insulin, whereupon it is phosphorylated on specific threonine 
and serine residues (Thr308 and Ser473 in the case of PKBa). By making 
PKB mutants in which both of these residues were mutated to alanine 
residues, Kasuga et al illustrated how the normal 2-fold insulin-dependent 
activation of PDE3B was completely inhibited (Kasuga et al., 2000). This 
suggested PKB involvement in the insulin-dependent activation of 
PDE3B. In order to determine how PKB was activating PDE3B, several 
serine residues on PDE3B were mutated, and this revealed serine 273 to be 
important for insulin-induced activation. This was also nicely illustrated 
by immunoprecipitating the wild type and mutant PKB enzymes and 
determining which residues of PDE3B were being phosphorylated by 
PKB. Interestingly, further evidence for the links between PKB and 
PDE3B in mediating the anti-lipolytic effects of insulin were illustrated by 
the ability of mutant PKB to inhibit the normal effects of insulin to reduce 
cellular cAMP levels (Kasuga et al., 2000). Therefore, although we have 
seen conflicting evidence regarding a role for PKB in insulin-stimulated 
glucose transport, it is likely that PKB does play a role in at least one of 
the important actions of insulin in adipocytes, that of anti-lipolysis. With 
regard to the phosphodiesterase enzymes, there are many different 
isoforms expressed in mammalian cells, the functions of many currently 
under debate. It is therefore feasible that isoforms other than PDE3B may 
have some role to play in the anti-lipolytic effects of insulin. Finally, 
insulin has been seen to reverse the translocation of HSL to the lipid 
droplet induced by lipolytic agents (Botion et al., 1999).
All of the effects described in Sections 1.4 to 1.6 relate to the metabolic 
actions of insulin. Although these effects are undoubtedly the most 
important effects of insulin and the main focus of this thesis, it is also 
necessary to consider the other important biological effects. Perhaps the 
best understood of these effects are the growth-promoting actions.
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1.7 Mitogenic actions of insulin
Aside from the metabolic actions of insulin it is a mitogenic hormone, able 
to stimulate protein synthesis in a variety of mammalian cells, including 
fat and muscle. Some of the pathways mediating these effects are outlined 
in Figure 1.7.
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Figure 1.7 Potential pathways mediating the growth stimulatory 
actions of insulin
adapted from Malarkey et a i, 1995; Gould, 1997
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The mitogen-activated protein kinase (MAPK, also known as extracellular 
regulated kinase (ERK)) pathway was one of the earliest and best 
characterised pathways mediating the growth promoting effects of many 
different growth factors (Malarkey et a l, 1995). Most growth factor 
receptors couple to this pathway by an interaction of phosphotyrosine 
residues on the activated growth factor receptor with the SH2 domain of 
the adaptor molecule Grb2 (Malarkey et a l ,  1995). This links the 
receptor, via the nucleotide exchange factor, mammalian son of sevenless 
(mSOS, the homologue of the related protein first discovered in 
Drosophila), to the small G-protein Ras. Activated Ras then initiates the 
cascade of events outlined in Figure 1.7, culminating in the alteration of 
events at the DNA level (Malarkey et ah, 1995).
With regard to insulin, the receptor links to this pathway in a slightly 
different way from the other growth factors. The receptor links to this 
growth stimulatory pathway through the association of either 1RS proteins 
or SHPTP2 with the Grb2 adaptor protein (Malarkey et al., 1995). 
Downstream of Grb2 the insulin receptor then signals through this 
pathway in the same manner as the other growth factors. It is believed that 
MAPK-activated gene responses are involved in the early phases of 
activation of DNA synthesis in many cell types (Malarkey et al., 1995). 
This process is also known to be of importance in the insulin-induced 
increase in GLUTl expression (Gould, 1997).
However, the MAPK pathway is not the only pathway through which 
insulin is able to influence events at the DNA level. Instead many of the 
actions are mediated through PI3’K, mammalian target of rapamycin 
(mTOR) and p70 S6kinase-dependent pathways (Wang et al., 2000). 
Indeed, many different transcription factors have been identified as 
important in mediating the effects of insulin, and most of these can be 
inhibited by inhibitors of the proteins mentioned above. These include 
eukaryotic initiation factors (elF’s), 4E binding proteins, and eukaryotic 
elongation factors (eEF2) (Proud and Denton., 1996; Proud and 
Denton.,1997; Wang et al., 2000). Although there is considerable
43
complexity in the action of insulin on these translation factors, some of the 
general control mechanisms thought to operate are outlined below in 
Figure 1.8.
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Figure 1.8 Some of the important translation factors mediating the 
growth promoting effects of insulin
adapted from Proud and Denton., 1996; Proud and Denton., 1997; Wang et 
al., 2000
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Interestingly, it is now emerging that although the metabolic and 
mitogenic effects of insulin appear to utilise similar early intermediates, 
there is clearly divergence in the pathways. This is of relevance in many 
situations, not least because it allows for selective activation of the 
different pathways as required. This is not only of interest with regard to 
understanding how the different processes occur at the biochemical level, 
but also in conditions such as insulin resistance, where there are likely to 
be selective impairments in different branches of the pathways.
1.8 Insulin Sensitivity and Insulin Resistance
In view of the complexities of insulin signalling to its biological effects as 
discussed above, it is not hard to comprehend why there are a multitude of 
disorders associated with dysregulation of these processes. Indeed it was 
displayed by Himsworth as early as the 1930’s that even within a normal 
population there exists inter-individual differences in the hypoglycaemic 
response to insulin (Himsworth, 1936). In some individuals however, 
there is a marked loss of sensitivity to insulin: a phenomenon known as 
insulin resistance. In all cases of insulin resistance, there is a sub-normal 
biological response to a given dose of insulin in target tissues. This results 
in lower levels of uptake from the blood into the target tissues 
predominantly skeletal muscle and to a lesser extent adipose tissue. 
Therefore, the blood glucose levels become raised: a phenomenon known 
as hyperglycaemia. In a bid to overcome the hyperglycaemia, in the face 
of reduced tissue sensitivity to insulin, more insulin is secreted resulting 
also in a characteristic hyperinsulinaemia. In the majority of pre- or early- 
phase diabetics, this elevated secretion of insulin is enough to overcome 
the tissue insensitivity and patients can exist in a hyperinsulinaemic but 
euglycaemic state. Eventually, however, the hyperinsulinaemic response 
may become inadequate (due to pancreatic p cell dysfunction) to overcome 
the deficit and these subjects become both hyperinsulinaemic and 
hyperglycaemic. At this point, patients will then be classified as suffering 
from non-insulin dependent diabetes mellitus (NIDDM).
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1.9 Insulin Resistance and NIDDM
As with many metabolic disturbances the severity of insulin resistance 
varies between different disease states and within distinct disease groups. 
Perhaps one of the best defined syndromes of insulin resistance is that 
present in NIDDM, where there is generally a profound reduction in the 
ability of insulin to stimulate glucose uptake (Dale et al., 1996; Gould, 
1997; Brady and Saltiel., 1999). Indeed the presence of insulin-resistance 
in an individual is accepted as an excellent marker of subjects highly likely 
to develop overt diabetes.
As a direct consequence of the high incidence of diabetes, and the 
complications associated with the disease, the search for the underlying 
cause(s) is of high priority.
1.9.1 GLUT4 in insulin resistance
Due to the central nature of GLUT4 in insulin-stimulated glucose transport 
a wealth of studies have focused on this protein, both in human studies and 
in animal models of insulin resistance and diabetes. The observation that 
there is a defective stimulatory effect of insulin in skeletal muscle from 
NIDDM patients suggests that either GLUT4, or another protein linked to 
its activation, is somehow dysfunctional (Dale et al., 1996; Gould, 1997).
Interestingly levels of GLUT4 in adipocytes from NIDDM subjects do 
show a reduced GLUT4 protein content, due to a pre-translational 
suppression of GLUT4 gene expression (Gould, 1997). Although this can 
explain the resistance to insulin seen in isolated adipocytes, it is unclear 
exactly how this change contributes the insulin resistance seen at the 
whole body level. Although a similar reduction in GLUT4 content in 
muscle would explain this in part, no changes in GLUT4 expression are 
observed at the time when reduced insulin-stimulated glucose transport is 
manifest (Dale et al., 1996; Gould, 1997). Interestingly GLUT4 gene
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studies have revealed that no mutations were detectable in tissue from 
several diabetic subjects (Gould, 1997).
A similar picture has been generated in animal models of insulin resistance 
and diabetes. Although all of the different animal models undoubtedly 
have differing underlying physiology, they are still useful in ascertaining 
how GLUT4 may be altered in, or contribute to, states of cellular insulin 
resistance.
In the obese and spontaneously diabetic Rhesus monkey the first 
detectable signs of a pre-diabetic state are the hyper-secretion of insulin, 
followed by an obvious peripheral insulin resistance (Dale et al., 1996). 
This is later followed by pancreatic insufficiency defined by a deficiency 
in insulin secretion (Dale et al., 1996). These animals, however, exhibit 
no detectable change in GLUT4 content of fat or muscle (Dale et al., 
1996).
The genetically obese Zucker rat (fa/fa) is an animal model which is 
characterised by extreme obesity, insulin resistance, hyperinsulinaemia, 
hyperlipidaemia and a variable degree of glucose intolerance (Galante et 
al,, 1993). This rat therefore shares some of the characteristics of human 
NIDDM. The animals have impaired glucose uptake into isolated 
adipocytes and all major muscle groups (Livingstone et al., 1995; Dale et 
al., 1996). These changes are accompanied by a reduction in GLUT4 
content of adipose, with little change in skeletal muscle (Livingstone et al., 
1995; Dale et al., 1996). This is similar to the situation observed in many 
pre- or early- diabetes.
Interestingly, recent studies have highlighted the role of SNARE proteins 
in the development of insulin resistance. Maier et al, illustrated how the 
cellular levels of two v-SNARE’s- VAMP-2 and cellubrevin, and one t- 
SNARE- Syntaxin 4, were significantly elevated in skeletal muscle from 
ZDF rats (Maier et al., 2000). This elevation could be ameliorated by 
normalization of blood glucose levels using the thiazolidinedione anti­
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diabetic agent, rosiglitazone. This is of significance to human diabetes in 
that it is the first observation of altered expression of proteins known to 
regulate GLUT4 function, and secondly because it highlights how these 
proteins can be regulated by agents which also regulate insulin sensitivity. 
Although it may initially seem surprising in that these proteins are 
increased in insulin resistant states, it suggests a compensatory mechanism 
aiming to overcome some other defect. This animal is also considerably 
obese, and this is believed to contribute to worsening of the phenotype, as 
indeed obesity worsens the insulin resistance syndrome in humans.
1.9.2 Other signalling molecules and insulin resistance
Although there are observations of mutations in the insulin receptor and 
the 1RS proteins, none of these mutations appears to explain the presence 
of diabetes in the population as a whole. With the development of 
knockout mice, certain insights have been gained regarding the potential 
role certain proteins may play. Both IRS-1, IRS-2 and IRS-3 knockout 
mice have been studied. Intriguingly only the IRS-2 knockout develops 
overt diabetes, due to a peripheral insulin resistance and failure of p-cell 
compensatory mechanisms (Tamamoto et ah, 1994; Withers et ah, 1998; 
Liu et ah, 1999). The IRS-1 knockout has impaired growth and mild 
glucose intolerance whereas the IRS-3 knockout appeal's essentially 
similar to the wild type litter-mates (Tamamoto et ah, 1994; Liu et ah,
1999). Large scale naturally occurring defects such as these, however, 
have not been observed in animal models of insulin-resistance or in human 
studies. Similar studies have been carried out with phosphotyrosine 
phosphatase (FTP) knockout mice. Although these do develop insulin 
resistance to varying degrees, again defects in these proteins have not been 
observed in the diabetic population or animal models (Kahn, 2000). 
Perhaps one of the most interesting of the recent studies came from Jiang 
and colleagues, who illustrated the involvement of the IRS-1/2 PI3’K 
pathway in resistance to insulin signalling in the vasculature of Zucker 
(fa/fa) rats (Cusi et ah, 2000). Importantly this was a selective resistance,
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and insulin mediated-signalling through the MAPK pathway was normal. 
Although this study does not use a classical insulin responsive tissue, it 
presents an interesting idea, in that selective resistance to the metabolic but 
not mitogenic actions could contribute to worsening of the disease 
phenotype.
1.10 Insulin Resistance and Hypertension
It was first observed in 1966 by Wellborn (Wellborn, 1966) that insulin 
levels in hypertensive patients are often raised, and thirty years later the 
association is now well established. More detailed studies have revealed 
that lean, non-diabetic essential hypertensives are hyperinsulinaemic 
compared with well-matched normotensive controls (Mitchell et aL, 
1990). Data from the San Antonio Heart Study revealed that by the fifth 
decade of life eighty-five percent of diabetics are hypertensive and obese. 
Similar observations were made in a study by Modan et al (Modan et ah, 
1985) examining the links between hypertension, obesity and glucose 
intolerance in an Israeli population. They concluded that there was both a 
higher prevalence of elevated blood pressure in subjects with impaired 
glucose tolerance and obesity, and increased post-prandial insulin levels in 
treated and non-treated hypertensives. Numerous other studies have 
clearly illustrated the close association between insulin sensitivity, 
elevated blood pressure and obesity; an association that increases with age 
(Moms and Connell., 1994). Furthermore, it now also well established 
that the relation between insulin resistance and hypertension exists 
independently of age, obesity and renal function (Morris and Connell., 
1994). Elevated blood pressure and insulin resistance have also been seen 
to cluster with elevated circulating triacylglycerol (TAG) and diminished 
HDL-cholesterol levels in certain subjects. This condition, known as 
Syndrome X can often precipitate the development of certain 
cardiovascular conditions such as atherosclerosis (Morris and Connell.,
1994).
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Although a role for insulin in primary hypertension and associated diseases 
has been well established the exact relationship between the two 
syndromes is more controversial. Julius et al have proposed that 
hypertension may precede the development of insulin resistance and 
hyperinsulinaemia and may in fact be the cause (Julius et al., 1993). They 
suggest that reduced muscle blood flow and microvascular disease leads to 
reduced glucose uptake. Certainly there is clinical evidence to support this 
(Donnelly et al., 1992), but this theory fails to explain the wealth of 
convincing data from both human subjects and animal models which 
indicates that the opposite situation is true (Morris and Connell., 1994). 
Indeed, it has been shown that when primary hypertension and NIDDM 
co-exist, the hypertension is eight times more likely to antedate the 
development of NIDDM. The spontaneously hypertensive rat (SHR), a 
genetic model of hypertension, also develops insulin resistance (Reaven et 
al., 1989). The insulin resistance, as documented by defective glucose 
transport into adipocytes, develops long before any elevations in blood 
pressure are apparent. Further evidence to reinforce this comes also from 
studies of primary and secondary hypertensives, in that insulin resistance 
is prevalent only in subjects with primary and not secondary hypertension 
(Donnelly et al., 1992). The lack of association between secondary 
hypertension and insulin resistance provides evidence therefore that 
elevated blood pressure per se does not automatically lead to insulin 
resistance. This has also been shown in rodent models, where rats made 
hypertensive by renal artery clipping do not go on to develop insulin 
resistance or hyperinsulinaemia (Buchanan et al., 1991). This, taken 
together, suggests that it is unlikely that the development of hypertension 
precedes insulin resistance in primary hypertensives.
1.10.1 How might Insulin Resistance lead to Hypertension ?
Insulin and hyperinsulinaemia can potentially lead to the activation of 
several systems which, alone or in co-operation, can promote elevations in 
blood pressure. These include the actions of insulin on the sympathetic
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nervous system, sodium balance, and effects on vascular smooth muscle 
and endothelial cells (Morris and Connell., 1994; Donnelly et al., 1992).
1.10.2 The Metabolic Syndrome
Clearly, hypertension and insulin resistance can co-exist in a variety of 
different clinical situations, and it is not a simple task to begin to classify 
these in any way. Nevertheless, many groups have observed that certain 
key metabolic and haemodynamic disorders appear to cluster together in a 
broad but coincident manner. For example, many insulin resistant primary 
hypertensives also display other metabolic disturbances such as disrupted 
blood lipid profiles (generally elevated circulating triglycerides, reduced 
HDL-cholesterol levels or both) and impaired catecholamine mediated free 
fatty acid uptake (Ginsberg, 2000). These disorders, often occurring in 
conjunction with abdominal obesity, are referred to as the Metabolic 
Syndrome (also known as Syndrome X or Reaven's Syndrome). It is 
generally believed that patients who fit this description are at greater risk 
of subsequently developing atherosclerotic lesions and related conditions.
1.10.3 Lessons from animal models
As discussed above, animal models have proved useful in understanding 
the development of insulin resistance and how insulin resistance may 
affect other associated diseases. Several different animal models have 
yielded valuable information regarding the potential relationships between 
insulin resistance and hypertension. This is discussed below.
The Milan Hypertensive (MHS) Rat is a well characterised rodent model 
of hypertension. The strain exhibits a markedly elevated blood pressure 
compared to the normotensive control strain (MNS), with blood pressures 
of around 120mm Hg in the MHS, compared to aroud 95mm Hg in the 
MNS (Dall’Aglio et a l,  1991). The MHS also exhibits an enlarged left
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ventricular mass and a slower heart rate than weight matched controls 
(Ferrari et ah, 1987). In addition to the cardiovascular defects observed in 
these animals, there is an apparent defect in carbohydrate metabolism. 
Dall’Aglio et al have demonstrated that although blood glucose levels are 
similar between the two strains, the MHS display hyperinsulinaemia and 
hypertriglyceridaemia. (Dall’Aglio et a l, 1991). Interestingly Livingstone 
et al have demostrated a loss of GLUT4 expression in skeletal muscle , a 
major insulin-responsive glucose consuming tissue (Livingstone et al.,
1995). Similar reductions in GLUT4 content of skeletal muscle are rarely 
observed in the metabolic syndrome in humans, and this suggests that the 
altered cardiovascular and metabolic phenotype observed in the MHS 
differs from that observed in humans. Nevertheless, the demonstration of 
altered carbohydrate metabolism in a rodent model of hypertension further 
highlights the complex relationships that can exist between the 
haemodynamic and metabolic status.
The obese Zucker rat, described in Section 1.9.1, is another model that 
displays a phenotype similar to that observed in the human metabolic 
syndrome, although again there appears to be a different underlying 
abnormality. It appears that much of the defect observed in the Zucker is a 
direct result of obesity (Livingstone et al., 1995). Although obesity 
undoubtedly contributes to the worsening of many of the defects seen in 
the metabolic syndrome, it is well documented that they occur 
independently of obesity.
Although the models described above have been beneficial in 
understanding the relationship between insulin resistance and 
hypertension, perhaps the most useful models are the spontaneously 
hypertensive rats (SHR’s).
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1.10.4 SHR
The spontaneously hypertensive rat (SHR) is a rodent model of genetic 
hypertension which has been employed as a tool to study the development 
of hypertension and metabolic syndromes in humans. Originally 
developed by Okamoto’s group in Japan, the SHR was derived through 
extensive inbreeding of Wistar rats, specifically selecting for off-spring 
with elevated blood pressures (Okamoto et ah, 1974). These animals were 
then subsequently brother x sister mated for several generations, in order to 
generate the SHR colony (Okamoto et ah, 1974).
Of particular advantage in using the SHR is that it displays many of the 
metabolic disturbances which often occur in conjunction with hypertension 
in humans, namely hyperinsulinaemia, hypertriglyceridaemia and 
resistance to the cellular effects of insulin (Iritani et ah, 1977; Reaven et 
ah, 1989; Aitman et ah, 1999). Reaven et al first showed in the late 
eighties that the SHR displayed resistance to the effects of insulin in vitro. 
Isolated epididymal adipocytes showed a diminished ability to mediate 
insulin-stimulated glucose transport (Reaven et ah, 1989). Data generated 
using oral glucose tolerance tests (OGTT) have generally produced 
concordant results (Aitman et ah, 1997).
In addition to defects in carbohydrate metabolism, the SHR exhibits further 
defects analogous to those seen in the human metabolic syndrome, namely 
abnormalities in lipid metabolism. Although the ability of insulin to 
modulate catecholamine-mediated lipolysis is not altered in the SHR, the 
maximum isoprenaline stimulated lipolysis is indeed reduced (Reaven et 
ah, 1989). The SHR also displays elevated serum triglyceride levels 
compared to WKY controls (Aitman et ah, 1999), again a feature common 
to the human metabolic syndrome.
Due to these apparent similarities it is therefore of interest to define the 
underlying abnormalities responsible for the phenotype observed in the
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SHR. In order to do this Aitman et al employed an essentially genetic 
strategy (Aitman et al., 1999).
1.10.4.1 Potential defects underlying the metabolic abnormalities 
in the SHR
In order to identify and characterise markers that segregate with the 
phenotypes of interest in the SHR, that is defective insulin action, increased 
basal triglycerides and reduced effect of isoprenaline, extensive genetic 
analyses were carried out. In order to facilitate detection of Quantitative 
trait Loci (QTL’s), a large F2 cohort was produced by back crossing two 
previously produced inbred WKY and SHR strains. Extensive phenotypic 
and genotypic analysis of these animals revealed the presence of several 
QTL’s for SHR defects in glucose and fatty acid metabolism, hypertension 
and hypertrigyceridaemia, and that several of these QTL’s map to a single 
locus on rat chromosome 4 (Aitman et al., 1999).
Recently further analysis of these QTL’s has yielded valuable information 
regarding the phenotype observed in the SHR. To further confirm the 
importance of this region on chromosome 4, a congenic rat strain was 
produced where the SHR QTL on chromosome 4 was replaced with the 
corresponding region of chromosome 4 from the normotensive and non­
insulin resistant Brown-Norway (BN) rat. The resultant SHR.4 exhibited a 
partial correction in the defect in insulin-mediated glucose uptake, and a 
complete correction of the defect in isoprenaline mediated lipolysis 
(Aitman et al., 1999). This provides very strong evidence therefore for the 
involvement of this area in regulating both carbohydrate and lipid 
metabolism.
To characterise further the QTL region on chromosome 4 this SHR.4 strain 
was then used in conjunction with normal control SHR and WKY. By 
using an elegant technique known as cDNA micro-array analysis, several 
clones were identified where the expression between SHR and SHR.4 was
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significantly different. One of these clones mapped in the centre of the 
QTL using radiation hybrid mapping, and was functionally therefore a very 
likely candidate. This clone was revealed to encode the gene for the 
putative fatty acid transporter Cd36/Fatty Acid Translocase (FAT), which 
is known to map to chromosomes analogous to rat chromosome 4 in both 
mouse and human (Aitman et al., 1999). The location of the Cd36 gene 
therefore identified the gene as potentially central to the deficits in glucose 
and fatty acid metabolism mapping to chromosome 4 in SHR rats.
Since Aitman’s group identified the apparent importance of the Cd36 gene 
product, other groups have generated similar data that reinforces this. 
Pravenec et al were also able to partially correct the SHR defects in 
glucose and lipid metabolism by transferring a segment of BN 
chromosome 4 (including the Cd36 region) into the SHR chromosome 
(Pravenec et al., 1999). This work not only reinforces a role for the Cd36 
gene product, but also demonstrates that a single chromosome region can 
influence a broad spectrum of cardiovascular risk factors involved in the 
metabolic syndrome. Despite the convincing demonstration of the linkage 
between the Cd36 defect and the SHRSP phenotype however, the actual 
cellular mechanisms involved in this link remain elusive.
1.10.4.2 Cellular functions of the Cd36 protein
(i) Fatty Acid Transport
Although transport of long chain fatty acids (FA) across plasma 
membranes was once thought to involve simple diffusion, a strong body of 
evidence now indicates that long chain FA transporter proteins are 
involved, implicating a facilitated process (Febbraio et al., 1999). Certainly 
expression of long chain FA transporters is prevalent in tissues such as 
adipose, mammary epithelia, small intestine and both cardiac and skeletal 
muscles (Febbraio et ah, 1999); where increased FA transport would be 
expected to occur.
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The Cd36/FAT (Fatty Acid Translocase) protein, identified to be of 
importance in the SHR by Aitman’s group, encodes such a Fatty Acid 
Receptor/Transporter protein (Aitman et ah, 1999). Growing evidence 
implicates this protein as central to long chain FA transport in tissues 
where there is strong demand for FA's. (Febbraio et ah, 1999). Much of 
the work carried out in order to elucidate a role for Cd36 has involved 
studies where the protein is either over-expressed or deleted completely, in 
mouse models (Febbraio et al., 1999; Ibrahimi et al., 1999).
Work from Ibrahimi’s group demonstrated that muscle from mice over­
expressing Cd36 displayed an increased capacity for FA oxidation, and 
increased FA uptake from the blood (Ibrahimi et al., 1999). The mice also 
had lower total and Very Low Density Lipoprotein (VLDL)-TAG, and a 
general decrease in total body fat (Ibrahimi et al., 1999).
In contrast to this, Febbraio’s group by generating Cd36 null mice, created 
the reverse phenotype. Studies using these animals have revealed a 
striking phenotype, which includes elevated fasting plasma (serum) 
cholesterol, non-esterified FA and triacylglycerol (TAG) levels (Febbraio 
et al., 1999). This suggests a role for Cd36 in clearing these substances 
from the blood stream and promoting their uptake into the relevant tissues, 
functioning indeed as a fatty acid transporter. Cd36 null mice also show a 
diminished ability to transport oleate (a typical long chain FA) at low 
FAiBovine Serum Albumin (BSA) ratios, analogous to those present in 
physiological situations. Should Cd36 function in such a role suggested by 
these studies, then absence could play a role in the development of any 
conditions where there are abnormalities in lipid metabolism.
(i) Receptor for modified LDL species
More recent work however, again by Febbraio’s group, has suggested that 
the reverse could also be true. Cd36 is a member of the Scavenger 
Receptor Family, a large group of trans-membrane proteins which all
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possess the ability to bind large negatively charged molecules, such as 
oxidised or modified LDL (ox-LDL/m-LDL) (Febbraio et al., 2000). 
Scavenger receptors are believed to play an important role in the 
development of atherosclerosis, where they function in atherosclerotic 
plaque formation. Although plaque formation is ultimately dependent on a 
variety of circulating and locally released factors, lipid deposition in the 
plaque is central to its development and progression. This lipid deposition 
is achieved by the insertion of foam cells, monocyte-derived macrophages 
that have taken up large amounts of m-LDL, into the intima and vessel 
walls. By allowing entry of m-LDL into the macrophages (therefore 
allowing them to turn into foam cells) the importance of Cd36 in this 
process is believed to be by functioning as a receptor for the m-LDL 
(Febbraio et al., 2000). Indeed Febbraio showed that Cd36 knockout mice, 
when crossed in to an ApoE  gene (postulated to play a role in protection 
against development of atherosclerosis) negative environment, decreased 
the development of atherosclerosis. This is backed up by a reduction in 
foam cell production, measured in vitro (Febbraio et al., 2000). Finally, 
the ability of Cd36 to bind and promote uptake of nitro-LDL species has 
also been observed (Podrez et al., 2000). This is thought to be of relevance 
as monocytes themselves have systems responsible for generating reactive 
nitrogen species, which easily react with circulating-LDL.
1.10.5 SHRSP
Derived from the same lines as the stroke-resistant SHR (referred to 
through-out this thesis as the SHR), the stroke-prone SHR represents a 
sub-group of SHR which displays even higher blood pressures than the 
SHR and, as the name suggests, is more prone to cerebrovascular lesions 
resulting in stroke (Okamoto et al., 1974). Although extensive studies 
have aided in characterising the vascular abnormalities in the SHRSP, 
there have been a lack of studies aimed at examining the metabolic status 
of this particular sub-strain. This issue is also addressed in Chapter 3 of
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this thesis, where the metabolic phenotype of the SHRSP is examined with 
relevance to the SHR and potential importance of the CD36 deletion.
1.11 Insulin Resistance and other Metabolic disorders
Although insulin resistance is most often associated with conditions such 
as NIDDM and Syndrome X, the condition also forms a part of many other 
diseases. One of the most important of these is in disorders of the female 
endocrine system where insulin resistance forms an integral part of the 
disease phenotype, for example Polycystic Ovarian Syndrome (PCOS). 
This is a complex disease and although it is unclear whether the insulin 
resistance is a cause or consequence, its presence undoubtedly worsens the 
outcome. The links between PCOS, insulin resistance and intra-cellular 
signalling by insulin are extensively discussed in Chapter 4, with an aim to 
addressing how defective insulin resistance could contribute to the 
phenotype observed in PCOS.
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1,12 Aims
As discussed in the introduction to this chapter, insulin action within 
mammalian tissues is a complex process, regulated at several different 
levels. Because of this complexity insulin action in mammalian cells can 
easily be perturbed. Perhaps the most obvious illustration of this is in 
Insulin Dependent Diabetes Mellitus (IDDM), where there is a primary 
defect in insulin secretion and patients require the addition of exogenous 
insulin to survive. More common however than IDDM is NIDDM. 
NIDDM occurs when there is a resistance to the actions of insulin in the 
peripheral target tissues, principally muscle and adipose tissue; and a 
failure of the pancreas to secrete adequate amounts of insulin to overcome 
this. Insulin resistance also occurs in other conditions, and it is found 
particularly associated with cardiovascular disease syndromes where 
hypertension, abnormal lipid metabolism and obesity also occur.
Animal models have been very useful in studying the links between insulin 
resistance. Ones of the aims of this thesis is to address the relationship 
between metabolic disorders and hypertension in a genetic model of 
hypertension, the SHRSP. This will involve characterization of the 
SHRSP phenotype with regard to carbohydrate and lipid metabolism, with 
an aim to determining how this relates to the SHR phenotype. Insulin 
signalling in isolated adipocytes will also be examined in a bid to 
determine if altered signalling may underlie any metabolic defects detected 
in SHRSP adipocytes.
As discussed in Section 1.11 (and also later in Chapter 4) insulin 
resistance is also commonly associated with disorders of the female 
endocrine system, of which PCOS is the best characterised example. A 
further aim of this thesis is to determine potential mechanisms by which 
abnormal levels of important female sex hormones can influence the 
development of insulin resistance in a cell culture model of a peripheral 
insulin-sensitive tissue. Again, the main aim of this work is to relate this
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to the intracellular signalling pathways activated by insulin in adipose 
tissue.
61
2 Materials and Methods
2.1 Materials
All reagents used during this project were of the highest quality available 
and were obtained from the following suppliers:
2.1.1 General Reagents
Alpha Laboratories, Eastleigh, Hampshire, UK
WAKO NEFA-C Kit
Boehringer Mannheim, GmbH, Germany
Complete ™ Protease Inhibitor Tablets
Bio-Rad Laboratories, Hemel Hempstead, Hertfordshire, UK
N, N, N ’, N ’,-tetramethylethylenediamine (TEMED)
BDH, Loughborough, Leicestershire, UK
acrylamide
ammonium persulphate
Dow Coming silicone oil, 100/200CS
D-glucose
glycerol
glycine
Hepes
hydrochloric acid 
methanol
potassium chloride
sodium dodecyl sulphate (SDS)
sodium chloride
sodium dihydrogen orthophosphate dihydrate 
sodium diaminoethanetetra-acetic acid (EDTA) 
sodium hydrogen carbonate
6 2
Gelman Sciences Ltd., Northampton, UK
sterile acrodisc 0.2jxM filters
Gibco BRL, Paisley, Lanarkshire, UK
Tris base
Kodak Ltd., Hemel Hempstead, Hertfordshire, UK
RP X-Omat liquid fixer/replenisher 
RP X-Omat liquid developer/replenisher 
X-Omat AR film
Lome Laboratories, Twyford, Essex, UK 
collagenase- type 1 for adipocyte isolation
Merck Ltd. (BDH), Lutterworth, Leicestershire, UK
calcium chloride hexahydrate 
dimethyl sulphoxide (DMSO) 
magnesium chloride hexahydrate 
magnesium sulphate heptahydrate
NovoNordisk, DK-2880, Bagsvaerd, Denmark
Human Actrapid® Insulin solution- 100 lU/ml 
Porcine Insulin
Packard Instruments B.V.- Chemical Operations, Groningen, The 
Netherlands
Ultima-Flo scintillation fluid
Premier Brands UK, Knighton Adbaston, Staffordshire, UK
Marvel powdered milk
Schliecher & Schuell
nitrocellulose membrane (0.45pM)
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Sigma Chemical Company Ltd., Poole, Dorset, UK
adenosine
aprotinin
BSA (A-7030) used for protein estimations
BSA (A-7888) used for adipocyte buffers
bromophenol blue
cytochalasin B
2-deoxy-D-glucose
diisopropyl fluorophosphate (DFP)
DL-dithiothreitol
E64
estriol
estrone
Pepstatin A
Triton X-100
Whatmann International Ltd., Maidstone, UK
Whatmann 3mm filter paper
2.1.2 Antibodies
Amersham International Pic, Aylesbury, Buckinghamshire, UK
Horseradish peroxidase (HRP)-conjugated donkey anti rabbit IgG 
antibody
HRP-conjugated donkey anti mouse IgG antibody
Sigma Chemical Company Ltd., Poole, Dorset, UK
HRP-conjugated donkey anti sheep IgG antibody 
HRP-conjugated mouse anti sheep/goat IgG antibody
TCS Biologicals, Botolph Claydon,Buckingham, UK
"immunoaffinity purified" rabbit IgG directed against the C-terminal 14 
amino acids ([CJYASINFQKQPEDRQ) of rat liver lRS-1
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"Protein A-purified" rabbit IgG directed against a GST Fusion protein 
containing amino acids 976-1094 of mouse IRS-2
"Protein A-purified" rabbit IgG directed against a GST fusion protein 
containing the full-length 85kDa sub-unit of PI3 Kinase 
"immunoaffinity purified" sheep IgG directed against a GST fusion 
protein corresponding to residues 1-149 of human Akt-1 (PKBa) 
Pleckstrin Homology domain
"immunoaffinity purified" sheep IgG directed against a 15 residue 
synthetic peptide (RPHFPQFSYSASGTA) corresponding to the C- 
terminal (residues 466-480) of rat Akt-1 (PKBa)
"immunoaffinity purified" sheep IgG directed against a KLH conjugated 
synthetic peptide (RYDSLGSLELDQRTH) corresponding to amino acids 
455-469 of rat Akt-2 (PKBp)
sheep IgG directed against the C-terminal 14 amino acids of human 
GLUT4
2.1.3 Cells 
American Type Culture Collection, Rockville, USA
3T3-L1 fibroblasts
2.1.4 Tissue Medium and Reagents 
Gibco BRL, Paisley, Lanarkshire, UK
Foetal Calf Serum (FCS)
Newborn Calf Serum (NCS)
Dulbecco’s Modified Eagles Medium (DMEM)
Sigma Chemical Company Ltd., Poole, Dorset, UK
Penicillin Streptomycin 
Trypsin
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2.1.5 Cell Culture Plastics
AS Nunc, DK Roskilde, Denmark
50ml centrifuge tubes
Bibby Sterilin, Ltd., Stone, Staffordshire, UK
sterile pipettes
Costar
75cm^ tissue culture flasks
Fred Baker Ltd.
10cm tissue culture dishes 
6 well tissue culture plates
2.1.6 Radioactive Materials
Amersham International Pic, Aylesbury, Buckinghamshire, UK
[y32p]_atp
NEN DuPont (UK) Ltd., Stevenage, Herts, UK
[3r ] 2-deoxy-D-glucose
2.2 Buffers and medium
2.2.1 Cell Culture medium 
Serum Free DMEM
lOOU/mL Penicillin, lOOU/mL Streptomycin in DMEM 
NCS DMEM
lOOU/mL Penicillin, lOOU/mL Streptomycin in DMEM, 10% (v/v) NCS
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in DMEM 
FCS DMEM
lOOU/mL Penicillin, lOOU/mL Streptomycin in DMEM, 10% (v/v) FCS in 
DMEM
Sterile Trypsin solution for cell passage
25% (w/v) trypsin in PBS (see section) was syringe filtered through a 
0.2pM membrane and stored in 50ml sterile centrifuge tubes at -20^C.
2.2.2 Adipocyte Buffers 
Collection Buffer
118mM NaCl, 5mM NaHCOg, 4.7mM KCl, 1.2mM KH2PO4, 1.2mM 
M gS04.7H20, 25mM Hepes, 0.2pM adenosine, 2.5mM CaCl2, 1% (w/v) 
BSA (Fraction V), 3.0mM glucose
Digestion Buffer
llSm M  NaCl, 5mM NaHCOg, 4.7mM KCl, 1.2mM KH2PO4, 1.2mM 
MgS0 4 .7H2 0 , 25niM Hepes, 0.2pM adenosine, 2.5mM CaCl2, 1% (w/v) 
BSA (Fraction V), 3.0mM glucose , Type 1 collagenase (for exact 
amounts see 2.7.8)
Wash Buffer
118mM NaCl, 5mM NaHCOg, 4.7mM KCl, 1.2mM KH2PO4, 1.2mM 
MgS0 4 .7H2 0 , 25niM Hepes, 0.2|iM adenosine, 2.5mM CaCl2 , 1% (w/v) 
BSA (Fraction V)
2.2.3 General Buffers 
Hes Buffer
20mM Hepes, ImM  EDTA, 225mM sucrose, pH 7.4
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KRP Buffer
64mM NaCl, 2.5mM KCl, 2.5mM NaH2P0 4 .2H2 0 , 0.6mM
MgS0 4 .2H2 0 , 0.6mM CaCl2 (pH 7.4)
Lysis Buffer
50mM Hepes, pH 6.5, 150mM NaCl, lOOmM NaF, lOmM NaP04, ImM 
Na3V04, ImM  EOT A, 1.5mM MgCl2, 10% (v/v) glycerol, 1% (v/v) 
Triton-X 100,10pg/ml leupeptin, lOpg/ml aprotinin, lOpg/ml PMSF.
Phosphate Buffered Saline (PBS)
150mM NaCl, lOmM NaH2PO4.dH20 pH 7.4
2.2.4 SDS-PAGE Buffers 
Electrode Buffer
25mM Tris base, 192mM glycine, 0.1% (w/v) SDS 
Sample Buffer
93mM Tris-HCl pH 6.8, 20mM dithiothreitol, ImM Na-EDTA, 10% (w/v) 
glycerol, 2% (w/v) SDS, 0.002% (w/v) bromophenol blue
2.2.5 Immunoblot Buffers
To whin Buffer (for transfer of proteins onto nitrocellulose)
25mM Tris Base, 192mM glycine, 20% (v/v) methanol
Wash Buffer
20mM Tris base, 150mM NaCl, 0.03% (v/v)Tween-20, pH 7.4
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2.3 Cell Culture
2.3.1 Growth and maintenance of 3T3-L1 Fibroblasts
3T3-L1 fibroblasts were seeded into 75cm^ flasks and maintained at 
370C/5% CO2 in a humidified incubator. Cells were fed every two days 
with DMEM/10% (v/v) NCS/lOOU/ml Pen strep until they reached 
confluency.
2.3.2 Trypsinisation of 3T3-L1 Fibroblasts
Medium was aspirated from cells in a 75cm^ flask and the cells then 
washed with lOmls pre-warmed sterile PBS. This PBS was then removed 
and replaced with Trypsin (in sterile PBS). Cells were returned to the 
incubator and left for around 5 minutes to allow cells to detach. After this 
the trypsin was neutralized by the addition of lOmls medium, and cells
seeded as desired. On average the cells from one 75cm^ flask were 
seeded onto ten 10 cm plates.
2.3.3 Preparation of fibroblast differentiation medium
Differentiation medium containing 10% FCS (v/v), 0.5mM methyl 
isobutylxanthine, 0.25mM dexamethasone, and insulin (Ipg/ml) was 
prepared as outlined below.
A 500X stock of dexamethasone was prepared by a 1:20 dilution of 
2.5mM dexamethasone in ethanol with 10% (v/v) FCS/DMEM prior to 
use. A 500X sterile stock solution of methyl isobutylxanthine (IBMX) 
was prepared by dissolving 55.6mg IBMX in 1.0ml of 0.35M KOH and 
passing the solution through a 0.22 micron filter. Insulin (1 mg/ml) was 
prepared in lOmM HCl, and again filtered by passing through a 0.22 
micron filter.
69
3T3-L1 fibroblast differentiation medium was prepared by diluting both 
the dexamethasone and IBMX solutions to a IX  concentration in 10% 
(v/v) FCS/DMEM and finally adding insulin to a concentration of Ipg/ml.
2.3.4 Differentiation of 3T3-L1 Fibroblasts
Cells were routinely differentiated 48 hours post-confluency. Medium 
was aspirated from cells and replaced with lOmls differentiation medium 
(outlined above) per 10cm plate. Cells were incubated in this medium for 
two days. After this time the medium was carefully aspirated and replaced 
with DMEM/10% (v/v) FCS/lOOU/ml Pen strep containing Ipg/ml 
Insulin. Cells were incubated in this medium for a further two days. Cells 
were then fed every two days with DMEM/10% (v/v) FCS/lOOU/ml Pen 
strep. Cells were used between days 8-13 after differentiation, the point at 
which insulin stimulated glucose transport is maximum.
2.3.5 Freezing and storage of 3T3-L1 Fibroblasts
Confluent cells from a 75cm^ flask were removed as described in 2.3.2. 
Cells were then centrifuged (1000 x g at room temperature for 5 minutes) 
in a 13.5ml centrifuge tube to pellet cells. Medium was then aspirated off 
and replaced with 1ml sterile 10% (v/v) NCS/DMEM containing 10% 
(v/v) glycerol which had been pre-equilibrated in 10% CO2 for 1 hour. 
Cells were transferred to sterile cryovials (0.5ml per vial), wrapped in
cotton wool and frozen at “SO^C overnight. The next day the cotton wool 
was removed and the vials were transferred to a liquid N2 for long term 
storage.
2.3.6 Resurrection of 3T3-L1 Fibroblast stocks
lOmls of sterile DMEM/NCS/1 OOU/ml Pen strep was placed in a 25cm^ 
flask and left in the incubator for at least 30 minutes to allow medium to 
equilibrate with CO2 and humidity. During this time a vial of cells was
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removed from liquid nitrogen storage and placed in a flask containing 
liquid nitrogen for transfer to the culture hood. The vial was removed 
from the nitrogen and sprayed with ethanol, whereupon the cap was 
loosened to relieve pressure. The cap was slightly tightened and the vial
swirled in a 37*^C water bath for approximately two minutes. The vial 
was then removed from the water bath whilst a small amount of frozen 
medium remained in the vial. The vial was sprayed with ethanol again, 
the pre-equilibrated flask returned to the hood, and the cells rapidly 
transferred to the flask using a sterile plastic pipette. Cells were left to 
attach and then medium was replaced the next day.
2.3.7 Measurement of 2-Deoxy-D-Glucose uptake in 3T3-L1 
adipocytes
Uptake of 2-deoxy-D-glucose was measured using the method adapted 
from Campbell, PhD thesis, 1997.
Adipocytes in 6 or 12 well plates were quiesced in serum-free DMEM for 
at least two hours. Cells were then transferred to the hot plate, where the
medium was aspirated and replaced with 1ml KRP (37^C). This was then
aspirated and replaced with 1ml KRP/1% (w/v) BSA (37^C). For 
stimulation insulin was added where desired and plates swirled briefly to 
ensure adequate mixing throughout the plate. Following stimulations, to 
half of the wells at each condition IjLil of ImM Cytochalasin B was added 
to give a final concentration of lOpM. After 1 minute uptake was initiated 
by the addition 50pl of 2-deoxy-D-glucose (deGlc) solution (50pM, 
0.5pCi/well). Plates were gently mixed and after a further three minutes 
radioactivity was removed. Plates were then rapidly washed by 
immersing 3 times in a beaker containing ice-cold PBS. Plates were then 
allowed to dry and, after this time, 1ml of 1% (v/v) Triton X-100 was 
added to each well and the plates wrapped in Cling-film to avoid 
evaporation. Cells were then solubilised by shaking at room temperature 
for two hours. After this time the solution from each well was removed to
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a scintillation vial, ensuring the volumes had not altered dramatically, 
scintillant was added, and the radioactivity was measured using a 
Beckman Scintillation counter. Data was quantified as picomoles 2-deoxy- 
D-glucose transported per minute per million cells, assuming 2.1 x 106 
cells per well of a 6 well plate (Brant, thesis, University of Glasgow, 
1994).
2.3.8 Hormonal treatment of 3T3-L1 adipocytes
3T3-L1 adipocytes in 10cm dishes or 6 well plates were treated for 12 
(membrane/1 ysate preparation) or 48 hours (transport assay) with lOOnM 
of the desired steroid, in FCS/DMEM. The next day the cells were 
quiesced in serum-free DMEM for at least two hours. After this time, 
insulin was added where desired and cells then subjected to transport 
assay (refer 2.3.7) or membranes (refer to 2.3.9) or lysates (refer to 2.3.10) 
prepared.
2.3.9 Preparation of total membranes from 3T3-L1 adipocytes
Adipocytes in 10cm dishes were quiesced in serum-free DMEM for at 
least two hours. Cells were then transferred to the hot plate. For 
stimulations insulin was added where desired and plates swirled briefly to 
ensure adequate mixing throughout the plate. After the desired time 
medium was aspirated and dishes washed 2 times in ice cold PBS (pH 7.4) 
(see section 2.2.3). This was then replaced with 1ml ice-cold Hes (see 
section 2.2.3) plus protease inhibitors. Cells were harvested by scraping 
with a plastic cell scraper and then homogenised in a hand-held 
Homogeniser (20 up/down strokes). Samples were then transferred to
13.5ml centrifuge tubes and centrifuged at 1000 x g (4^C) for 10 minutes, 
to pellet nuclear material and any un-broken cells. The resulting
supernatant was then centrifuged at 100,000 x g ( 4 ^ 0  to yield soluble 
protein (supernatant) and membrane fractions (pellet). The pellet was 
usually re-suspended in 10 times volume of Hes plus protease inhibitors.
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Samples were then subjected to protein assay (see section 2.6) and snap- 
frozen in aliquots.
2.3.10 Preparation of whole cell lysates from 3T3-L1 adipocytes
Adipocytes in 10cm dishes were quiesced in serum-free DMEM for at 
least two hours. Cells were then transferred to the hot plate. For 
stimulation insulin was added where desired and plates swirled briefly to 
ensure adequate mixing throughout the plate. After the desired time 
medium was aspirated and dishes washed 2 times in ice cold PBS (pH 7.4) 
(see section 2.2.3). This was then replaced with 1ml ice cold Lysis buffer 
(see section 2.2.3) plus protease inhibitors. Cells were harvested by 
scraping with a plastic cell scraper and then homogenised in a hand-held 
Homogeniser (20 up/down strokes). Samples were then transferred to 1.5
Eppendorf tubes and centrifuged at 30,000 x g (4°C) for 10 minutes, to 
pellet nuclear material and any whole cells. The resulting lysate 
(supernatant) was then subjected to protein assay (see section 2.6) and 
snap-frozen in aliquots.
2.3.11 PKB Activity Assay in 3T3-L1 adipocytes
Eppendorf tubes were set up containing 50|il of a 50% Protein G 
Sepharose bead slurry. These beads were then washed three times by 
centrifugation in the lysis buffer outlined in 2.2.3. The washed Protein G 
beads were then incubated with 4p,g anti-PKBo/PH (see section 2.1.2), 
with shaking at 4°C to allow the antibody to pre-couple to the beads. 
After two hours 300-500|ig cell lysate prepared as outlined in 2.3.9 was 
added to each the eppendorf and left to incubate for at least 2 hours on a 
rotary wheel at 4°C. After this the Eppendorfs were briefly centrifuged to 
collect the immunoprecipitates. These were washed two times in lysis 
buffer minus Triton-X 100 and then washed and re-suspended in 25pi 
kinase buffer containing 50mM Tris, pH 7.6, lOmM MgClg, ImM DTT. 
The kinase reaction was initiated by the addition of a mix containing
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50pM ATP, 3pCi [y^^PJATP and 30pM PKB specific substrate peptide 
(RPRAATF, kindly donated by Dr Robin Plevin) in a 5pl volume. After 
30 min at 15°C, the reaction was stopped by adding lOpl of 300mM 
orthophosphoric acid to give a final concentration of 75mM. The samples 
were then spotted onto Icm^ squares of p81 paper, placed in a covered 
sandwich tub and washed twice in 75mM orthophosphoric acid, twice in 
water and allowed to dry. They were then counted.
2.4 Animals
2.4.1 Animal upkeep and blood pressure measurement
WKY and SHRSP rats were housed within the Joint Animal Facility 
within the University of Glasgow. Animals were maintained on a 12 hour 
light/dark cycle, fed standard laboratory chow and allowed access to water 
ad libitum. Blood pressure measurements were made by insertion of 
telemetry probes and by tail cuff measurements, according to standardised 
techniques (Jeffs et al.. 1997).
2.4.2 Adipocyte dissection and preparation
Epididymal fat pads were removed from rats killed by CO2 overdose and 
placed immediumtely into a 50 ml centriufuge tube containing pre­
warmed (37*^0) collection solution in a Dewar flask (see 2.2.6) for 
transfer to the laboratory. Cells were then weighed and rapidly transferred 
to a fresh pre-warmed tube containing digestion solution, to which 
collagenase was added (4mls of a 2mg/ml solution per gram of fat). Fat
pads were finely minced using scissors and then placed into a 37®C water 
bath. Digestion was then carried out with rapid shaking for around 30 
minutes, whereupon it was terminated by the addition of a large (15-20ml) 
volume of wash buffer. The solution was then passed through a plastic tea 
strainer to allow digested cells and buffer to pass through but keep any
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undigested fat or other material away from the cells. The cells were then 
allowed to float to the top of the tube and the medium from below 
removed and replaced with 15mls fresh buffer. This washing stage was 
repeated 3-4 times over a 30-minute period, ensuring that the tube was
always immersed in the water bath so that the cells were kept at 37^C 
constantly. Finally, washed cells were aliquoted at 40% (v/v) cytocrit for 
storage (not normally longer than 30 minutes).
2.4.3 Measurement of 2-Deoxy-D-Glucose uptake in rat primary 
epididymal adipocytes
Adipocytes were aliquoted into the desired number of pre-warmed 50ml 
centrifuge tubes at 10% (v/v) cytocrit (100p,l cells/900|il buffer per tube). 
For stimulations insulin was added where desired, then both treated and 
basal tubes were shaken gently for the desired time. Following 
stimulations, to one tube at each condition 10p,l of Im M  Cytochalasin B 
was added to give a final concentration of lOp-M. After 1 minute uptake 
was initiated by the addition 25|4l of 2-deoxy-D-glucose (deGlc) solution 
(lOpM, 2.5pCi/ml). Tubes were gently mixed during uptake and after a 
further three minutes three 200|il aliquots were removed to 0.5ml 
eppendorf tubes containing 200 j l i 1 Dow Coming Oil. Tubes were then 
rapidly centrifuged (500 x g/30-secs) and the adipocytes (which float on 
the oil above the aqueous layer) were then removed to scintillation vials 
using glass pasteur pipettes. The cells were then solubilised in 1ml Triton 
X solution (1% v/v) for at least 30 minutes. Scintillant was added and 
samples then counted using a Beckman Scintillation Counter. Data was 
quantified as picomoles 2-deoxy-D-glucose transported per minute.
2.4.4 Measurement of fatty acid release from rat primary 
epididymal adipocytes
Adipocytes were aliquoted into the desired number of pre-warmed 50ml 
centrifuge tubes at 10 %(v/v) cytocrit (lOOpil cells/900jLtl buffer per tube).
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For treatment, insulin or isoproterenol was added as indicated in the 
legends to the figure legends in chapter 3. Following stimulations, 50p,l of 
the buffer was removed to a glass test-tube. Fatty acid release was then 
measured using the WAKO NEFA-C kit exactly as described in the 
protocol provided, using an oleic acid internal standard. Fatty acid 
concentration was quantified as mmoles per litre.
2.4.5 Preparation of total membranes from rat primary epididymal 
adipocytes
Adipocytes were prepared and stimulated as for transport assay (see 
section 2.4.3), To terminate stimulation medium was aspirated from 
below and the cells were washed 2 times in warmed KRH (pH 7.4). Next 
this was replaced with 500pl ice-cold Hes plus protease inhibitors per 
2mls of packed cells, and cells were then rapidly homogenised by repeated 
passage through a 23G needle attached to a 1 or 2ml syringe. Membranes 
and soluble proteins were then prepared as described in Section 2.3.8. The 
membrane pellet produced from a 2ml cell volume was then typically 
suspended in lOOpl Hes plus protease inhibitors.
2.4.6 Preparation of whole cell Lysates from rat primary epididymal 
adipocytes
Adipocytes were prepared and stimulated as for transport assay (see 
section 2.4.3). To terminate stimulation medium was aspirated from 
below and cells washed 2 times in warmed KRH (pH 7.4). This was 
replaced with 1ml ice cold Lysis buffer protease inhibitors and cells were 
then rapidly homogenised by repeated passage through a 23G needle 
attached to a 1 or 2ml syringe. Samples were then transferred to 1.5
eppendorf tubes and centrifuged at 10,000 x g (4°C) for 10 minutes to 
pellet nuclear material, matrix proteins and any remaining whole cells. 
The resulting lysate (supernatant) was then subjected to protein assay (see 
section 2.6) and snap-frozen in aliquots
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2.5 Protein Assay
2.5.1 Bichiconnic Acid Assay
The assay was carried out essentially as per manufacturers protocol, with a 
few minor modifications.
A working stock of assay reagent was prepared by diluting concentrated 
reagent A 1 in 50 with reagent B. Eight standard BSA solutions were 
prepared (ranging from 0 to 5mg/ml in 2 fold increments) and these 
solutions were prepared in the same buffer as unknown sample wherever 
possible. Duplicate 10p,l lots of each sample were then added to a 96 well 
plate, followed by 200pl of diluted reagent. The plate was incubated at 
37C for 30-minutes, and after this time the absorbance of the samples was 
read on an automated plate counter. The standard curve was plotted 
according to a 2"^ order polynomial fit using Cricket Graph II ™, and 
unknown protein concentrations were calculated according to the 
corresponding equation.
2.6 SDS-PAGE
SDS/Polyacrylamide gel electrophoresis was carried out using Bio-Rad 
mini-PROTEAN II or Hoefer large gel apparatus.
The Bio-Rad mini-PROTEAN II slab gels had a stacking gel of 2cm and 
the Hoefer stacking gel was 5cm. The stacking gel was composed of 5% 
acrylamide/0.136% bisacrylamide (v/v) in 125mM Tris-HCl (pH 6.8), 
0.1% (w/v) SDS, polymerised with 0.1% (w/v) ammonium persulphate 
and 0.05% (v/v) TEMED.
The resolving gel consisted of 6.5-10% acrylamide/0.18-0.28% 
bisacrylamide in 0.383mM Tris-HCl (pH 8.8), 0.1% (w/v) SDS,
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polymerised with 0.1% (w/v) ammonium persulphate and 0.01% (v/v) 
TEMED. The protein samples were solubilised in sample buffer (see 
section 2.2.3) and loaded into the wells in the stacking gel. The gel was 
then immersed in electrode buffer (see section 2.2.3), and the gel 
electrophoresed until the tracking gel had reached the desired position. 
For Bio-Rad mini-PROTEAN gel a constant voltage of 100-120 volts for 
1-2 hours (depending on percent acrylamide in resolving gel) was used. 
Large gels were electrophoresed for around 5 hours at 150 volts.
2.7 Immunoblotting of proteins
After separation of the proteins as described in 2.5, the gels were removed 
from the plates and equilibrated in Towbins buffer (see 2.2.5) for 10 
minutes. Each gel was then placed on top of a piece of nitrocellulose 
paper (0.45pM pore size) which had been cut to the size of the gel and 
pre-soaked in Towbins buffer. This was then sandwiched between two 
layers of Whatmann 3MM filter paper, which had also been pre-soaked in 
Towbin buffer. The sandwich was then placed in a cassette and transfer of 
the proteins onto the nitrocellulose was performed using either a Bio-Rad 
trans-blot tank for large gels, or the Bio-Rad mini trans-blot tank for the 
mini gels. Transfer was achieved at a constant current of 255mA for 2 
hours at room temperature. The nitrocellulose membranes were then 
removed and the efficiency of transfer was determined by staining the 
nitrocellulose with Ponceau S solution prior to blocking.
2.7.1 Immunodetection of GLUTl, GLUT4, IRS-1, IRS-2, PKBcx/p, 
PI3’K p85 sub-unit, phospho-tyrosine containing proteins and CD36 
on nitrocellulose membranes
To block non-specific binding sites on the nitrocellulose the membrane 
was incubated was shaken in 5% (w/v) non-fat milk (M arvel’)/Wash 
buffer for at least 1 hour. The nitrocellulose was then placed into 1%
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(w/v)(non-fat milk/Wash buffer, containing either GLUTl (serum 1:200), 
GLUT4 (serum 1:500), IRS-1 (Ipg/ml), IRS-2 (Ipg/ml), PK B a (Ipg/ml), 
PI3K  p85 sub-unit (Ipg/ml), 4G10 (phospho-tyrosine residues) (Ipg/ml), 
or CD36 (serum 1:2000), (see section 2.1.2 for more detail). The
nitrocellulose was then incubated overnight at 4°C on a shaking platform. 
The next day the nitrocellulose was washed five times at ten-minute 
intervals with Wash buffer. The nitrocellulose was then incubated with 
either HRP linked-donkey anti-rabbit (GLUTl, GLUT4, IRS-1, IRS-2, 
PI3K  p85 sub-unit), HRP linked-donkey anti-sheep (PKBoc/P), or HRP 
linked-anti-mouse (phospho-tyrosine, CD36) all at a concentration of 
Ipg/ml. The nitrocellulose was then washed as before. Finally the 
nitrocellulose was subjected to Enhanced Chemi-Luminescence (ECL) 
using an Amersham kit according to the manufacturers protocol. The blot 
was then wrapped in cling-film, exposed to film for 30 seconds - 10 
minutes, and developed using an X-Omat processor.
2.8 Statistical analysis
Unless otherwise indicated, results are expressed as means ± standard 
error. Statistically significant differences were determined using a 
Students t-test.
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3.1 Insulin Resistance in the SHRSP is not linked to aberrant Cd36 
expression
3.1 Introduction
3.1.1 SHR and CD36
As discussed in Section 1.10, aberrant expression of Cd36 protein shows 
strong linkage some aspects of the SHR phenotype, although it’s precise 
role remains elusive. We saw how one hand Cd36 absence in mouse 
models appear to lead to elevated circulating lipids, a well known 
cardiovascular risk factor. The SHR strain (with aberrant Cd36 
expression), also has elevated triglycerides. These data strongly suggest a 
role for Cd36 in promoting FA uptake, since uptake is reduced in its 
absence. Interestingly, in spite of the cardiovascular risk factors present in 
the SHR, it does not however develop atherosclerosis. This is concordant 
with the view that Cd36 (and other proteins of the scavenger receptor 
family) play a role in development of foam cells and subsequent 
atherosclerotic lesions, and hence absence will reduce potential to develop 
atherosclerotic lesions.
Nevertheless, in spite of the apparent links between Cd36 and lipid 
abnormalities in the SHR it is unlikely to completely explain the observed 
phenotype. Indeed, as discussed in Section 1.10, only 40% of the defect in 
glucose metabolism is linked to Cd36 deletion, and nothing is known 
regarding the effect at the cellular level. This strongly suggests that some 
other factor or locus contributes to the phenotype seen in the SHR. 
Interesting in this regard is the demonstration that there exists an SHR 
strain which although phenotypically similar to Altman’s Cd36 deletion 
strain, has normal Cd36 expression. Indeed Gotoda et al., have 
demonstrated lack of the Cd36 deletion in an SHR strain maintained 
independently of Aitman’s NTH derived SHR’s. Interestingly the SHR
deletion variant of Cd36 is also not observed in strain of the stroke-prone 
SHR (SHRSP) maintained by Pravenec et al. This group showed, by
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Southern blotting, that their SHRSP strain possessed a Cd36 cDNA band 
pattern identical to that observed in the non-insulin resistant normotensive 
BN rat (Pravenec et a l ,  1999). Although this further discounts the role of 
Cd36 in the development of spontaneous hypertension, no metabolic 
parameters were included in this study. There is, therefore, a need to 
address the role of Cd36 deletion within syndromes where spontaneous 
hypertension and altered carbohydrate metabolism are demonstrated to 
exist in parallel.
Clearly, by addressing this issue we will begin to further understanding of 
the importance of Cd36 variants in the development of spontaneous 
hypertension and metabolic syndromes.
3.1.2 Aims
The work in this chapter aims to address this issue by measuring whether 
any defects in glucose and fatty acid metabolism are present in adipocytes 
from our SHRSP strain, and whether these defects associate with a deletion 
variant of Cd36.
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3.2 Results
3.2.1 Establishment of linearity of 2-Deoxy-D-glucose (DeGlc) uptake 
in rat primary epididymal adipocytes
As early as the 1960’s Rodbell demonstrated that it was possible to 
measure glucose uptake into isolated primary adipocytes, and that this 
glucose uptake was markedly enhanced by the addition of insulin (an effect 
now known to be primarily mediated by the GLUT4 glucose transporter 
isoform) (Robdell, 1964). Based on the work of Rodbell others, DeGlc 
uptake into primary adipocytes is generally studied within a 3 or 5 minute 
time period (Rodbell, 1964; Olefsky, 1976; and Ciaraldi, 1988). Figure 3.1 
shows, using an adaptation of the method of Rodbell, that glucose uptake 
in our system is also in the linear range within the chosen 3 minute uptake 
time and beyond, both in the presence or absence of insulin. For this 
reason a 3 minute uptake has been used routinely in these experiments.
3.2.2 Typical dose-response curves to insulin in WKY and SHRSP 
adipocytes
Figure 3.2 illustrates a typical dose-response curve to insulin established 
using the 3 minute DeGlc uptake outlined above. Insulin stimulation was 
carried out for 15 minutes, although maximal responses were reached at 
around 10 minutes and the effect persisted for up to 30 minutes.
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Figure 3.1 2-Deoxy-D-glucose uptake falls within the linear range 
when uptake is studied over a 3 minute time period
Epididymal adipocytes were prepared as described in Section 2.2.4. DeGlc 
uptake was performed essentially as described in Section 2.4.3, although 
both 3 and 10 minute uptake times were included.
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adipocytes
Typical Dose Response Curve to insulin in WKY
Epididymal adipocytes were prepared and DeGlc uptake assayed as 
described in Sections 2.4.2 and 2.4.3. Data is taken from one experiment, 
and values are an average of three triplicate 200pl aliquots from each 
stimulation. Standard Errors (SE) within the assay are minimal (typically 
less than 1%) and are therefore not shown.
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3.2.3 Glucose transport in WKY and SHRSP adipocytes as a 
measure of in vitro insulin sensitivity
Although there is variability in the response to insulin observed in both the 
WKY and SHRSP sub-sets, Figure 3.3 shows how there is clearly an 
overall strain-related difference in the ability of insulin to promote glucose 
transport. As there is no significant difference between the size of the cells 
(1.60 ± 0.06 arbitary units WKY, vs 1.71 ± 0.05 arbitary units SHRSP), 
data are expressed as picomoles DeGlc transported per minute per 20pl 
packed cells. When expressed in this way, the maximal response observed 
in SHRSP adipocytes is clearly diminished compared to WKY (3.2 ± 1 .7  
versus 20.1 ± 7.8 fold respectively; p<0.05). There is however no 
significant difference between basal rates of glucose transport between 
WKY and SHRSP.
3.2,4 NEFA release in WKY and SHRSP adipocytes- the effects of 
isoprenaline and insulin
Resistance to the effects of insulin in the SHR is not only restricted to 
glucose disposal but also present at the level of fatty acid release. There 
are no such data regarding this action of insulin in the SHRSP. In Figure 
3.4, it can be seen that basal and isoprenaline-stimulated fatty acid (NEFA) 
release do not differ between WKY and SHRSP adipocytes. In contrast, 
however, the ability of insulin to inhibit lipolysis is markedly reduced in 
SHRSP adipocytes. When data are expressed as a percentage of maximum 
WKY response, the ability of insulin to inhibit isporenaline stimulated 
NEFA accumulation is reduced in the SHRSP compared to the WKY. For 
example, in Figure 3.5 it can be seen that, at 0.05nM insulin, there is a 72 
± 3% reduction in WKY compared to 15 ± 2% in SHRSP.
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Figure 3.3 Glucose transport in WKY and SHRSP adipocytes as a 
measure of in vitro insulin Sensitivity
Epidiymal adipocytes were prepared and DeGlc uptake was measured 
according to the methods outlined in Section 2.4.2 and 2.4.3. Data from 
three individual experiments is presented, and error bars represent the 
standard error of the mean. Statistical significance was determined using 
the Students t-test. Using this test, there was found to be no significant 
difference between the basal rates in SHRSP and WKY adipocytes, 
whereas the insulin-stimulated response (50nM insulin/15 minutes) was 
significantly reduced in SHRSP adipocytes compared to WKY (p=0.01).
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Figure 3.4 NEFA release in WKY and SHRSP adipocytes- the 
effects of isoprenaline and insulin
Epidiymal adipocytes were prepared according to the method outlined in 
Section 2.4. Cells were incubated in the presence of isoprenaline (200nM), 
isoprenaline plus insulin (0-50nM) or neither for 30 minutes, and NEFA 
release then measured according to the methods outlined in Section 2.4.4. 
Data from four individual experiments is presented, and error bars 
represent the standard error of the mean. Using the Students t-test, there 
was found to be no significant difference between the basal rates of 
lipolysis in SHRSP and WKY, whereas the effect of insulin to reduce 
lipolysis was dramatically reduced in SHRSP adipocytes (p<0.05).
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Figure 3.5 Impaired ability of insulin to inhibit isopreanline- 
stimulated NEFA release in SHRSP adipocytes
This figure illustrates the impaired ability of insulin to inhibit lipolysis in 
SHRSP adipocytes. Using the data presented in Figure 3.4, every 
response was expressed as a percentage of the maximum lipolysis 
stimulated by isoprenaline in WKY or SHRSP adipocytes (although these 
values did not differ significantly). It is clear in WKY adipocytes that 
insulin is able to effectively reduce lipolysis even at relatively low 
(0.05nM) insulin concentrations, and that it reduces it to basal levels or 
below (data not shown). In contrast, in SHRSP adipocytes, much higher 
doses of insulin are needed and even then the response is much poorer 
than that seen in WKY. Data is expressed as percentage maximum WKY 
response, and error bars represent S.E.M. P< 0.05 at all data points for 
SHRSP versus WKY, using the students t-test.
3.2.5 Serum levels of Insulin, Glucose, NEFA’s and Triglycerides in 
WKY and SHRSP
Table 3.1 highlights the major differences in serum levels of several 
metabolic and cardiovascular markers in the SHRSP and WKY. As has 
been observed in the SHR (and indeed in human hypertension), serum 
triglycerides are markedly elevated in SHRSP compared to WKY animals 
(0.8 ± O.lmM in WKY versus 1.8 ± 0.3mM in SHRSP; p<0.001, using the 
students t-test). Despite the impairment in the ability of insulin to inhibit 
lipolysis in adipocytes, the overall serum NEFA levels are not significantly 
different between the two strains. All other parameters, aside from blood 
pressure, did not differ significantly between SHRSP and WKY.
3.2.6 Levels of Cd36 mRNA in WKY and SHRSP adipocytes assessed 
by Northern blotting
To determine expression level and transcript size cDNA Northern analysis 
of Cd36 expression was carried out in adipose tissue from SHR, SHRSP, 
WKY and BN rats. Using a probe from the 5’ end of the Cd36 cDNA, the 
overall level of expression was found to be similar in all four strains. In 
Figure 3.6 it can be seen that the transcript size in SHRSP was identical to 
the major 2.8kb transcript seen in WKY and BN. The two major transcripts 
(3.8kb and 5.4kb) in SHR were not observed in the SHRSP or other 
controls. (This experiment was performed on our behalf by Anne M. 
Glazier, Hammersmith Hospital, Middlesex, UK).
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WKY SHRSP
Systolic blood pressure 131 ± 12 180 ± 14^**
(telemetry)(mm Hg)
Diastolic blood pressure 94 ±10 128 ± 10***
(telemetry)(mm Hg)
Serum TG (mmol/L) 0.8 ± 0.1 1.8 ± 0.3*
Serum NEFA (mmol/L) 0.39 ± 0.07 0.30 ± 0.06
Serum glucose (mmol/L ) 8.3 ± 0.5 7.9 ± 0.4
Table 3.1 Blood Pressures and Serum levels of Glucose, NEFA’s 
and Triglycerides in WKY and SHRSP
All blood pressure measurements were made according to the methods 
outlined in Section 2.4.1. Glucose was measured using the glucose oxidase 
technique, and triglycerides were measured using standard enzymatic 
techniques. NEFA’s were measured according to the methods outlined in 
Section 2,4.4. 6 animals were used for each measurement, and the errors 
respresent the standard error of the mean. *** denotes p<0.05, * denotes 
p<0.001, using the students t-test.
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3.2.7 Sequence analysis of Cd36 cDNA from WKY and SHRSP 
adipocytes
Based on the experiment outlined on page 92, it is apparent that the SHRSP 
cDNA is identical to the WKY cDNA, except for a Glutamine to Arginine 
substitution at position 262, as shown in Table 3.2. Although this 
substitution does introduce a charge difference, it is also present in the BN 
rat, indicating that it is unlikely to be related to hypertension or the other 
observed defects since the BN rat is defined as normal in these respects. 
Further evidence against a selection role for this mutation is that, in this 
region both the WKY and the SHR express a glutamine residue. (This 
experiment was performed by Anne M. Glazier, Hammersmith Hospital, 
Middlesex, UK).
3.2.8 Expression of Cd36 protein in WKY and SHRSP total 
adipocyte membrane fractions assessed by immunoblotting
In order to determine whether the Cd36 gene encoded a synthesised 
protein, we performed immunoblotting. Figure 3.7 illustrates that the 
amount of Cd36 protein in adipocyte total membranes does not differ 
between SHRSP and WKY. Clearly this does not rule out the presence of 
any functional mutations in SHRSP. However it does distinguish the 
SHRSP from the SHR, since Cd36 is completely missing from SHR 
adipocyte membranes.
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Figure 3.6 Levels of CD36 mRNA in WKY and SHRSP adipocytes 
assessed by Northern blotting
Total RNA, prepared from epididymal fat by acid phenol extraction, was 
separated by electrophoresis on formaldehyde gels. The RNA was 
transferred onto Hybond-N (Amersham). A cDNA probe was then PCR 
amplified from the 5’ end of the WKY cDNA, extending from nucleotides 
462 to 1052 of the published sequence (Abumrad et al, 1993), and the 
probes labelled and purified using the RediPrime random prime labelling 
system and a G50 Nick Spin Column (Pharmacia).
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Strain Codon 262
Amino acid 
Sequence
Nucleotide
Sequence
SHRSP CGA Arg
SHR/NCrlBr CAA Gin
WKY CAA Gin
BN CGA Arg
Table 3.2 Sequence analysis of CD36 cDNA from WKY and 
SHRSP adipocytes
PCR amplification of cDNA with AmpliTaq Gold (Perkin Elmer) was 
carried out with Dnase treated total RNA extracted from epididymal 
adipose tissue with the DNA/RNA extraction kit (Qiagen). cDNA was 
prepared with the 1®^ Strand Synthesis Kit (Boehringer), and purified 
through a G50 Spin Column (Pharmacia). PCR products were purified 
with Centricon 100 columns (Millipore) and directly sequenced with the 
BigDye Sequencing Kit (Perkin Elmer) on an BI Prism 377 DNA 
sequencer.
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Figure 3.7 Level of Cd36 protein in WKY and SHRSP total 
adipocyte membranes assessed by Immunoblotting
Total membranes were prepared from WKY and SHRSP adipocytes as 
outlined in section 2.4.5. Samples were separated by SDS-PAGE, as 
outlined in section 2.6, and then immunoblotted for Cd36 protein using a 
mouse monoclonal antibody as described in section 2.7. Shown is a 
representative immuno-blot, which was typical of a result obtained on 
three separate occassions.
The position of the Molecular Weight marker is shown, and Cd36 
identified by the arrow at the right.
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3.3 Discussion
3.3.1 Glucose metabolism in epididymal adipocytes
Although adipose tissue only accounts for up to around 10% of whole body 
glucose uptake from the blood, the other main sites being muscle and brain 
(Chapter 24, Zubay, 1996), the primary adipocyte has become widely 
accepted as a model system for studying the mechanisms of glucose 
transport. This is due in part to problems faced when using muscle, 
particulaily in manipulation of whole muscle and difficulties in 
maintaining muscle cell cultures. Although the adipocytes can be obtained 
from several different fat depots within the rat, it is generally accepted that 
epididymal adipocytes represent one of the best model systems (Gliemann, 
1968; Gliemann, 1971; Ciaraldi, 1988),as these cells are easy to dissect and 
generally retain good responses to insulin.
Within the adipocyte, basal glucose requirements are maintained largely by 
glucose entry via the GLUTl glucose transporter which, as discussed in 
Chapter 1, resides predominantly at the plasma membrane in the basal 
state. Upon insulin stimulation, the large amount of glucose entering the 
cell can be explained by the movement of more glucose transporter 
proteins to the plasma membrane. Although a small amount of these 
transporters are likely to be GLUTl, the predominant transporter in this 
phase is the GLUT4 isoform (discussed in more detail in Chapter 1). 
GLUT4 translocates from intracellular stores to the plasma membrane in 
order to facilitate the entry of such large amounts of glucose (see Section
1.4 and 1.5).
When attempting to quantify movement of glucose transporters such as 
this, several factors have to be considered with regard to the primary 
adipocyte. Of relevance is the fact that the cells themselves are relatively 
fragile, meaning that the manipultions need to be carried out rapidly and 
under strictly controlled conditions of temperature, pH, etc. Care must also 
be taken to ensure that the cells do not become unnecessarily stressed, as
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this could ultimately activate pathways that may interfere with the 
experimental measurements. Fortunately the inclusion of stabilising 
compounds, such as BSA, into the media surrounding the cells overcomes 
the majority of these problems.
It is well documented that adipocytes in vivo are exposed to a variety of 
paracrine and endocrine factors that can have positive and negative effects 
on adipocyte metabolism. Perhaps one of the best studied is adenosine, 
and addition of adenosine to the media has proved to be most useful when 
manipulating these cells in vitro (Ciaraldi, 1988; Bush, 1988). Endogenous 
adenosine is released from the cells as they are maintained in suspension, 
and it has been observed that fluctuations in this adenosine release can 
dramatically alter the basal activity and viability of the adipocyte. To 
overcome this, large amounts of adenosine are included in the media, thus 
in a sense, desensitising the cell to the effects of any locally released 
adenosine.
Apart from problems regarding adipocyte health, similar challenges are 
faced regarding expression of the data in a meaningful way. Unlike the 
majority of cells maintained in culture, which generally grow uniformly on 
dishes, primary adipocytes are maintained in suspension. This in itself 
creates difficulty when attempting to standardise between different 
incubations. Although there are several potential ways of doing this none 
are completely satisfactory. Ideally data should be expressed per cell 
number but this has drawbacks. As previously mentioned, adipocytes are 
fragile and obtaining reliable and accurate numbers is very difficult. Even 
though there is no significant difference in the cell size between these two 
strains, inevitable handler error in measurements such as this may skew 
data. Similar problems are encountered with other methods, for example 
fluid volume of sample, which are again dependent on a variety of factors 
which may differ between cells from different strains. Measurements of 
protein or dry weight are commonly used, although these encounter similar 
problems and also do not take in to account the percentage of dead cells at 
the time of assay. Thus, data presented here is simply expressed as a factor
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of packed cell volume. Although this may have drawbacks it does allow 
consistency of approach between experiments. When data are expressed in 
this manner, it is apparent in Figure 3.3 that the ability of SHRSP 
adipocytes to transport DeGlc in the basal state is not altered, when 
compared to WKY controls. It is reasonable therefore to conclude that the 
machinery involved in mediating basal glucose transport (discussed in 
detail in Section 1.4.1) appears to be similarly functional in SHRSP and 
WKY.
In contrast to this, however, the ability of SHRSP adipocytes to mediate 
insulin-stimulated DeGlc uptake is clearly reduced. This data argues 
strongly that insulin-stimulated glucose transport is impaired in the SHRSP 
compared to the WKY, and Figure 3.3 illustrates for the first time that the 
SHRSP is indeed insulin-resistant at the level of glucose uptake. The 
potential mechanisms behind this are extensively discussed in Chapter 4.
3.3.2 Lipid metabolism in the SHRSP
Human subjects with hypertension not only commonly have defects in 
carbohydrate metabolism, but also an altered state of lipid metabolism 
characterised by elevated triglycerides and LDL-cholesterol. (Iritani et al., 
1977; Reaven et ah, 1989; and Aitman et ah, 1999).
The effect of insulin on fatty acid metabolism can be most easily studied by 
measuring its ability to modulate catecholamine-mediated NEFA release. 
Stimulation of cells with a synthetic catecholamine such as isoprenaline 
will result in activation of G sa  which will, by presently poorly defined 
mechanisms involving cAMP, activate the Hormone Sensitive Lipase 
(HSL) (Clifford et ah, 2000). Once activated the HSL will cleave 
intracellular fatty acids to generate and release NEFA’s into the 
extracellular environment. Since insulin is an anabolic hormone, it 
functions to inhibit the action of the HSL, again by poorly defined 
mechanisms. The SHR displays abnormal catecholamine-mediated fatty
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acid release, a phenomenon also observed in human hypertension (Aitman 
et ah, 1999). Obviously an important biological process, lipolysis is 
subject to tight regulation within the cell, and a large part in this process is 
played by negative-feedback regulation. Indeed after a period of stimulated 
release NEFA’s will eventually cause a negative feedback on further 
release from the adipocyte. Nevertheless, over a shorter period of time (up 
to around half an hour), it is possible to gain a measure of the activity of 
the HSL in response to exogenous agents simply by measuring NEFA 
release.
In the absence of any lipolytic stimulus, basal NEFA secretion from 
adipocytes is generally low (Aitman et ah, 1997) and, as can be seen from 
Figure 3.4, this does not differ in SHRSP and WKY adipocytes. Thus the 
basic machinery involved in maintaining basal adipocyte NEFA production 
appears not to be altered in these cells. It appears that the lipolytic effect of 
isoprenaline is also not significantly different. Figure 3.4 indicating that 
SHRSP adipocytes possess an equal capacity to activate the HSL over the 
time period measured. Importantly however, the ability of insulin to inhibit 
NEFA release is impaired in the SHRSP, as demonstrated in Figures 3.4 
and 3.5. This is of particular relevance, in that the SHRSP adipocytes are 
able to activate lipolysis normally but are unable to exert at least one 
important physiological control on this. Whether normal negative feedback 
responses to NEFA (initiated in response to elevated NEFA’s over a long 
time period) are also altered in SHRSP adipocytes remains to be addressed, 
although again this would be of relevance since any impairment would also 
result in elevated NEFA release for a longer time period.
Although this impairment would be expected to alter the overall levels of 
NEFA within the blood. Figure 3.6 shows that there is no overall difference 
in NEFA levels in serum of SHRSP and WKY rats. This is possibly 
because the rats are not specifically fasted and given access to standard 
chow ad libitum. In addition there are other factors which could 
contribute. It is possible that the epididymal adipocyte is not the major 
regulator of NEFA levels, and it is likely that many of the effects seen in
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this particular fat depot are at the local level. Obviously it would therefore 
be of interest to measure anti-lipolysis in other fat depots which may play a 
larger role. Secondly, although adipocytes are clearly important in fat 
metabolism, other tissues like muscle are also involved (Febbraio et a l,  
1999; and Ibrahimi et al., 1999). Again therefore, it would be of interest to 
examine NEFA metabolism in other tissue types such as muscle. Finally, it 
is possible that changes will be observed in serum NEFA levels in older 
animals, as they are exposed to continually altering fat metabolism over a 
longer time period and any compensatory mechanisms could be reduced 
with age.
In contrast to the NEFA levels, the SHRSP clearly has elevated levels of 
triglycerides in serum compared to the WKY controls. This is similar to 
the hypertriglyceridaemia observed in human hypertension, thought to be 
implicated in the development of atherosclerosis (Donnelly et al., 1992; 
Connell et al., 1994).
Clearly it is thus emerging that the phenotype observed the SHR, and now 
the SHRSP, is similar to that seen in humans and therefore places them 
central to understanding the development of human hypertension and 
related conditions such as Syndrome X. In summary, the SHR displays 
elevated blood pressure, reduced insulin-stimulated glucose uptake and a 
reduced insulin-mediated inhibition of lipolysis. Although the SHR also 
has elevated blood pressure and defective insulin-mediated glucose 
disposal, there are subtle differences. Interestingly, the basal rate of 
glucose transport in the SHR appears elevated compared to WKY controls 
(Reaven et al., 1989) in addition to the reduced maximal stimulation. Only 
the maximal response is altered in the SHRSP. The ability of isoprenaline 
to stimulate lipolysis is also impaired in SHR adipocytes, in contrast to the 
apparent normal stimulation in SHRSP adipocytes. Thus although the 
SHRSP and SHR phenotypes are clearly similar, there are important 
differences. Subsequently this suggests the presence of different 
underlying abnormalities.
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3.3.3 Potential defects behind the SHRSP phenotype
The nature of the defect in the SHRSP suggests the involvement of some 
locus which, either directly or indirectly has global effects on carbohydrate 
and lipid metabolism and blood pressure regulation. This is discussed 
below.
3.3.4 Cd36
As discussed in the introduction to this chapter and in Chapter 1, the 
emerging role of Cd36 in the SHR has placed it central to understanding 
how hypertension and metabolic defects develop in spontaneous 
hypertension in general (Aitman et al., 1999; Pravenec et al., 1999; de 
Winther et al., 2000). It has emerged however, that although it certainly 
plays a role in the SHR, its significance in other cases is less clear. For 
example, although some hypertensive patients who also exhibit metabolic 
disorders have missing or dysfunctional Cd36, this is not a feature in the 
majority of patients with elevated blood pressure (de Winther et al., 2000).
Indeed, this also seems to be the case with other animal model systems. 
For example, Gotoda et al were also able to observe the presence of a Cd36 
deletion mutation in three SHR sublines derived from the NIH but not in 
SHR/Izm and SHRSP/Izm strains (one of which exhibited insulin 
resistance) that had been maintained in Japan (Gotoda et al., 1999). Thus, 
these findings led to the conclusion that the SHR Cd36 deletion has 
somehow arisen de novo in the NIH colony. Our studies show that the 
SHRSP strain maintained in Glasgow (derived from NIH stocks) similarly 
does not display the Cd36 deletion, indicating that the Cd36 deletion 
identified by Aitman’s group probably arose after the Glasgow SHRSP 
strain was derived. Nevertheless, the data from Aitman and Pravenec are 
very convincing that in their SHR strain Cd36 is, or is close to, the major 
locus accounting for the abnormalities in lipid and glucose metabolism.
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Taken in context, these studies indicate that there are clearly several factors 
other than the Cd36 locus involved in the pathogenesis of spontaneous 
hypertension. Also of relevance is that only up to 40% of the defect in 
glucose metabolism observed in the SHR is explained by the Cd36 deletion 
(Aitman et al., 1999) and other factors of potential importance in the 
SHRSP could also be involved in this aspect of the SHR phenotype.
Interestingly however, it must be considered that Cd36 itself could be one 
of these other factors, in that the gene expression is normal but the function 
is somehow altered. In the introduction to this chapter (Section 3.1.3), the 
involvement of Cd36 in mediating the effects of ox-LDL was discussed. It 
has emerged recently that one of these effects is to cause the movement of 
eNOS from caveolae in endothelial cells. This effect was found to be 
related to the localisation of Cd36 to caveolae, illustrated both by 
immunoblotting and co-immuno-precipitation of Cd36 with a caveolin-1 
antibody (Uittenbogaard et al., 2000). Although this study has 
undoubtedly given insight into the cellular functions of Cd36, it also 
highlights the apparent importance of cellular localisation in Cd36 
function.
This consequently raises the question of whether Cd36 localisation (and 
hence potentially some functions) are different in the SHRSP and WKY. 
In the results section of this Chapter (Figure 3.7) we observed that Cd36 
protein expression in total membrane preparations was not altered. Recent 
observations in our laboratory have revealed that Cd36 is distributed 
similarly between WKY and SHRSP adipocytes, in that Cd36 is present in 
both the plasma membrane (PM) and the Low Density Membrane (LDM) 
fractions (Ian Salt, personal communication, data not shown). This is 
similar to the distribution observed by Bonen et al, where they found Cd36 
to be located primarily in the intracellular membrane (EM) and PM 
fractions in skeletal muscle cell study (Bonen et al, 2000). Interestingly 
they observed that Cd36 moved from the IM to the PM in response to 
insulin in these cells, in a manner analogous to GLUT4. In contrast Cd36 
did not appear to move significantly in response to insulin (IpM  for 15
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minutes) in our WKY or SHRSP adipocytes. This is quite possibly 
however a reflection both of differences in the conditions studied and the 
sub-cellular fractionation procedure, and hence further studies are needed. 
This will involve further sub-cellular fractionation under different 
conditions, and also eventual separation and characterisation of caveolae 
from both WKY and SHRSP adipocytes.
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3.4 Conclusions
Although the SHRSP has been well characterised previously with regard to 
hypertension, the results in this chapter represent the first demonstration 
that this strain also has impairments in carbohydrate and lipid metabolism. 
This is therefore of considerable importance as it allows the more effective 
use of the strain as a model for the development of spontaneous 
hypertension in conjunction with metabolic disorders.
Of further importance is the discovery that the Cd36 putative fatty acid 
transporter is normally expressed in adipocytes from SHRSP, in contrast to 
the deletion observed in the related SHR (Aitman et al., 1999). This 
reinforces the growing theory that, although altered Cd36 expression 
certainly plays a key role in the SHR and a limited role in human 
hypertension, it clearly does not explain the metabolic changes in all cases 
of spontaneous hypertension.
Clearly there exist other underlying deficits which must explain the SHRSP 
phenotype. This is of interest at the level of the SHRSP phenotype and 
could quite possibly impinge on other syndromes of spontaneous 
hypertension. Indeed in the SHR, Cd36 deletion does not account for all of 
the observed phenotype and so it is quite possible that some similar deficit 
functions here and in the SHRSP. A similar scenario could be envisaged in 
cases of spontaneous hypertension in humans; Cd36 deletion has been 
shown to play a limited role and it is quite possible that defects in the 
SHRSP play a role here.
Further analysis of Cd36, concentrating specifically on sub-cellular 
localisation studies and analyses of Cd36 transporter activity, may reveal 
other potential mechanisms underlying the SHRSP phenotype. Also of 
relevance is a cellular analysis of insulin action, including the role of 
signalling and trafficking (discussed in Chapter 4), processes which are key 
to all of the biological effects of insulin. Finally, genetic profiling 
strategies are undoubtedly central to studies such as this and will begin to
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provide answers to what genes and molecules may be significant in the 
phenotype of these animal models, and ultimately humans. This is 
discussed in more detail in the general discussion (Section 5.2.3).
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4 Sex Hormones and Insulin Resistance
4.1 Introduction
4.1.1 Insulin Resistance and Polycystic Ovarian Syndrome
As outlined in the previous chapters, resistance to the effects of insulin is a 
phenomenon present in, and central to a wide variety of disease states. 
Polycystic Ovarian Syndrome (PCOS) is yet another example of such a 
disorder, where reduced insulin sensitivity appears to be an integral 
characteristic of the disease (Dunaif et al., 1992; Rosenbaum et al., 1993; 
Taylor and Marsden., 2000; Lyall and Gould., 2000).
In order to understand how defective insulin action can impinge on a 
condition such as PCOS it is necessary to define the underlying endocrine 
abnormalities present within the disease state. This, in turn, calls for an 
understanding of the normal regulatory steps involved in ovarian hormone 
action. This is described below.
4.1.2 Oestrogen Function
Oestrogens are responsible for the development and maintenance of the 
female reproductive cycle. In pre-pubertal females, the level of circulating 
oestrogens is low, however in response to an increase in hormone 
secretion from the anterior pituitary and the hypothalamus there is a rapid 
increase in sex steroid secretion at the onset of puberty. These oestrogens 
are synthesised mainly by the ovary and throughout puberty the hormones 
are directly responsible for the maintenance of the reproductive organs, 
and the development of secondary sexual characteristics. There is also an 
accelerated growth phase and closure of the epiphyses of the long bones, 
representing the point at which adult height is reached. From this point 
on, and throughout the reproductive lifetime, the oestrogens are then 
responsible for maintenance of the menstrual cycle and the hormone
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changes associated with pregnancy. This function is however not 
performed alone, but in conjunction with progestérones and other 
gonadotrophic hormones (extensively reviewed in Speroff, 1994).
4.1.3 Ovulation and Annovulation
Just before the onset and during ovulation, escape from the negative 
feedback effects of oestrogen, progesterone and inhibin allows for a rapid 
increase in the secretion of follicle stimulating hormone (FSH) from the 
anterior pituitary. This surge in FSH levels acts to promote growth of the 
emerging follicles within the ovary, and enhances the ability of these 
developing follicles to carry out steroidigenesis (Speroff, 1994). 
Continued growth of the follicles, promoted by both autocrine and 
paracrine factors maintains the high sensitivity to FSH, thus allowing the 
conversion from a microenvironment dominated by androgens to one 
largely influenced by oestrogens. One important aspect of this is the FSH- 
mediated stimulation of the appearance of luteininzing hormone (LH) 
receptors, a prerequisite for ovulation and luteinization. The rapidly 
increased levels of circulating oestradiol are then responsible for triggering 
ovulation, that is release of one mature follicle from the ovary (Speroff, 
1994). This follicle is the one which has acquired the highest level of LH 
receptors and ability to carry out steroidigenesis (defined by highest levels 
of aromatase activity) in response to FSH. This successful follicle is also 
characterised by high oestrogen (for central feedback action) and greatest 
inhibin production (for local and central effects) (Speroff, 1994). 
Following release of this follicle there is a 2nd surge of oestrogen, this 
time accompanied also by a surge in progesterone levels. This point is 
known as the luteal phase, where FSH and LH levels begin to fall, and 
eventual demise of the corpus luteum occurs. As a result of degeneration 
of the corpus luteum, the local ovarian environment if freed from the 
action of oestrogen and progesterone, allowing FSH levels to once again 
rise and hence initiate the next cycle (Speroff, 1994).
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From events described above it is apparent that normal ovarian function is 
regulated by the complex interaction of several hormones, the levels of 
which change dramatically at different phases. This complex regulation 
does not occur in annovulatory subjects suffering from PCOS. Indeed 
PCOS patients do not display the fluctuations in hormone levels seen in 
normal subjects, instead many of the ovarian hormones can be described as 
being in a ’steady-state’ (Speroff, 1994). This does not necessarily mean 
that the levels are always low, simply that they are secreted in a manner 
that is unable to promote normal follicular growth, development and 
release. Phenotypes within the disease are diverse and patients will 
general display several other characteristics, including the presence of 
polycystic ovaries as defined by ultra-sound, oligo- or ammenorrhoea, 
raised testosterone, androstenedione, dehydroepiandrosterione (DHA), 
DHA sulphate, luitenizing Hormone (LH), 17-hydroxyprogesterone and 
oestrone concentrations, and abdominal obesity. Current lines of evidence 
indicate that the testosterone, androstendione and DHA are predominantly 
derived from the ovary, whereas the DHA suphate is predominatly adrenal. 
The increased circulating levels of oestrogens are thought to be less due to 
a direct increase in secretion, but more due to the peripheral conversion of 
the excess andostenedione to oestrone (Speroff, 1994).
4.1.4 Annovulation, PCOS and insulin action
Central also to a large majority of PCOS sufferers is the presence of a 
marked reduction in sensitivity to insulin, existing with the other 
endocrine disorders in an apparently integrated fashion (Dunaif et a l, 
1992; Rosenbaum et al., 1993).
Perhaps the first documented observations of a relationship between 
ovarian function and insulin sensitivity was the observation of ‘Diabetes 
des femmes a barbe’ or ‘Bearded-diabetic women’, in France in the early 
part of the last century, the beard resulting from the hyper-androgenism 
and the diabetes reflecting the impaired insulin sensitivity (Archard and
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Thiers, 1921). Subsequently further evidence that excess of insulin could 
influence ovarian function came from observations on six PCOS sufferers 
who showed extreme syndromes of insulin resistance. Although the 
insulin resistance could be attributed to Insulin Receptor antibodies in 
three of these cases, other insulin resistant PCOS subjects without 
antibodies were soon identified (Taylor and Marsden., 2000). 
Subsequently Burghen et al, using an Oral Glucose Tolerance Test 
(OGTT), demonstrated that a cohort of PCOS patients displayed a low 
sensitivity to insulin compared to non-PCOS sufferers (Burghen et al., 
1980)
Perhaps one major caveat regarding early studies on insulin sensitivity in 
PCOS subjects concerns the obesity often seen in these patients. Indeed 
there are clearly relationships between obesity and insulin sensitivity 
independent of PCOS, in that increased adiposity usually reflects a 
reduced sensitivity to insulin. Thus the insulin resistance itself may not be 
so much related to the endocrine disorders but rather the obesity. 
Nevertheless this has actually proved not to be the case and further studies 
(utilising both OGTT techniques and clamps) have demonstrated that the 
insulin insensitivity of PCOS subjects exists independently of obesity, in 
large well-characterised and matched groups of patients (Taylor and 
Marsden., 2000)
4.1.5 Characteristics of the Insulin Resistance of PCOS
In order to understand how insulin resistance affects or is affected by the 
abnormalities observed in PCOS subjects it is necessary to define this 
insulin resistance at the cellular level. The insulin resistance of PCOS, as 
described by Dunaif in 1989, is due to peripheral and not hepatic 
insensitivity to insulin (Dunaif et al., 1989). Indeed Marsden et al studied 
isolated adipocytes from PCOS patients and revealed that both insulin 
receptor binding and insulin-stimulated glucose uptake were markedly 
impaired when compared to age, sex and weight matched normal controls
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studied during the follicular phase of the normal menstrual cycle (Marsden 
et ah, 1999). An important feature of this study is that patients who had 
polycystic ovaries but regular menses were, thus affording a greater 
differentiation between normal and the characteristic PCOS group. These 
studies therefore suggest that some association exists between impairment 
in the ability to mediate normal ovulation and reduced insulin sensitivity.
4.1.6 Insulin Resistance of PCOS- cause or consequence?
Clearly the studies described above indicate that insulin resistance and 
annovulation are associated. Nevertheless, whether insulin resistance is 
indeed a cause or consequence of the other factors remains to be 
addressed. It is well established that improvements in insulin sensitivity 
can be obtained in Type 2 Diabetics by treatment with insulin sensitising 
agents such as metformin or the thiazolidinediones, troglitazone or 
roziglitazone (Fonseca et al., 2000; Raskin et al., 2000). If the insulin 
resistance in PCOS is responsible for the other defects then potentially 
correction of insulin insensitivity with such drugs could also ameliorate 
the other symptoms of PCOS. Treatment of PCOS subjects with 
metformin revealed indeed that fasting and glucose-stimulated insulin 
levels could be reduced. Interestingly, metformin treatment also reduced 
the activity of p450cl7a, an enzyme important in steroid metabolism and 
known to be elevated in PCOS (Lyall and Gould., 2000). Nevertheless 
other studies have produced conflicting results, in some studies insulin- 
sensitisers causing normalisation of menstrual cycles and hormone levels 
but having little effect in other studies (Taylor and Marsden., 2000). This 
probably reflects the complexity of PCOS as a disease and careful control 
and monitoring of phenotypes studied may reduce some of this conflict in 
responses.
In agreement with a role for insulin in causing the other endocrine 
abnormalities observed in PCOS is the fact that insulin is able to influence 
circulating androgen levels in different ways. Human ovaries possess
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insulin receptors and insulin is able to directly stimulate androgen release 
from the ovary in PCOS sufferers (Lyall and Gould., 2000). This agrees 
with the view that ovarian and not adrenal androgens are the main source 
of excess androgens in PCOS. The apparent inability of insulin to mediate 
normal biological effects in peripheral tissues but still retain a stimulatory 
effect on the ovary could be explained in several ways. This could include 
either activation of distinct or slightly different signalling pathways or 
receptors within the ovary and peripheral cells, maintenance of some other 
interacting pathway or sensitising mechanism within the ovary but not 
within the periphery (or some inhibitory pathway in periphery but not 
ovary), or even an indirect effect on the ovary via insulin action in the 
pituitary. Indeed insulin receptors are present in the pituitary and the 
ability of insulin to alter anterior pituitary function has been shown in vitro 
(Lyall and Gould., 2000).
Within the body the levels of free sex hormones are also influenced by 
their binding to sex hormone binding globulins (SHBG’s). PCOS subjects 
will generally display around a 50% reduction in SHBG levels, hence 
contributing to the elevated levels of free and available steroids in this 
condition. Interestingly, insulin is able to cause reductions in SHBG 
levels and hence indirectly causes elevations in free sex hormone levels 
(Lyall and Gould., 2000).
Thus clear evidence exists which implicates insulin as being responsible, 
at least in PCOS and related disorders, for modulating sex hormone levels 
and hence ovarian function.
Nevertheless there is also evidence to suggest the reverse, that excess 
circulating ovarian hormones themselves can indeed promote the 
development of insulin resistance. Perhaps one of the best illustrations of 
this is in pregnancy where marked increases in circulating oestrogens and 
progestogens occur early on and, as a result carbohydrate, lipid and 
intermediary metabolism become less sensitive to the effects of insulin 
(Taylor and Marsden,, 2000). Further evidence is that women on the
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combined oral contraceptive pill (containing an oestrogen and a 
progestogen) will often develop impaired glucose tolerance and a degree 
of insulin resistance with long term usage (Kasdorf and Kalkoff., 1988). 
Similar problematic reductions in insulin sensitivity are also observed in 
post-menopausal women on hormone replacement therapy (HRT), where 
HRT is often advised to maintain the cardio-protective effects of 
oestrogens (Taylor and Marsden., 2000).
Thus there are clearly a plethora of diseases where oestrogen reduction of 
peripheral insulin sensitivity may exacerbate, or even initiate disease 
development. For example in PCOS, although oestrogen effects on 
peripheral insulin responsive tissues are unlikely to explain the whole 
disease phenotype, undoubtedly effects such as these will make the 
condition worse. It is therefore important to understand how oestrogen 
treatment is able to influence insulin responsiveness in target tissues.
4.1.7 Insulin Resistance in other chronic annovulatory states?
If the insulin resistance of PCOS is reflective simply of the lack of 
ovulation in these patients, it follows that other chronic annovulatory states 
may also be associated with insulin insensitivity even under a completely 
different hormone profile. To try to answer this question patients suffering 
from hypogonadotrophic hypogonadism (HH) were studied with regard to 
measuring insulin sensitive responses in primary adipocytes. Interestingly 
this revealed that insulin receptor binding was reduced by around 40%, as 
was the maximum glucose uptake in these patients (Taylor and Marsden., 
2000). This clearly demonstrates a further link between insulin resistance 
and annovulation at least in part independent of hormone profile, since 
PCOS and HH differ in this regard.
I l l
4.1.8 Potential mechanisms of oestrogen-induced insulin resistance 
in target cells
The signalling pathways activated by insulin in fat and muscle are outlined 
in detail in Chapter 1. Essentially, oestrogens could modulate any of the 
important steps in insulin signalling, shown below in Figure 4.1.
The most likely explanation however, given the known mechanisms of sex 
steroid action, is that the oestrogens are acting at the level of DNA 
transcription and influencing the production of proteins important in 
insulin action.
Sex steroid receptors are members of a super-gene family that includes 
receptors for steroids, thyroid hormones, vitamin D3 and Retinoic acids 
(Hyder et al., 1999). All of these receptors are intracellular. Binding of 
the ligand to the receptor results movement of the complex to the nucleus, 
where it the acts as a transcription factor to influence DNA directed RNA 
and protein synthesis.
There are actually two different oestrogen receptor forms, derived from 
two different gene products- oestrogen receptor (HR) a  and (3, both of 
which bind to oestrogen response elements (ERE’s) present within distinct 
DNA sequences (Hyder et al., 1999). It is generally believed that the E R a 
and ERP bind to different ERE’s with different affinities, and this is likely 
to be one mechanism of selectivity (Hyder et al., 1999). ER action is also 
putatively influenced by a 160kDa associated protein. Oestrogen Receptor 
Associated Protein (ERA? 160). Indeed mutational analysis of this protein 
has revealed that the ability of ER to activate transcription parallels the 
ability to bind ERA? 160 (Halachmi et al., 1994).
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Figure 4.1 Putative signalling pathways mediating the metabolic 
effects of insulin in 3T3-L1 adipocytes
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4.1.9 Aims
This study was designed to answer the question of whether sex steroids are 
able to exert a direct effect on insulin responsive tissues. To avoid the 
problems associated with biopsy tissue, such as availability and difficulties 
in manipulation, a model cell line was used, the 3T3-L1 adipocyte. The 
3T3-L1 adipocyte is derived from the 3T3-L1 fibroblast by selective 
induction into an insulin-responsive phenotype according to the methods 
outlined in 2.3.3 and 2.3.4. Once differentiated, the 3T3-L1 adipocyte 
responds well to insulin and many of the insulin-responsive signalling 
pathways are well characterised. Unfortunately, it is not possible to 
culture the 3T3-L1 adipocytes in an environment exactly mimicking that 
seen in conditions such as PCOS, where the cells are exposed to 
consistantly elevated levels of hormone over long-periods of time, since 
these cells only retain the insulin-responsive phenotype for around 5 days. 
As an alternative these cells have been incubated with physiological or 
pharmacological doses of sex steroid for up to 24 hours. Although this 
treatment is not ideal, it is thought to be a broadly representative 
adaptation using this model.
Previous work by Ian Campbell has shown that treatment of 3T3-L1 
adipocytes with either oestradiol (El), oestrone (E2) or oestriol (E3) 
causes a marked reduction in the ability of these cells to mediate insulin- 
stimulated glucose transport (Campbell, Ph.D Thesis, University of 
Glasgow, 1997). The aim of this chapter is to determine whether this 
effect is due to a direct action on insulin signalling in these cells.
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4.2 Results
4.2.1 The effect of E l, E2 and E3 on insulin-stimulated glucose 
transport in 3T3-L1 adipocytes
Previous work by Ian Campbell has established that treatment of 3T3-L1 
adipocytes with either E l, E2 or E3 was able to markedly reduce the 
ability of these cells to mediate insulin-stimulated glucose transport, the 
effect being significant after 8 hours and maximal at 24 hours (data not 
shown). Maximal effects of each sex steroid were seen at a dose of 
lOOnM. Figure 4.2 shows that 12 hours of treatment with lOOnM E l, E2 
or E3 was similarly able to reduce the maximum insulin-stimulated 
glucose transport in 3T3-L1 adipocytes in my hands, with an order of 
potency equal to that seen in previous studies (E2 > E3 > E l).
4.2.2 The effect of E l, E2 and E3 on total levels of GLUT4 in 3T3-L1 
adipocytes
As described in detail in Chapter 1, the main insulin-responsive glucose 
transporter is the GLUT4 isoform, which translocates from intracellular 
stores to the plasma membrane in response to insulin. Since GLUT4 is so 
central to this process, it follows that any alterations in expression of this 
protein could explain diminished glucose transport. This appears not to be 
the case in this system. Figure 4.3 shows how GLUT4 expression remains 
unaltered after 12 hours of steroid treatment. This is also illustrated in 
Figure 4.8, where data from three experiments is quantified. In contrast 
plasma membrane lawn assays (carried out by Gwyn Gould, University of 
Glasgow) revealed that the translocation to the plasma membrane in 
response to insulin was reduced by 65 + 8% in El-treated cells, 54 + 8% in 
E2-treated cells and 51 + 9% in E3-treated cells (p<0.05 using the students 
t-test in each case) (data not shown).
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Figure 4.2 The effect of E l, E2 and E3 on insulin-stimulated 
glucose transport in 3T3-L1 adipocytes
3T3-L1 adipocytes, 4 days post-differentiation, were incubated over-night 
in the presence of vehicle or lOOnM E l, E2 or E3. The next day cells 
were washed and then incubated in serum-free DMEM for a minimum of 2 
hours. After this time 2-Deoxy-D-Glucose uptake assays were carried out 
according to the method outlined in 2.3.7, using lOOnM insulin for 15 
minutes to stimulate uptake.
Data shown is representative of 3 such experiments, and the error bars 
represent the standard error of the mean.
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Figure 4.3 The effect of E l, E2 and E3 on total levels of GLUT4 in 
3T3-L1 adipocytes
Steroid treatments were carried out on 10cm dishes of 3T3-L1 adipocytes 
in the same way as outlined in Figure 4.2, and whole cell lysates prepared 
as outlined in Section 2.3.10. Samples were resolved by SDS-PAGE, as 
outlined in section 2.6, and then immuno-blotted for GLUT4 protein using 
a rabbit polyclonal antibody as described in section 2.7.
The blot shown is typical of a representative set of data obtained on three 
separate occasions. The position of the molecular weight marker is shown, 
and GLUT4 identified by the arrow at the right.
Quantification of three experiments of this type revealed no significant 
difference in GLUT4 levels between the 4 treatment groups (see Figure 
4.8).
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4.2.3 The effect of E l, E2 and E3 on total levels of IRS-1 and IRS-2
in 3T3-L1 adipocytes
Since GLUT4 levels are normal but both insulin-stimulated glucose 
transport and GLUT4 translocation are reduced within these cells, it 
follows that levels or functionality of some other protein leading to these 
steps must be altered. As outlined in Chapter 1 there are potentially 
several signalling molecules, alterations in the activity or levels of which 
could reduce insulin signalling. IRS-1 and IRS-2 are the two of first 
effector molecules activated in response to insulin (see Section 1.4.3), and 
they have been illustrated to be of vital importance. Figure 4.4 illustrates 
that E l, E2 and E3 are indeed able to alter the total cellular expression of 
IRS-1 and although E2 and E3 appear more potent than E l, all steroids are 
able to significantly reduce the levels of the protein. Also seen in Figure
4.4 is the ability of the steroids to reduce total cellular levels of IRS-2, 
with an almost complete abolition by all 3 steroids. This is demonstrated 
graphically in Figure 4.8, where data from three experiments is quantified.
4.2.4 The effect of E l, E2 and E3 on total levels of PI3’Kinase in 
3T3-L1 adipocytes
It is well established that the main innnediate downstream target of the 
1RS proteins is PI3’Kinase, and so the effect of E l, E2 and E3 on cellular 
levels of this protein was examined. In common with the 1RS proteins, 
steroid treatment caused a dramatic reduction (> 50% reduction compared 
to vehicle) in the levels of the p85 sub-unit of PI3 K as can be seen in 
Figure 4.5. Data from three such experiments is quantified in Figure 4.8.
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Figure 4.4 The effect of E l, E2 and E3 on total levels of IRS-1 and 
IRS-2 in 3T3-L1 adipocytes
Whole cell lysates were prepared as outlined in Figure 4.3. Samples were 
then resolved by SDS-PAGE, as outlined in section 2.6, and immuno- 
blotted for IRS-1 or IRS-2 protein using a rabbit polyclonal antibody as 
described in section 2.7.
The blot shown is typical of a representative set of data obtained on three 
separate occasions. The position of the molecular weight marker is shown, 
and IRS-1 and IRS-2 are identified by the arrows at the right.
Quantification of three experiments of this type revealed that all three 
steroids were able to significantly reduce the levels of IRS-1 and IRS-2 in 
whole cell lysates (see Figure 4.8).
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Figure 4.5 The effect of El, E2 and E3 on total levels of PI3’Kinase 
p85 sub-unit in 3T3-L1 adipocytes
Whole cell lysates were prepared as outlined in Figure 4.3. Samples were 
then resolved by SDS-PAGE, as outlined in section 2.6, and immuno- 
blotted for p85 protein using a rabbit polyclonal antibody as described in 
section 2.7.
The blot shown is typical of a representative set of data obtained on three 
separate occasions. The position of the molecular weight marker is shown, 
and p85 is identified by the arrow at the right.
Quantification of three experiments of this type revealed that all three 
steroids were able to significantly reduce the level of p85 PI3’K subunit in 
whole cell lysates (see Figure 4.8).
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4.2.5 The effect of E l, E2 and E3 on total levels and activity of PKB
in 3T3-L1 adipocytes
The precise role of PKB in mediating glucose transport is still 
controversial. Nevertheless many studies support a role for this protein. 
Certainly insulin-stimulation will cause a rapid increase in PKB activity 
within 3-5 minutes. In contrast to the effects of the sex steroids to reduce 
cellular levels of the ERS proteins and PI3’K however, Figure 4.8 and 
Figure 4.6A illustrate that total PKB levels remain unchanged in response 
to steroid treatment. In spite of this however, steroid treatment is able to 
di'amatically reduce the extent of PKB activation in response to insulin 
stimulation (E l, E2 and E3; 34.5 ± 9.6, 25.5 ±8.1 and 82.5 ± 13.1 percent 
maximum insulin response respectively, n=3, p<0.05 using students t-test).
This reduction in activity in spite of normal expression suggests that the 
reduction in PKB activity is a consequence of impaired up-stream IRS- 
PI3’K interaction, and presumably activation.
The rank order of potency of E l, E2 and E3 for this effect on PKB is 
different than that seen for the effects on glucose transport and the up­
stream proteins. This agrees with the belief that other intermediary 
proteins (which may or may not be regulated by the steroids) are involved 
in the steps between PI3’K and PKB.
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3T3-L1 adipocytes
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Figure 4.6 The effect of El, E2 and E3 on levels and activity of 
PKB in 3T3-L1 adipocytes
For legends see next page
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Figure 4.6 The effect of E l, E2 and E3 on levels and activity of
PKB in 3T3-L1 adipocytes
Panel A
Whole cell lysates were prepared as outlined in Figure 4.3. Samples were 
then resolved by SDS-PAGE, as outlined in section 2.6, and immuno- 
blotted for PKB protein using a rabbit polyclonal antibody as described in 
section 2.7.
The blot shown is typical of a representative set of data obtained on three 
separate occasions. The position of the molecular weight marker is shown, 
and PKB is identified by the arrow at the right.
Quantification of 3 experiments of this type revealed no significant 
difference in PKB levels between the 4 treatment groups (see Figure 4.8).
Panel B
3T3-L1 adipocytes, 4 days post-differentiation, were incubated over-night 
in the presence of vehicle or lOOnM E l, E2 or E3. The next day cells 
were washed and then incubated in serum free DMEM for a minimum of 2 
hours. After this time, half of the cells from each treatment were 
stimulated with lOOnM Insulin for 5 minutes. Lysates were then prepared 
as above, and then subjected to a PKB activity assay exactly as outlined in 
Section 2.3.11.
Data shown is representative of 3 such experiments, and is expressed 
relative to the maximum stimulation obtained in control (vehicle-treated) 
cells, with the error bars representing the standard error of the mean
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4.2.6 The effect of E l, E2 and E3 on sub-cellular distribution of IRS-
1 and IRS-2 in 3T3-L1 adipocytes
Although the effect of the steroids to reduce the total levels of 1RS proteins 
and PIS’K could easily explain the inhibition of insulin action observed in 
these cells, it is also of interest to determine whether the steroids are able 
to influence the sub-cellular distribution of the ERS proteins. This is 
largely due to the emerging importance of sub-cellular localisation in 
insulin-induced activation of the 1RS proteins, and possibly in the 
development of insulin resistance. As outlined in Chapter 1 activation of 
ERS-1 and ERS-2 occurs while engaged in a ‘scaffold network’ situated 
within the plasma membrane environment. Stimulation with insulin is 
believed to release this protein into the cytosol. This is believed to be of 
great importance as aberrant movement is believed to play a role in the 
development of insulin resistance. Indeed in Figure 4.7 it can be seen that 
treatment of 3T3-L l’s with E l, E2 or E3 results in a dramatic reduction in 
the levels of IRS-1 in the membrane fraction and a concomitant increase in 
the cytosolic fraction. Steroid treatment also appears to reduce the amount 
of membrane-associated IRS-2 but, in contrast to the effects observed with 
ERS-1, Figure 4.7 shows that this is accompanied by a similar decrease in 
the soluble fraction.
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Figure 4.7 The effect of E l, E2 and E3 on sub-cellular distribution 
of IRS-1 and IRS-2 in 3T3-L1 adipocytes
In order to determine the effects of E l, E2 and E3 on the intracellular 
distribution pattern of IRS-1 and IRS-2, membrane and cytosolic fractions 
were prepared after steroid treatment as outlined in Section 2.3.9. Samples 
were resolved by SDS-PAGE, as outlined in section 2.6, and then 
immuno-blotted for 1RS-1 or IRS-1 protein using a rabbit polyclonal 
antibody as described in section 2.7.
The blot shown is typical of a representative set of data obtained on three 
separate occasions. Note that approximately 10% of the membrane and 
5% of the cytosolic protein obtained from one 10cm dish was loaded per 
lane.
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Figure 4.8 Quantification of the levels of GLUT4, IRS-1, IRS-2, 
p85 and PKB in steroid treated lysates
The bar graph illustrates a quantification of blots typical of those obtained 
in Figures 4.4 to 4.6. Expression levels in steroid treated cells are 
expressed as a percentage of expression in control (vehicle)-treated cells. 
Error bars represent the standard error of the mean. P<0.05, using the 
students t-test.
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4.3 Discussion
4.3.1 Effects of E l, E2 and E3 to inhibit insulin-stimulated glucose 
transport
Although the association between circulating oestrogen levels and 
impaired insulin action has long been appreciated there has up until now 
been a failure to demonstrate a direct effect of sex steroids on peripheral 
insulin-sensitive tissues. The data presented in Figure 4.2 however are a 
direct demonstration of such an effect, where E l, E2 and E3 are able to 
effectively inhibit insulin-stimulated glucose transport in the 3T3-L1 
adipocyte, a suitable cell-culture model of an insulin-sensitive peripheral 
tissue. Although the 3T3-L1 adipocyte is clearly far removed from the 
adipocytes of human PCOS subjects (discussed in more detail in Section 
4.1.6) the results presented clearly have implications for the development 
of such disorders.
Current lines of evidence do not favour a role for oestrogen action on 
peripheral tissues in initiating the onset of PCOS (Taylor and Marsden., 
2000), nevertheless it is thought that such an action does likely have a role 
in propagating the disease once it has began to develop. Indeed, some 
current lines of evidence suggest that the persistent hyper-insulinaemia of 
PCOS is able to influence the elevated oestrogen secretion and that the 
reverse is also true (refer to Section 4.1.4).
With regard to the insulin resistance present in PCOS, Dunaif et al 
illustrated that this is a peripheral and not a hepatic insulin resistance 
(Dunaif et ah, 1989). In other words, the insulin resistance is not related 
to any impairment at the level of the liver to exert normal control over 
glucose homeostasis but more a reduced ability of peripheral tissues to 
respond normally to insulin. This therefore suggests impairment in some 
mechanism within the peripheral tissues, which is responsible for 
mediating the steps between insulin binding and the biological effects. 
This fits well will the data presented in Figure 4.2, since oestrogen
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treatment is also affecting some machinery within the 3T3-L1 adipocyte,
resulting in development of cellular insulin resistance.
The data presented also has implications for other disorders where insulin 
resistance is associated with an altered sex hormone profile. Pregnancy, 
long-term use of the combined-oral contraceptive pill and the use of HRT 
can all result in a state of cellular insulin resistance. Although it is perhaps 
not ideal to group these three conditions together, they do all develop into 
an insulin resistant state by apparently similar mechanisms- the presence 
of elevated circulating levels of oestrogens. Therefore it is quite possible 
that the development of insulin resistance in these conditions follows a 
similar pattern to that observed in the 3T3-L1 adipocyte cell system.
Due therefore to the potential similarity between mechanisms observed in 
the 3T3-L1 and potential mechanisms of peripheral insulin resistance in 
the conditions discussed above it is of interest to further define the 
mechanisms of insulin resistance in the 3T3-L1.
4.3.2 Effects of E l, E2 and E3 on GLUT4 Function and Expression
In common with the ability of the sex steroids to inhibit insulin-stimulated 
glucose transport, reductions in movement of GLUT4 to the plasma 
membrane have also been observed (Campbell, PhD thesis. University of 
Glasgow, 1997). Thus therefore suggests that defects are present either at 
the level of GLUT4 itself, or in the upstream signalling proteins.
Rosenbaum et al have shown similar reduction in sensitivity to insulin in 
PCOS patients, which is apparently due to an obesity-independent 
reduction in GLUT4 expression in adipocytes (Rosenbaum et al., 1993). 
This is not the case in our study where the expression of GLUT4 is not 
altered after a 12 hour incubation with sex steroids. It is however quite 
likely that the differences observed in our system may relate to how the 
parameters are actually measured. Indeed PCOS patients observed at the
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early stages of this disease may show a lesser reduction in GLUT4 content 
and conversely, were it possible to treat 3T3-Ll’s with steroid for much 
longer periods, reductions in GLUT4 expression may be observed.
Despite the lack of effect of the sex steroids on GLUT4 expression, they 
are clearly able to reduce insulin-stimulated GLUT4 translocation and 
transport in the 3T3-L1 adipocyte. It therefore follows that sex steroids 
are able somehow to modulate some of the other key steps leading to 
glucose transport.
4.3.3 Effect of E l, E2 and E3 to reduce levels of key insulin 
signalling molecules
The early signalling pathways activated by insulin binding to the receptor 
are well appreciated. This is discussed in more detain in Section 1.4.2. 
Due to the key role of many of these proteins they are key targets for 
oestrogen-induced inhibition of glucose transport.
(i) IRS-1 and IRS-2
Although the actions of IRS-1 and IRS-2 overlap, and can be partly 
replaced by other 1RS proteins such as IRS-3 (see Section 1.4.3), 
numerous studies have high-lighted the vital roles of both proteins in 
mediating insulin-stimulated glucose transport (Holman and Kasuga, 
1997). The observation in Figure 4.4 that total levels of IRS-1 and IRS-2 
are dramatically reduced suggests that this effect is least partly responsible 
for the impairment in insulin-stimulated glucose transport in observed 
response to oestrogen treatment. Obviously a reduction such as this has 
implications for all metabolic actions of insulin, since these proteins are 
vital adaptor molecules, linking the upstream binding of insulin to its 
receptor to activation of all downstream responses. One of these 
downstream responses, activation of PI3’K, is discussed below.
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(ii) PD ’K
Undoubtedly, the reduction in 1RS protein levels will have dramatic effects 
on the activation of PI3’K simply as a consequence of there being a 
reduced capacity for activation. Nevertheless there is little doubt that any 
alterations in expression of PI3’K itself will also fundamentally impair the 
ability of insulin to signal effectively. Therefore it is of interest that the 
1RS proteins appear not unique in being targets of the sex steroids. Indeed 
it can be seen in Figure 4.3.4 that the levels of the p85 sub-unit of PI3’K 
are significantly reduced also. Since many studies using inhibitors or 
dominant negative enzyme sub-units (see Section 1.4.4) have 
demonstrated how reduced p85 expression can dramatically impair 
insulin-stimulated glucose transport it is very likely that this will also 
contribute to the development of cellular insulin resistance in these cells.
Thus it appears that the oestrogen induced-insulin resistance in 3T3-L1 
adipocytes develops as a result of reduced levels of three important 
signalling molecules, IRS-1, IRS-2 and the p85 sub-unit of PI3’K. This 
will ultimately reduce the capacity of these cells to transduce the signals 
leading to the normal insulin-activated responses. The links between an 
altered biological response in spite of normal expression of key mediators 
of that response- glucose transport/GLUT4, and impaired upstream 
signalling has therefore been well illustrated. However it is also of interest 
to determine whether other downstream responses are similarly affected.
(i) PKB
It does appears that the reduction in 1RS-1/2 and p85 levels is able to affect 
downstream biological responses other than activation of glucose 
transport. Insulin causes a rapid and transient activation of PKB in 
adipocytes and although PKB activation is believed to play some role in 
glucose transport the exact mechanisms are unclear. Certainly studies 
using over expression of specific PKB isoforms have illustrated how 
insulin-stimulated glucose transport is enhanced (Foran et al., 1999; Hill et
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a l,  1999), In contrast however studies where PKB expression is reduced 
by various means have often failed to show any effect on glucose transport 
(still to find refs). PKB is also thought to be involved in mediating the 
anti “lipolytic effects of insulin, another important physiological effect 
induced by insulin in these cells. This is discussed in more detail in 
Section 1.4.5.1. Nevertheless, regardless of the specific role(s) of PKB it 
is undoubtedly intrinsically linked to insulin signalling and biological 
effects. As Figure 4.6 illustrates, although the expression of PKB remains 
unaltered, the insulin-stimulated activity is significantly reduced in 
response to sex steroid treatment indicating that the reduced levels of 1RS 
proteins and PI3’K contribute to reduced activation of downstream targets 
other than those classically involved in glucose transport. Importantly the 
basal activity of PKB is unaltered, further suggesting that the defect is not 
at the level of the downstream response but with the up-stream proteins, 
IRS-1, IRS-2 and PI3’K.
(ii) Mitogenic signalling
From the results presented in this chaper it appears that sex steroid induced 
changes in the levels of upstream signalling molecules are able to 
effectively reduce metabolic signalling events such as glucose transport in 
3T3-L1 adipocytes. It remains to be addressed whether this inhibition also 
impinges on the mitogenic effects of insulin, for example MAPK or 
p70s6K activation in unclear. It is likely that 1RS-1/2 and PI3’K activated 
events may be altered in some way, simply as a consequence of the 
reduced levels of upstream proteins. Nevertheless, several mitogenic 
actions of insulin can be activated independently of the 1RS proteins and 
PI3’K, including activation of MAPK, and it is feasible that the activity 
and levels of these proteins will be unaltered. This would be analogous to 
the work recently reported by Cusi et al, where a group of NIDDM 
patients were seen to have impaired IRS-1/2 PI3’K coupling but normal 
MAPK activation (Cusi et a l ,  2000). It remains to be addressed whether 
such as situation exists in the 3T3-L1 adipocyte and indeed the functional 
implication of such a situation in a condition like PCOS.
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4.3.4 Impaired 1RS-1/2 function in sex steroid-induced insulin 
resistance- potential mechanisms
Although the reduced expression of IRS-1/2 and PI3’K can easily explain 
the observed reduction in insulin-stimulated glucose transport, it has 
recently emerged that many factors other than protein expression are 
important in the activation of signalling cascades (White and Kahn., 1994; 
Inoue et al., 1998; Clark et al., 2000),
In the field of 1RS-1/2 signalling, the importance of tyrosine 
phosphorylation has long been appreciated, the phosphorylation of both 
proteins on distinct tyrosine residues being essential for their interaction 
with downstream signalling molecules (refer to Section 1.4). Recently 
however it has also emerged that the cellular localisation of the 1RS 
proteins is crucial to their functioning (Inoue et al., 1998; Clark et al., 
2000; and also refer to section 1.4.3). Indeed, recent work by Clark et al 
has illustrated that the 1RS proteins appear to associate with a cytoskeletal 
fraction that is insoluble in non-ionic detergents and associates with the 
particulate fraction of cell membranes. It is believed that this complex 
may perform a unique function, allowing the 1RS proteins to interact with 
the IR and also providing a location for 1RS interaction with downstream 
target molecules. 1RS proteins are subsequently released from this 
scaffold after insulin stimulation occurs. Interestingly, release from this 
platform is also associated with development of insulin resistance, the 1RS 
proteins failing to interact with or being abnormally released from the 
scaffold, hence preventing the normal interactions (Clark et al., 2000).
It appears that sex steroid treatment of 3T3-L1 adipocytes also induces 
resistance to the effects of insulin in a mechanism similar to this. It can be 
seen from Figure 4.7, that both IRS-1 and IRS-2 are located largely in the 
membrane fraction of basal 3T3-L1 adipocytes, but steroid treatment 
dramatically alters this. In the case of IRS-1, there is an apparent 
movement of the protein from the membrane to the soluble protein 
fraction, presumably reflecting disassembly of IRS-1 from its normal site
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inside the cell. Assuming a mechanism similar to that outlined by James et 
al, this movement of IRS-1 will alter the subsequent ability of IRS-1 to 
interact with the ER and its ability to interact with downstream effector 
molecules. Importantly, however, the IRS-1 increase in the soluble 
fraction is much less than the amount of IRS-1 released from the 
membrane complex. This is in agreement with the view that a large 
percentage of the released protein does not remain within the cell and is 
actually degraded (Clark et ah, 2000).
Similar reductions, shown also in Figure 4.7, are observed in the IRS-2 
content of membranes after sex steroid treatment. This presumably 
reflects a similar disassociation of IRS-2 with a key membrane component 
to which it localises to function properly. Little 1RS-2 was found in the 
soluble fraction, again reinforcing the thought that the released protein is 
indeed degraded.
There are potentially several reasons why the levels of IRS-1 in the 
membrane and the cytosol appear higher than those of IRS-2. Firstly, it 
may simply be a reflection of there being higher total levels of IRS-1 
within the cell. Another possibility is that IRS-2 is simply degraded more 
rapidly than IRS-1, and hence is less easy to detect. It is also possible that 
the IRS-1 antibody has a higher affinity than the IRS-2 antibody, and as a 
result more easily detects a signal. Indeed a combination of both these, 
and other, factors is likely to be involved. In this regard, it can be seen 
that the levels of IRS-1 and IRS-2 in whole cell lysates (Figure 4.4) appear 
to be less than the total amount detected in the membrane and cytosol 
fractionation (Figure 4.7). Although this might be due to differential 
protein loading this is unlikely as similar amounts of protein were loaded 
per lane for each blot. Another more likely explanation is simply 
differences in processing of the blots, in that although the western blots 
were carried using the same protocol, there could possibly be subtle 
differences between experiments.
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Nevertheless, the data presented in this Chapter clearly illustrates the
ability of sex steroids to modulate insulin-mediated biological responses,
by inhibiting the function of key upstream signalling molecules.
4.3.5 Potential Mechanisms of sex steroid action in 3T3-L1 
adipocytes
The effect of the sex steroids to reduce the intracellular levels of insulin- 
sensitive signalling components could quite easily be explained by an 
action of the steroids at the gene level (discussed in Section 4.1.8). 
Although the genes expressed in the mature 3T3-L1 adipocyte will 
undoubtedly differ significantly form the genes expressed in the cells of 
the ovary, the general mechanism of oestrogen action will be similar. 
Although there is a lack of data regarding characterisation of sex steroid 
receptors in 3T3-L1 adipocytes, several studies have revealed the presence 
of oestrogen receptors in mature human adipose tissue (Pedersen et al., 
1992; Pedersen et al., 1996). In our study, it was observed that steroid 
treatment didn’t reduce the total recovery of protein (data not shown) from 
the cells and so it is unlikely that the steroids are having a general effect to 
suppress protein production.
More likely the steroids are acting at specific EREs located within the 
genes, to selectively modulate RNA and protein synthesis. EREs within 
the 1RS or p85 genes have not been extensively studied but it is highly 
likely that such sites will exist. The apparent differing potencies of the 
steroids is likely to be due to a combination of several factors, including 
potency of ligand-binding to receptor or expression of different ER 
isoforms which may favour binding of one steroid over another.
The ability of the sex steroids to influence intracellular location of the 1RS 
proteins (discussed in Section 4.3.4) is perhaps more difficult to explain. 
One possible explanation is that the sex steroids are influencing expression 
of other, as yet unidentified, accessory proteins which are important in
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targeting of the 1RS proteins. Should the expression of specific proteins 
be up- or down-regulated, then mis-targeting (and hence destruction) 
would occur. Another possible, but perhaps less likely, explanation is that 
perhaps the ligand-bound ER complex has some other biological function 
and is able to directly influence the formation of insulin signalling 
components.
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4.4 Conclusions
Many studies have demonstrated associations between endocrine disorders 
such as PCOS and impaired insulin sensitivity but the molecular 
mechanisms behind these are poorly understood. It is generally perceived 
such conditions are multi-factorial and that sex steroid induced changes in 
peripheral insulin-sensitive tissues are not sufficient to fully explain the 
observed phenotype (Taylor and Marsden., 2000). Nevertheless it is 
feasible that a direct action of oestrogens to supress insulin action could 
influence already activated disease states (Taylor and Marsden., 2000). To 
date, however, there have been a lack of studies looking from this aspect. 
This study aimed to address this by studying the effect of oestrogens on 
insulin sensitivity in 3T3-L1 adipocytes.
Oestrogen action on 3T3-L1 adipocytes was indeed found to significantly 
inhibit insulin-stimulated glucose transport. Interestingly this was not due 
to any change in GLUT4 expression but in fact due to aberrant expression 
and localisation of the up-stream signalling intermediates IRS-1 and IRS- 
2. This effect is undoubtedly in part mediated by direct effects of 
oestrogen-ER complexes to influence the new synthesis of the 1RS 
proteins, and other accessory proteins. A direct action of ligand-ER 
complexes on formation of insulin-signalling complexes must also be 
considered.
These observations are of interest not only with regard to insulin signalling 
and the development of insulin resistance in culture models, but also of 
clinical relevance. As already illustrated, there are many conditions where 
there is an excess of sex steroids and impaired insulin-sensitivity. 
Although it is unlikely that the affects seen will adequately explain all 
such conditions, it is likely that similar effects could contribute to the 
development and worsening of the disease state.
Further work would be aimed at looking more closely at different aspects 
of the effects of the sex steroids on 3T3-L1 adipocytes, for example effects
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on levels and activity of mitogenic signalling intermediates in order to 
determine whether this pathway is similarly affected. It would also be of 
interest to look more closely at the 1RS genes, and determine the presence 
and location of specific oestrogen responsive areas. Finally the ultimate 
aim would be to take this forward into human adipocytes, and determine 
the whether similar defects could be observed in adipocytes obtained from 
PCOS subjects or similar compared to controls.
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5 General Discussion and Further Work
5.1 Insulin action and inaction
As discussed throughout this thesis, insulin resistance is a phenomenon 
present in a variety of disease states. Perhaps the most obvious of these is 
NIDDM, where the profound insulin resistance in target tissues is coupled 
with an inadequate pancreatic P cell compensatory response (Dale et ah, 
1996; Gould, 1997; Brady et al., 1999). NIDDM is not unique in this 
regard however, and insulin resistance is also associated with a variety of 
cardiovascular disorders. Indeed, as discussed in more detail in Section 
1.10, there is a well established interaction between primary hypertension 
and insulin resistance (Mitchell et al., 1990; Morris et al., 1994)., and this 
frequently couples with abnormal lipid metabolism in a condition referred 
to as the Metabolic Syndrome or Syndrome X (Morris et al., 1994). 
Insulin resistance is also a common feature of disorders of the female 
endocrine system, and is particularly associated with PCOS and HRT users 
(Dunaif et a l ,  1992; Rosenbaum et al., 1993; Taylor and Marsden., 2000; 
Lyall and Gould., 2000).
Since the insulin resistance present in all of these conditions exists at the 
level of peripheral target tissues (Morris et al., 1994; Taylor and Marsden., 
1994), it is reasonable to assume that there may be a defect at the level of 
insulin signalling within these cells. As discussed in Section 1.4 to 1.6, the 
early pathways involved in propagating the insulin signal to the inside of 
the cell are fairly well characterised (reviewed in Holman and Kasuga., 
1997), although the precise mechanisms of GLUT4 translocation are less 
clear. Changes in any of these signalling events could potentially indicate 
a primary defect, or alternatively may reflect an adaptive response to a 
change within some other tissue such as muscle.
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5.2 Insulin action in the SHRSP
5.2.1 Potential roles of Cd36
Although the SHR was first demonstrated to be insulin resistant over ten 
years ago, defective expression of the putative fatty acid transporter Cd36 
was the first abnormality observed at the molecular level (Aitman et al.,
1999). With the demonstration that around 40% of the defect in 
carbohydrate metabolism and almost all of the defect in lipid metabolism 
could be accounted for by absence of this protein (Aitman et al., 1999; 
Pravenec et al., 1999), a suggestive role in the development of 
spontaneous hypertension in general arose. Interestingly however, 
although this protein may be linked to an enhanced risk of developing 
abnormal lipid metabolism (Ginsberg, 2000), its links with spontaneous 
hypertension in humans is less clear. Only a small percentage of cases of 
spontaneous hypertension are associated with abnormal Cd36 expression 
(de Winther et al., 2000). Interestingly Gotoda and colleagues have 
studied an SHR strain, the SHR/Izm, that displays normal Cd36 
expression, despite being similar to Aitman’s SHR in other ways (Gotoda 
et al., 1999). These lines of evidence are therefore suggestive that 
although Cd36 undoubtedly plays a role in some cases of spontaneous 
hypertension, it is unlikely to have such a universal role as once 
anticipated.
In agreement with this the data presented in Chapter 3 illustrates how the 
similarly hypertensive relative of the SHR, the SHRSP, exhibits metabolic 
abnormalities similar to those seen in the SHR, but in common with the 
SHR/Izm has normal Cd36 expression.
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5.2.2 Further SHRSP studies
5.2.2.1 Cd36 and other molecules
Although Cd36 gene expression and protein levels are normal in SHRSP 
adipocytes, the question remains as to whether it could contribute in other 
ways. As discussed in Section 3.3.4, localisation to specific cellular 
compartments appears essential for at least some of the functions of Cd36, 
particularly its role in mediating uptake of ox-LDL. It is therefore feasible 
that Cd36 could contribute to the SHRSP phenotype, not through reduced 
expression but by a somehow altered cellular distribution that impinges on 
normal function. Current ongoing studies are aimed at determining 
whether Cd36 protein is similarly distributed between different cellular 
compartments in SHRSP and WKY adipocytes, and whether this 
distribution can be differentially affected by insulin stimulation.
5.2.2.2 Insulin Signalling
It is highly likely however that there are other molecules which are 
important in the SHRSP phenotype, and which could also contribute to 
aspects of the SHR phenotype not explained by the Cd36 deletion, and in 
cases of spontaneous hypertension in humans. The observation that the 
SHRSP is indeed insulin resistant at the level of glucose uptake into 
adipocytes (discussed in Chapter 3) and skeletal muscle (personal 
communication from Declan James) suggests that the abnormality may lie 
at the level of insulin signalling in these cells.
The molecules known to be important in transducing the signalling steps 
activated by insulin include the IR, IRS-1 and IRS-2 and PI3K  (Holman et 
ah, 1997). Future work in this area will concentrate firstly on determining 
whether the key molecules in insulin-stimulated GLUT4 translocation are 
not only expressed normally, but also activated normally. With regard to 
IRS-1 and IRS-2 this will involve the specific immuno-precipitation of
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these proteins, followed by inununoblotting with specific phospho-tyrosine 
antibodies. In this regard it would also be of interest to determine the 
serine phosphorylation of either of the proteins, as serine phosphorylation 
of IRS-1 and 1RS-2 is associated with the development of insulin 
resistance (DeFea et al., 1997; Li et al., 1999; Wang et al., 1998). It will 
also be necessary to determine the specific sub-cellular localisation of each 
of the proteins, as removal from specific sites is believed to be important 
in the development of insulin resistance in 3T3-L1 cells chronically treated 
with insulin (Clark et al., 2000). Assessment of the activity of important 
signalling enzymes such as PI3K, PKC i, Ç and X, and PKBP will also be 
carried out in order to establish whether defects at this level could 
contribute to the SHRSP phenotype.
In addition to the important intracellular signalling molecules involved in 
mediating the effects of insulin, there are multiple proteins involved in the 
GLUT4 translocation (see Section 1.5). Analysis of the levels and 
expression of these proteins in SHRSP and WKY cells will reveal whether 
aberrant expression of these proteins could contribute the phenotype of the 
SHRSP.
S.2.2.3 Genetic studies
With the aim of further characterising the SHRSP phenotype at the genetic 
level, and identifying important loci and marker molecules other than 
Cd36, extensive genetic and phenotypic studies will be carried out. The 
studies presented in this thesis have revealed a significant impairment in 
insulin-stimulated glucose uptake and inhibition of lipolysis in SHRSP 
adipocytes compared to WKY. The p-values are however within the range 
of 0.01, a value considered inadequate for QTL mapping studies, and thus 
strategies to enhance the differences between SHRSP and WKY 
phenotype will be therefore employed. Pravenec and colleagues have 
described a method where rats fed a high (60%) fructose diet display an 
exaggerated insulin resistance (Pravenec et al., 1999). Phenotypic
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analyses of SHRSP and WKY fed such a diet can then be carried out, 
including measurement of serum markers, insulin-stimulated glucose 
uptake and anti-lipolysis, and of systolic and diastolic blood pressures. 
Such an approach will allow for selection of animals with a robust 
phenotype, and these animals can then be used to generate an Fi 
generation via SHRSP x WKY crosses (male SHRSP x female WKY, and 
vice versa). The mode of inheritance of a given phenotype in these Fi 
hybrids will be established, and results from this will dictate the approach 
for further breeding strategies. The approach outlined above should result 
in the identification of one or more QTL’s for insulin resistance in the 
SHRSP. These QTL’s are however likely to represent large chromosomal 
regions (spanning around 20-30cM), and the ultimate aim is to identify 
progressively smaller regions. This will be achieved using congenic 
strains, where regions containing potential QTL’s of interest in one strain 
(the recipient) are replaced with the homologous region from another 
strain (the donor). Should transfer of a particular area of DNA confer a 
phenotype different from the control recipient strain, then it can be 
concluded that this area is important in a specific trait. In the long term 
work would be aimed at advancing towards very small areas (IcM ), using 
techniques such as positional cloning and cDNA microarray analyses.
5.3 Insulin resistance in PCOS
5.3.1 Characteristics of PCOS
As discussed in Chapter 4, insulin resistance is a feature present in a 
variety of syndromes associated with an abnormal balance of hormones in 
the female reproductive system. This includes users of the combined oral 
contraceptive pill, HRT, and PCOS subjects (Taylor and Marsden., 2000). 
With regard to PCOS it is though that the peripheral insulin resistance is 
unlikely to be the primary defect, although its presence is thought to 
contribute to worsening of the disease phenotype (Taylor and Marsden.,
2000). For this reason it is of value to determine how an altered sex
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hormone profile may lead to the development of insulin resistance in 
insulin sensitive tissues, in an aim to understanding how it could be 
prevented or reduced.
5.3.2 Potential contribution of insulin resistance in PCOS
Interestingly it was observed in a cell culture model of a peripheral insulin 
sensitive tissue, the 3T3-L1 adipocyte, that treatment with three different 
sex steroids was able to reduce the insulin sensitivity of these cells as 
indicated by a reduced insulin-stimulated glucose uptake. This effect 
involved a steroid-induced down-regulation of several proteins known to 
be important in insulin signalling processes. Protein levels of 1RS-1, IRS- 
2, and the p85 regulatory subunit of PI3K  were dramatically reduced in 
lysates from steroid treated cells. In addition, steroid treatment caused a 
redistribution of IRS-1 and IRS-2 from the membrane to the cytosolic 
fraction. Clark and colleagues described a similar scenario in 3T3-L1 
adipocytes, where they demonstrated a movement of IRS-1 and IRS-2 
away from a membrane associated compartment to the cytosol, resulting in 
development of a cellular insulin resistance (Clark et al,, 2000). 
Interestingly the altered signalling in the steroid treated 3T3-L1 cells, 
resulted in impairment of insulin-mediated responses other than glucose 
transport. Indeed, although expression of PKB was not dramatically 
altered by steroid treatment, the insulin-induced stimulation was 
dramatically reduced. This is similar to the scenario observed with 
GLUT4, where expression of the protein was unaltered but the response to 
insulin was dramatically impaired.
5.3.3 Further studies regarding the relationship between PCOS and 
insulin resistance
Although many studies have illustrated the links between these two 
conditions, little has been established regarding links at the molecular
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level. Studies focusing on GLUT4 levels in PCOS subjects have produced 
conflicting results, although it is generally thought that many PCOS 
subjects do have a significantly reduced level of GLUT4 in adipocytes 
(Rosenbaum et al., 1993). Obviously this does not agree with the results 
presented in Chapter 5, where the levels of GLUT4 remain unchanged by 
steroid treatment. This suggests that the reduced level of GLUT4 observed 
in PCOS subjects is an adaptive change, and occurs as a result of 
continuing abnormal hormone balance. As discussed in Chapter 5, 
treatment of 3T3-L1 adipocytes with high doses of sex steroids does 
broadly mimic the environment to which adipocytes from PCOS subjects 
will be exposed. Because it is not possible to expose these cells to steroids 
for long periods of time however, the long-term adaptive changes are 
unlikely to develop. In contrast if adipocytes could be obtained from very 
early stage PCOS subjects, as well as advanced cases, it may be possible to 
observe how GLUT4 levels change within these cells throughout the 
disease progression. Obviously it would also be of interest to establish 
how the insulin signalling pathways are modulated in these primary 
adipocytes from PCOS subjects, and to determine whether the defects 
observed in the 3T3-L1 adipocytes may also be of significance in PCOS 
adipocytes.
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